










Department of Chemistry 
 
 
In partial fulfillment of the requirements 
For the Degree of Doctor of Philosophy 
Colorado State University 
Fort Collins, Colorado 
Spring 2017 
Doctoral Committee: 




















A SELECTION OF NITRIC OXIDE-RELEASING MATERIALS INCORPORATING S-
NITROSOTHIOLS 
 
Nitric oxide (NO) is a diatomic radical that occurs as a crucial component of mammalian 
biochemistry. As a signaling molecule, NO participates in the regulation of vascular tone and 
maintains the natural antithrombotic function of the healthy endothelium. Furthermore, NO is 
produced by phagocytes as part of the immune response, and exhibits both antimicrobial and 
wound-healing effects. In combination, these beneficial properties have led to the use of 
exogenous NO as a multifunctional therapeutic agent. However, the comparatively short half-life 
of NO under physiological conditions often renders systemic administration infeasible. This 
limitation is addressed by the use of NO-releasing polymeric materials, which permit the 
localized delivery of NO directly at the intended site of action. Such polymers have been utiliz d 
in the development of antithrombotic or antibacterial materials for biointerfacial applications, 
including tissue engineering and the fabrication of medical devices. NO release from polymers 
has most frequently been achieved through the incorporation of functional groups that are 
susceptible to NO-forming chemical decomposition in response to appropriate environmental 
stimuli. While numerous synthetic sources of NO are known, the S-nitrosothiol (RSNO) 
functional group occurs naturally in the form of S-nitrosocysteine residues in both proteins and 
small molecule species such as S-nitrosoglutathione. RSNOs are synthesized directly from thiol 




corresponding disulfide as a relatively benign organic byproduct. For these reasons, RSNOs have 
been conscripted as practical NO donors within a physiological environment. 
This dissertation describes the synthesis and characterization of RSNO-based NO-releasing 
polymers derived from the polysaccharides chitin and chitosan, as well as the development of 
amino acid ester-based NO-releasing biodegradable poly(organophosphazenes) (POPs). The 
broad use of chitin and chitosan in the development of materials for tissue engineering and 
wound treatment results in a significant overlap with the therapeutic properties of NO. NO-
releasing derivatives of chitin and chitosan were prepared through partial substitution of the 
carbohydrate hydroxyl groups with the symmetrical dithiols 1,2-ethanedithiol, 1,3-
propanedithiol, and 1,6-hexanedithiol, followed by S-nitrosation. Similarly, thiol-bearing 
polyphosphazenes were synthesized and used to produce NO-releasing variants. 
Polyphosphazenes are a unique polymer class possessing an inorganic backbone composed of 
alternating phosphorus and nitrogen atoms, and hydrolytically-sensitive POP derivatives with 
organic substituents have been prepared with distinctive physical and chemical properties. 
Although POPs have been evaluated as biomaterials, their potential as NO release platforms has 
not been previous explored. This work describes the development of NO-releasing biodegradable 
POPs derived from both the ethyl ester of L-cysteine and the 3-mercapto-3-methylbutyl ester of 
glycine. The NO release properties of all polymers were evaluated at physiological temperature 
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1.1. The physiological role of nitric oxide 
1980 is often marked as a crucial milestone in the pharmacological history of nitric oxide 
(NO), following the publication of work by Furchgott and Zawadzki that demonstrated the 
essential role of endothelial cells in the relaxation of vascular smooth muscle.1 This work was the 
first to establish a clear link between regulation of vascular tone and a then-unknown 
endothelium-derived relaxing factor (EDRF).  The subsequent effort to identify EDRF 
culminated in a seminal 1987 paper by Ignarro et al. that demonstrated the chemical equivalence 
of EDRF and the diatomic radical NO.2 In the aftermath of this discovery, NO biochemistry 
became a burgeoning field of study, and the 1998 Nobel Prize in Physiology or Medicine was 
awarded jointly to Furchgott, Ignarro, and Murad for their work in identifying the physiologica  
importance of NO.3 It was through the contribution of the latter co-laureate that the 19th century 
roots of NO pharmacology were revealed. Murad and his colleagues had been among the first to 
propose that nitroglycerin exerted its vasodilatory function through the biocatalyzed release of 
NO.4 Since these formative studies, a clearer picture of NO’s role in physiology and both its 
mechanism of action and breadth of potential therapeutic applications has emerged. 
It is now known that the broad bioactivity of NO spans neurotransmission, regulation of 
vasodilation (as observed by Furchgott, Zawadski, and others), and antimicrobial effects when 
produced by certain phagocytes as part of the immune response.5 NO also functions as a 




thrombus formation under normal physiological conditions.6,7 In mammals, NO production 
proceeds through enzymatic conversion of the amino acid L-arginine to citrulline and NO 
through a family of NO synthase (NOS) enzymes.8 These isoforms include the so-called 
constitutive Ca2+-dependent neuronal (eNOS or NOS I) and endothelial NOS (nNOS or NOS 
III), as well as inducible NOS (iNOS or NOS II).9,10 Additional physiological NO generation 
occurs as a product of the nitrate-nitrite-nitric oxide pathway, which has been established to 
proceed in a NOS-independent manner.11  NO is poorly soluble in water, exhibiting a saturated 
concentration of 1.7 × 10-3 M at 25 °C (pNO = 1 atm).
12 In organic solvent and hydrophobic 
biological media (e.g. low-density lipoprotein), the solubility is significantly greater.13,14 The 
kinetic diameter of NO (0.317 nm) is smaller than other physiologically-relevant gases, including 
carbon dioxide (0.330 nm) and molecular oxygen (0.346 nm).15  The combination of 
lipophilicity, small size, and charge neutrality allows NO to easily permeate biomembranes.16 
NO may react within a physiological environment to produce other bioactive products, including 
both nitrite (NO2-) and nitrate (NO3-), as well as a multitude of reactive nitrogen species (RNS) 
such as peroxynitrite (ONO2-).17 As a consequence, it may be difficult to distinguish between the 
direct effects of NO and those resulting from the action of physiological products of NO. As a 
comparatively stable radical, NO exhibits limited oxidative reactivity toward organic molecules 
and is typically incapable of hydrogen atom abstraction from hydrocarbons.18 In a biological 
context, it has been observed that NO does not independently initiate lipid oxidation, and in fact 
inhibits propagation of lipid peroxidation through scavenging of lipid peroxyl radicals.19 Cases of 
NO-related oxidative stress are therefore more accurately attributed to the formation of RNS 




The mechanisms underlying the biological effects of NO are complex and subject to 
continuing study.  In the NO-cGMP signaling pathway, binding of NO to NO-sensitive guanylyl 
cyclase activates the enzyme, which catalyzes the formation of cyclic guanosine 3',5'-
monophosphate (cGMP) from guanosine triphosphate (GTP).20 It is through the formation of 
cGMP and the influence of this effector on a variety of proteins that NO ultimately functions as a 
regulator of vascular tone and platelet activity.21,22 During the normal function of the immune 
system, NO acts as a potent antimicrobial and tumoricidal agent. In macrophages, induction of 
iNOS activity by environmental stimuli (such as inflammatory cytokines) initiates production of 
NO.23 This NO production is responsible for killing or inhibiting the replication of microbial 
pathogens and the destruction of tumor cells.24 Although NO exhibits a degree of inherent 
toxicity, many of its effects are attributable to conversion of NO to peroxynitrite and other RNS 
through reaction with macrophage-produced superoxide (O2-).25 Certain RNS are capable of 
inducing direct damage to microbial DNA through the chemical alteration of nucleobases, and 
may also impair the function of critical proteins through nitrosation and subsequent deamination 
of amino acid residues.26,27 The collective effect of exposure to toxic, nitrosative RNS has been 
termed nitrosative stress, and is a major contributor to the antibacterial properties of NO.28 It has 
been proposed that the ability of NO and NO-derived RNS to deleteriously affect bacteria 
through multiple, simultaneous chemical processes inhibits the development of meaningful 
resistance.29  
NO has also been found to participate as an important factor in the wound healing process. 
By 1990, it had been demonstrated that supplemental L-arginine was capable of enhancing 
wound healing in healthy human subjects.30 It was later observed by Bulgrin et al. that 




wounds.31  This outcome was attributable to impaired NOS-mediated NO production as a 
consequence of L-arginine deficiency. In a murine model, the suppression of endogenous NO 
production by continuous intraperitoneal administration of NOS inhibitors lowered both the 
concentration of NO metabolites in wound exudate, and wound collagen accumulation.32 
Notably, Shi et al. found that impaired wound healing in diabetic rats could be improved by 
supplementation with L-arginine, suggesting the possibility of using NO to treat diabetes-related 
chronic wounds.33 
Due to the numerous biological effects of endogenous NO, its conscription as a therapeutic 
agent was a logical progression. However, the effective physiological delivery of NO is limited 
by its reactivity. Although it can be safely transported and stored, administration of gaseous NO 
is complicated by its comparatively rapid reaction with atmospheric oxygen to form toxic 
nitrogen dioxide (2 NO + O2 → 2 NO2).34 Nevertheless, the direct use of inhaled gaseous NO is 
known as an FDA-approved treatment for pulmonary hypertension.35 In other applications, the 
fundamental biochemistry of NO inhibits effective use by systemic administration. Although 
unreactive in deoxygenated aqueous solution, the physiological lifetime of NO is limited and 
dependent upon concentration.36 Biological consumption of NO is partially attributable to 
reaction with molecular oxygen, a process which is generally believed to occur slowly at 
physiological NO concentrations, although this reaction may be accelerated in the hydrophobic 
regions of biological membranes.37,38 In extravascular tissue, Thomas et al. estimated the half-life 
of NO to fall within the range of 0.09 to >2 s, depending on oxygen concentration.38 In 1991, 
Borland used the known second-order rate constant for the in vitro reaction of NO with 
erythrocytes (167 mM-1 s-1) to estimate an NO half-life of 4.6 × 10-4 s in blood.39 Later, Liu et al. 




phosphate buffered saline (PBS), leading to a calculated NO half-life of 1.8 × 10-3 s in whole 
blood.40  In blood, the disappearance of NO is largely the outcome of reaction with 
oxyhemoglobin (and to a lesser extent, hemoglobin and methemoglobin), which occurs at a 
nearly diffusion-controlled rate.41 A natural consequence of this bioreactivity is that the 
concentration of physiologically-produced NO (as in the case of generation by endothelial cells) 
decreases rapidly as it diffuses from the source.42  For this reason, therapeutic NO is uniquely 
suited for localized delivery, where production or release of NO occurs in close proximity to the 
intended target site. Such an approach permits the exploitation of NO’s antithrombotic, 
antibacterial, and wound-healing effects through the controlled administration of NO directly at 
biointerfaces. The pursuit of this strategy has led to the swift proliferation of NO-releasing 
biomaterials over the last several decades. 
 
1.2. Applications of nitric oxide and nitric oxide donors 
Identification of the biological activity of NO has led to the development of NO-releasing 
materials intended for a wide variety of therapeutic applications. Following implantation of a 
blood-contacting medical device (.g. stents and catheters), the initial biological response to the 
presence of the foreign body includes deposition of hemostatic proteins on the surface of the 
device.43 These proteins mediate a complex biochemical process that ultimately results in platelet 
adhesion, aggregation, and activation, leading to subsequent thrombus formation.44,45 The 
clinical outcome of thrombus formation frequently includes medical complications such as 
obstruction or embolism, and may result in total failure of the device.46 In the case of stents, the 
use of drug-eluting polymers incorporating anticoagulants such as heparin has been evaluated as 




inhibitor in a healthy, non-thrombogenic endothelium, the possibility of utilizing exogenous NO 
as a method of improving the blood compatibility of implantable biomaterials has been widely 
explored.48 The performance of indwelling medical devices may also be compromised by 
bacterial infection, which is a significant source of severe complications and morbidity following 
implantation.49 This process frequently results in the formation of adherent microbial biofilms 
that resist traditional antimicrobial treatments. During evaluation as a potential antimicrobial 
therapeutic, NO demonstrated potent antimicrobial effects against Acinetobacter baumannii (A. 
baumannii), Escherichia coli (E. coli), Pseudomonas aeruginosa (P. aeruginosa), and 
Staphylococcus aureus (S. aureus), among other bacterial species.23,50 It has been observed that 
NO is utilized as a signaling agent in the regulation of biofilm formation in a variety of bacteria, 
and administered NO has been found to inhibit biofilm formation and disperse mature biofilms in 
species such as P. aeruginosa.51 Collectively, the antithrombotic and antibacterial effects of NO 
have driven the pursuit of application-specific materials with NO-release capabilities. Such 
materials must demonstrate the ability to function as stores of releasable NO, and must 
consequently release that NO under an appropriate environmental stimulus. 
While the adsorption and release of gaseous NO has been demonstrated with metal–organic 
frameworks (MOFs) and zeolites, incorporation of compounds that decompose to form NO 
remains the primary method of producing NO from biomaterials.52,53  This process generally 
involves the blending of a suitable small molecule NO donor into a polymer, or the synthesis of a 
polymer that includes the donor as an integral, covalently-attached component. Certain 
compounds have proven more useful for this purpose than others. Although organic nitrates 
(such as nitroglycerin) and nitrites are known NO prodrugs, their metabolic activation requires 




Incorporation of small molecule organic nitrates and nitrites within polymer matrices restricts 
this type of bioactivation, and enzymatic recognition of macromolecular equivalents cannot be 
assured. However, examples of topical preparations that generate NO through acidification of 
inorganic nitrites are known and have been utilized as treatments for bacterial infection.55 In a 
physiological environment, sodium nitroprusside (Na2[Fe(CN)5NO]) decomposes spontaneously 
to form NO and has been utilized as a vasodilator since the late 1920s.56 However, nitroprusside 
is metabolized to form cyanide, and has been infrequently utilized in biomaterials.57,58  A variety 
of NO-releasing mesoionic heterocycles are known, including sydnonimines (such as 
molsidomine, a vasodilatory drug), 1,2,3,4-oxatriazolium-5-olates, and 1,2,3,4-oxatriazolium-
imidates. In the case of the sydnonimines, the liberation of NO occurs through a relatively 
complex pathway that involves consumption of O2 and the concomitant formation of O2-.59 Other 
heterocyclic NO donors include the furoxans (1,2,5-oxadiazole-N-oxides) and their analogs, the 
1,2,3-triazole-2-oxides. In general, the synthesis of these compounds is complex and requires 
multiple steps. Furthermore, their NO release is mechanistically complicated and may require 
biological activation (e.g. molsidomine) or reaction with endogenous thiols (e.g. furoxans).60,61 
As a consequence, these donors are rarely utilized in the development of NO-releasing materials.    
In the early 1990s, work by Keefer et al. proposed that adducts of NO and certain 
secondary amines (earlier described by Drago) were capable of controlled NO release.62 These 
N-diazeniumdiolates (NONOates) were found to exhibit vasorelaxant effects in an animal aortic 
ring model.  By 1996, Keefer et al. had demonstrated the non-covalent incorporation of 
NONOates within polymer matrices, as well as the covalent attachment of the NO-donor group 
directly to the natural polysaccharide dextran and crosslinked poly(ethylenimine).63 Grafts 




effects in baboons. NONOates have subsequently been utilized as NO sources in a variety of 
polymer systems, ranging from polysaccharides like chitosan to biomedical grade 
polyurethanes.64,65 However, the medical use of NONOate-based materials suffers from a critical 
drawback. The release of NO into oxygenated, aqueous solution has the potential to produce 
nitrosating agents such as HNO2 or N2O3. In the case of NONOates, this NO release regenerates 
the parent secondary amine, which may subsequently react with nitrosating species to produce N-
nitrosamines, compounds that have been identified as probable human carcinogens.66,67 Thi  
concern has been directly addressed in the literature, where Keefer recommended restriction of 
N-bound NONOate use to compounds where the anticipated nitrosamine derivative is non-
tumorigenic (e.g. N-nitrosoproline) or to non-biodegradable materials where toxic nitrosamines 
are not expected to enter physiological media.68 In general, synthetic NO donors exhibit a wide 
range of useful NO release properties and have been successfully incorporated within a variety of 
polymers. However, examples of NO release are not solely constrained to synthetic functional 




S-Nitrosothiols (RSNOs) are NO-releasing compounds derived from thiols, and occur 
endogenously in both small molecule and protein-bound forms (primarily as S-nitrosated 
cysteine residues) (Figure 1.1).69 RSNOs are known to decompose through thermal, photolytic, 
and transition metal-promoted pathways to form NO and the corresponding disulfide.70 Among 
NO donors, RSNOs are unique as natural components of mammalian biochemistry. Subsequent 




more consistent with S-nitrosocysteine.71 In 1992, Stamler et al. used chemiluminescence-based 
detection to determine an average RSNO concentration of 7 ε in human plasma, and suggested 
that S-nitrosoalbumin might serve as a physiological reservoir of NO in mammals.72 It has since 
been established that RSNOs are common in mammalian physiology, primarily in the form of S-
nitrosoalbumin and S-nitrosoglutathione (GSNO).73 Nevertheless, it has proven challenging to 
 





accurately quantify their physiological abundance, with reported concentrations that frequently 
range from low ε to nε.74 Tsikas et al. determined an S-nitrosoalbumin concentration of 
approximately 200 nM in human plasma by GC-MS analysis of derivatized nitrite , while Tyurin 
et al. reported a significantly larger value of 4.2 ε through fluorometric assay.75-77 More 
recently, Tsikas et al. utilized UPLC-MS/MS to quantify GSNO in human plasma, and 
concluded that the basal concentration was below 2.8 nM (limit of quantitation).78 With the 
notable exception of reports from Stamler and Tyurin, the majority of studies indicate that basal 
physiological RSNO concentrations are below 1 ε, with certain methodologies yielding values 
below 1 nM.76 Although accurate measurement of physiological RSNOs remains a developing 
field, their presence suggests the existence of an important biological function. In proteins, the 
reversible post-translational S-nitrosation of cysteine residues may alter their structure and 
activity.79,80 It has also been proposed that endogenous RSNOs may act as storage and transport 
agents, through their ability to indirectly capture and later release NO.72,81 Despite numerous 
studies that have examined the participation of RSNOs in various biochemical pathways, their 
physiological role has yet to be clearly elucidated. However, their potential biological 
significance and inherent physicochemical properties have led to the extensive characterization 
of both natural and synthetic RSNOs. 
RSNOs are formed directly from thiols by the formal replacement of the proton with 
nitrosonium (NO+), and have been known synthetically since a report from Tasker and Jones in 
1909.82 The conversion of thiols to RSNOs is generally rapid (approaching diffusion-limited, 
under certain conditions) in the presence of electrophilic nitrosating agents such as nitrous acid 
(HNO2), nitrosyl chloride (NOCl), or dinitrogen trioxide (N2O3).83 RSNOs may also be readily 




case, the nitrosonium cation (NO+) has been proposed as the active electrophilic species, and 
may also be formed during the use of other nitrosating agents under appropriately acidic 
conditions.85  Morris et al. evaluated S-nitrosation kinetics for eight different thiols using sodium 
nitrite and perchloric acid (forming HNO2 in situ), and first-order kinetics were observed with 
respect to thiol and acid concentration.86 It has generally been shown that, under mildly acidic 
conditions, S-nitrosation follows the rate equation k = [RSH][H+][HNO2], and that the nitrosating 
agent is H2NO2+ .87 It is also the case that the addition of halide or pseudohalides such as 
thiocyanate catalyze S-nitrosations with HNO2, likely through the formation of more reactive 
electrophiles.86  
The RSNO group can be characterized by UV-Vis spectroscopy and exhibits a π→π* 
transition centered near 330 nm, with typical molar extinction coefficients of 
approximately 1000 M-1 cm-1.87 A second, significantly less pronounced absorbance (20 
M-1 cm-1) assigned to the nN→π* transition occurs near 550 nm in primary and secondary 
RSNOs, and 600 nm in tertiary species. Bartberger et al. note that the weaker absorbance 
may be resolved as two distinct n→π* bands with a separation of approximately 30 nm.88 
As a consequence of the visible range absorbance, RSNOs display either a red/pink 
(primary and secondary) or green (tertiary) color. Using IR spectroscopy, absorbance 
bands at approximately 1500 and 650 cm-1 were assigned by Arulsamy et al. to N=O and 
N-S vibrational modes.89 Further characterization by 1H, 13C, and 15N NMR spectroscopy 
has also been demonstrated, but is less routine and may require low temperature to 





It has been proposed that the chemical behavior of RSNOs can be accurately described by 
three distinct resonance structures.92 As shown in Figure 1.2, the zwitterionic structure II  
possesses an S-N double bond that has been calculated to significantly influence the overall 
character of the functional group. As predicted by this model, the RSNO group is essentially 
planar, and occurs in nearly isoenergetic syn or anti conformations arising from rotation around 
the S-N bond.88,93 Interconversion is hindered (with an approximate 11 kcal mol-1 r tational 
barrier) and does not occur freely at room temperature, potentially supporting the argument for 
SNO delocalization.88,89,92 Nevertheless, reported crystal structures generally indicate an S-N 
bond length of 0.18 nm, a value more consistent with S-N single bonds.89,92 This elongation may 
be explained by structure III (Figure 1.2), where ion pairing is used to depict the S-N bond. The 
majority of computational studies support a small preference for the syn conformation in primary 
and secondary RSNOs. Yi et al. reported that the primary RSNO ethyl S-nitrosocysteinate 
 
Figure 1.2 Structural characteristics of S-nitrosothiols. (a) 
Hypothesized resonance structures and (b) conformations of the S-





hydrochloride exists exclusively in the syn conformation, and Bartberger et al. observed the 
same behavior in S-nitrosocaptopril (also primary).88,94 In contrast, the increased steric influence 
of the R group in tertiary RSNOs favors anti. As anticipated, X-ray crystallography of the tertiary 
RSNOs S-nitrosotriphenylmethanethiol and S-nitroso-N-acetylpenicillamine (SNAP) reveals an 
anti conformation in both compounds.89,95,96  
The most commonly accepted pathway for thermal or photolytic RSNO decomposition 
involves scission of the S-N bond (approximately 20-32 kcal mol-1) t  form the corresponding 
thiyl radical and NO.97 This pair may subsequently undergo unproductive geminate (or non-
geminate) recombination, or two thiyl radicals may react to produce the corresponding disulfide 
(approximately 60 kcal mol-1) and liberated NO, according to the overall equation 2 RSNO → 2 
NO + RSSR.98,99  This idealized description may not fully explain RSNO decomposition, 
particularly under oxygenated conditions.  Notably, the disulfide-forming reaction may occur 
between a thiyl radical and an RSNO molecule, given the greater abundance of the latter 
species.97 Furthermore, Zhao et al. noted that the gas phase homolytic BDEs of RSNOs typically 
fall within the upper end of the reported range (approximately 32 kcal mol-1), predicting half-
lives of years at room temperature.100 This calculation is frequently contradicted by the 
experimental decomposition of many RSNOs within minutes or hours. To explain this 
phenomenon, Grossi et al. proposed that the decomposition of solution-phase RSNOs is 
autocatalytic and dependent upon the concentration of O2 and NO (and therefore N2O3).101 This 
notion was supported experimentally by the observation that the rate of decomposition was 
reduced by removal of either O2 or NO from solution and enhanced by sparging with NO, 
leading the authors to suggest that N2O3 may act as a chain carrier during the decomposition 




reaction with NO+.100 In general, inconsistent (and occasionally non-integer) kinetic observations 
of RSNO decomposition support a more complex pathway than the straightforward equation 
provided previously. 
While GSNO can be readily isolated as a relatively stable solid, the majority of primary 
RSNOs are thermally unstable and rapidly decompose (particularly when concentrated).102 In 
contrast, several isolable tertiary RSNOs have been reported to be essentially stable at ambient 
temperature in the absence of light. S-Nitroso-N-acetylcysteine (SNAC) and SNAP differ only by 
the presence of the gem dimethyl group in the latter compound. However, SNAP exhibits 
indefinite stability when isolated as a solid, while SNAC rapidly decomposes and cannot be 
isolated.88,95 The explanation for the difference in stability between primary and tertiary RSNOs 
has been pursued by multiple researchers. Bainbrigge et al. utilized differential-scanning 
calorimetry (DSC) and thermogravimetric analysis (TGA) to observe that both SNAP and GSNO 
experience an NO-forming decomposition at 148 °C.102 This result may indicate a similar S-N 
bond strength for both compounds. Furthermore, Grossi et al. found that the thermal stability of 
tertiary RSNOs was generally ower than their less substituted equivalents.103 It was therefore 
reasoned that the remarkable stability of tertiary RSNOs may arise from an alternative 
explanation, such as the manifestation of steric effects during dimerization of thiyl radicals 
bearing a proximal gem dimethyl group. This argument was supported computationally by the 
calculation of an unusually high-energy, sterically congested conformation during formation of 
the disulfide bond.102  It was observed by de Oliveira et al. that RSNO concentration influences 
the rate of decomposition in a complex manner.104 When evaluating the stability of S-
nitrosocysteine, SNAC, and GSNO in aqueous solution, it was found that a ten-fold increase in 




order of magnitude for all three substrates. This result was attributed to an increase in the rate of 
non-geminate radical recombination at elevated concentration. A fi al increase in concentration 
to 6.1 × 10-2 M significantly accelerated the decomposition, which was argued to be a 
consequence of the autocatalytic reaction RS· + RSNO → RSSR + NO. However, the 
outcome of many kinetic studies of RSNO decomposition must be evaluated with the 
knowledge that experimental conditions (particularly with respect to O2/NO or transition 
metal ion concentration) may significantly influence the data. In the mid-1990s, Williams 
proposed that solution-phase RSNO decomposition was primarily induced by the presence of 
trace copper ions at concentrations as low as 10-6 M.98 This reasoning was supported by the 
observation that the addition of ethylenediaminetetraacetic acid (EDTA) to aqueous RSNO 
inhibited or entirely prevented decomposition. It is now understood that copper readily catalyzes 
the NO-forming decomposition of RSNOs.  Use of selective copper(I) chelators such as 
neocuproine demonstrate that Cu+ is the active species, which may be formed from copper(II) 
salts by reduction in the presence of trace thiol.98 The susceptibility of RSNOs to metal-
accelerated decompositon is by no means limited to copper ions. It has been observed that Fe2+ 
exerts a small, but detectable, effect on both the formation and decomposition of RSNOs.105 
Furthermore, both mercury (Hg2+) and silver (Ag+) ions have been found to greatly accelerate 
RSNO decomposition in a non-catalytic fashion.106 It has been shown that coordination of 
transition metals to the sulfur atom of the RSNO functional group decreases the S-N bond 
strength, thereby promoting homolytic dissociation. However, the precise mechanism through 






1.4. Reactivity considerations in the development of S-nitrosated polymers 
A wide variety of RSNO-based NO-releasing biomaterials have been proposed for 
antithrombotic, antibacterial, and wound-healing applications. In 2000, Bohl and West reported 
the polymeric incorporation of the amino acid cysteine within a poly(ethylene glycol)-based 
hydrogel.107 The subsequent S-nitrosation of this hydrogel using NaNO2 at low pH produced an 
NO-generating material with reported antiplatelet effects. In a second early example, cysteine 
was conjugated to both polyethylene terephthalate and medical grade polyurethane and 
converted to the corresponding RSNO by treatment with NaNO2/HCl, producing surfaces with 
reduced platelet adhesion relative to controls.108 Later reports of RSNO-based materials have 
included NO-releasing polysiloxanes and polysaccharides with antibacterial activity, as well as 
numerous biodegradable polyesters proposed for applications ranging from the fabrication of 
erodible medical devices to tissue engineering.109-114 Furthermore, macromolecular RSNOs have 
been demonstrated to improve outcomes in wound-healing applications.115 It has generally been 
shown that the use of RSNO-based biomaterials produces effective platforms for the controlled 
release of NO for therapeutic purposes. However, the attachment of covalently-bound thiols to 
polymers and their subsequent conversion to RSNO derivatives results in several unique 
synthetic considerations. Thiol groups are readily oxidized to disulfide, and this process may 
result in crosslinking that alters the physical and chemical properties of polymers.116,117 Several 
oxidants are known to effect this transformation, including molecular oxygen and iodine, while 
copper and iron ions are known to catalytically accelerate the reaction.118-120  In the case of 
molecular oxygen, disulfide formation may occur more rapidly in DMF under basic 
conditions.121 Moreover, disulfide may be produced through simple heating of thiols in the 




In the case of structurally complex polymers containing multiple functional groups, it 
cannot be presumed that nitrosating agents will selectively produce S-nitrosation. Exposure of 
primary aromatic amines to nitrous acid will result in the formation of unstable diazonium 
salts.123 Primary aliphatic amines undergo diazotization followed by the rapid elimination of 
nitrogen gas, as exploited in the Demjanov and Tiffeneau-Demjanov rearrangements.124,125 In the 
case of secondary aliphatic amines, stable (and potentially carcinogenic) N- trosamines are 
directly formed, while tertiary aliphatic amines slowly react in a dealkylative process that 
generates a secondary N-nitrosamine, carbonyl compound, and nitrous oxide.66,126,127 Even 
subsequent to RSNO formation, certain structures (.g. S-nitrosocysteine) may undergo 
transnitrosation reactions that result in diazotization of the amine group.128 N-Nitrosation is not 
confined to amines, but also occurs in amides and other weakly nucleophilic nitrogen-containing 
functional groups.129-132 Hydroxyl groups react in the presence of nitrous acid and other 
nitrosating species to form alkyl nitrites, which are independently capable of further nitrosation 
chemistry.83,133 Notably, this brief list encompasses functional groups that are reasonably 
expected to occur in polyesters, polysaccharides, polyurethanes, and many other polymers used  
to develop RSNO-based NO delivery platforms. Because there is a significant possibility that 
alternative nitrosation reactions may occur, it is critical to employ all practical characteriztion 
techniques in evaluating RSNO-based materials to ensure the retention of structure.  
 
1.5. Measurement of nitric oxide from S-nitrosothiol decomposition 
Characterization of the NO release properties of small molecule RSNOs is a crucial 
step in evaluating their pharmacological activity. In the case of RSNO-based polymeric 




their NO storage capabilities. Furthermore, measurement of NO release as a function of time 
permits assessment of the material’s performance as a source of therapeutic NO. To improve the  
biological relevance of such measurements, RSNOs are frequently incubated at physiological 
temperature and pH during the NO release period. The decomposition of RSNOs themselves 
may be measured spectrophotometrically, and has been related to the formation of NO through 
the equation 2 RSNO → 2 NO + RSSR.134  As described previously, it is possible to directly 
monitor the decay of RSNOs using characteristic absorptions occurring at 330 (π→π*)  and 550-
600 nm (nN→π*), with respective molar extinction coefficients of approximately 1000 and 
20 M-1 cm-1.87 In certain examples, it has been observed that this decay is accompanied by 
the appearance of an absorbance at approximately 250 nm that arises from disulfide bond 
formation.135 The RSNO absorbance centered near 330 nm is subject to interference from 
other species, including inorganic nitrite, nitrous acid, alkyl nitrites, and N-nitroso 
compounds.81,136,137 The 50-fold weaker absorbance at 550-600 nm may not be resolved at 
low concentrations. Moreover, the molar extinction coefficients of macromolecular 
RSNOs may differ significantly from small molecule counterparts, and must be 
independently determined.138 Because the rate of RSNO decomposition s altered by 
dissolution, solution-phase UV-Vis measurements of macromolecular RSNOs are 
unlikely to correspond to their NO release properties as solids.83 RSNO decomposition 
has also been shown to occur without the concomitant formation of NO in certain cases, 
particularly at high thiol concentration.139,140 For this reason, it should not be presumed a 
priori that a useful relationship exists between RSNO decomposition and NO formation 




In general, reliable measurement of NO release from RSNO decomposition requires 
detection of NO itself or the byproducts of NO decomposition (e.g. nitrite). Multiple NO 
measurement techniques have been developed, and the majority can be employed (with varying 
degrees of reliability) to quantify NO release from RSNOs. Although it is possible to observe 
NO directly with electron paramagnetic resonance (EPR), in practice it is necessary to utilize 
spin trapping to form stable adducts that are easier to observe and quantify.141 Most commonly, 
the routine measurement of NO release from RSNOs relies on colorimetric/fluorometric, 
electrochemical, or chemiluminescence-based methods. Since NO decomposes to form nitrite 
under aqueous, oxygenated conditions, nitrite quantification has frequently been used to 
indirectly measure the amount of NO formed within a solution. The Griess assay is a common 
colorimetric method of quantifying nitrite, and proceeds through acidification of nitrite to form 
nitrous acid.142,143 Reaction of nitrous acid with sulfanilic acid produces the corresponding 
diazonium compound, which is coupled to a suitable aromatic amine to generate an azo dye. This 
technique may also include a nitrate (another NO oxidation product) reduction step to fully 
quantify NO release.144 In general, limits of detection of approximately 500 nM are reported for 
the Griess assay.145 The Griess assay is not selective, and will quantify nitrite from all sources, 
including that which is unrelated to the decomposition of RSNOs. Since RSNOs are almost 
exclusively synthesized using nitrite or nitrite-forming reagents, the potential for contamination 
and false positives is evident. Furthermore, certain functional groups besides RSNO (e.g. alkyl 
nitrites) can be expected to hydrolyze to form nitrite under the conditions of the Griess assay.146 
To permit improved discrimination between nitrite sources, the Saville-Griess assay has been 
employed to selectively decompose RSNOs. In 1958, Saville observed that the addition of 




Saville-Griess assay exploits this phenomenon through the reaction of RSNOs with mercury, 
followed by the generation of an azo dye as in the traditional Griess assay.148 The amount of 
nitrite arising from RSNO decomposition has therefore been calculated as the difference between 
the Saville-Griess and standard Griess protocols. Fluorescent probes have also been utilized in 
the indirect fluorometric measurement of NO at concentrations as low as the nM range.145 These 
probe molecules are typically derived from 4,5-diaminofluorescein (DAF), and rely on the 
reaction of NO oxidation products (e.g. N2O3) to form a fluorescent triazole.149 Since these 
techniques typically require expensive reagents and are uniquely suited to the detection of 
intracellular NO, they are not generally used to characterize NO-releasing materials. 
The indirect colorimetric or fluorometric determination of NO does not permit the active 
monitoring of NO formation as it occurs. In contrast, real-time measurement of NO release is 
achievable using electrochemical or chemiluminescence-based methods. Typically, 
electrochemical NO measurement proceeds through the electrooxidation of NO to nitrite, 
according to the equations shown below.150 
 






 → HNO2 
 






Electrochemical techniques are generally reported to have limits of detection in the pM to low 




proposed for a porphyrinic microsensor with a detection limit of 10 nM.151,152 Common 
interferences include anionic species such as ascorbate and nitrite, however these species may be 
excluded from the electrode by the use of selective membranes.153 The electrochemical 
measurement of NO is possible within living tissue, and has been utilized to evaluate biological 
production of NO in vivo.154,155 It has been established that RSNOs themselves may be detected 
by electrochemical reduction, although this method does not result in the production of NO at 
physiological pH.156,157 Despite the established performance of electrochemical detection 
methods, quantification of NO by chemiluminescence is more frequently used to characterize 
NO release from RSNO-based materials. The chemiluminescent reaction between NO and ozone 
(NO + O3 → NO2* + O2) was originally reported in 1949 by Tanaka and Shimayu, and later 
characterized by Greaves and Garvin in 1958.158,159 The broad emission arising from the 
relaxation of excited-state NO2 occurs primarily in the red/infrared range, with a short 
wavelength limit of 590 nm, as described by Clyne et al.160 The chemiluminescent intensity is 
proportional to the pressures of NO and O3, and inversely proportional to total pressure (resulting 
from collisional deactivation), requiring the use of partial vacuum within the reaction chamber 
for reliable detection.161 In a typical procedure, an inert carrier gas is used to transfer NO from an 
external cell containing the sample to the reaction chamber within the instrument, which is 
maintained at reduced pressure. This chamber is supplied with ozone, and photons from the 
resulting chemiluminescent reaction pass through a filter (eliminating higher frequency light 
from potential side reactions) before reaching the detector. The transduction of this light 
emission has been widely used to measure NO from the decomposition of RSNOs under a 
variety of conditions, including directly within biological media such as plasma and whole blood 




may be reduced to NO using iodide or vanadium(III) under acidic conditions and detected by 
chemiluminescence.163-164 Furthermore, the real-time NO-forming decomposition of RSNOs may 
be monitored. In the case of overall NO determination, this decomposition can be accelerated 
through photolytic cleavage of the S-N bond by irradiation with UV light, or with the addition of 
copper ions.165,166 In all examples, the detection of RSNOs suffers from the notable drawback 
that it must be conducted under anaerobic conditions to avoid the premature consumption of NO. 
The absence of molecular oxygen and the fact that NO is continuously purged by inert gas from 
sample solutions containing dissolved or suspended RSNO may exert a considerable influence 
on the observed decomposition kinetics.101,103 Nevertheless, chemiluminescence-based analysis 
has been described as the gold standard in NO measurement, and remains a widely used 
approach to the characterization of NO release from RSNOs.167 
 
1.6. Dissertation overview 
This dissertation focuses on the synthesis and characterization of multiple RSNO-based 
NO-releasing polymers obtained from the polysaccharides chitin and chitosan, as well as from 
synthetic polyphosphazenes. Chitin is a biopolymer that primarily consists of N-
acetylglucosamine units, and occurs naturally in structures as diverse as the shells of crustaceans 
and the cell walls of fungi.168,169 Chitosan is produced from the amine-forming deacetylation of 
chitin and has been widely utilized as a biomaterial for its hemostatic and antimicrobial 
properties.168,170 Preparation of NO-releasing chitosan has largely been confined to the 
conjugation of NO donor groups to the  primary amine groups of oligosaccharidic forms, which 




the polysaccharides chitin and chitosan to include NO-donating RSNO moeities through 
replacement of hydroxyl groups is explored. 
Polyphosphazenes are a unique class of polymers containing an inorganic phosphorus-
nitrogen backbone, and are frequently substituted with variable organic pendant groups to confer 
new physical and chemical properties.173 In the mid-1960s, Allcock and Kugel first described the 
preparation of amine-substituted polyphosphazenes, which led to the subsequent development of 
biodegradable polyphosphazenes with amino acid ester substituents by 1977.174,175 Early 
examples included polymers bearing pendant groups derived from alkyl esters of glycine, 
alanine, and phenylalanine.176 Allcock et al. proposed that such materials would undergo 
hydrolytic degradation to harmless or metabolizable products that could lead to their use as 
implantable biomaterials.176,177 Biodegradable amino acid ester-based polyphosphazenes have 
since been subjected to a variety of in vitro and in vivo studies that demonstrate their potential 
utility for tissue engineering, drug delivery, and other biomedical applications.178-180 Chapters 3 
and 4 of this dissertation describe work toward the development of RSNO-based NO-releasing 
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NITRIC OXIDE-RELEASING S-NITROSATED DERIVATIVES OF CHITIN AND 




Nitric oxide (NO) is a biologically-active molecule with an important role in numerous 
physiological processes, most notably as a signaling agent in the regulation of vasodilation.1  
Moreover, NO is an active participant during several crucial stages of wound repair, modulating 
the severity of the inflammatory response and promoting cell proliferation and angiogenesis.2,3 
These properties have led to the extensive investigation of supplemental NO for wound-healing 
applications. This use of NO is of particular interest in cases where endogenous NO production 
has been impaired as a result of illness, a condition that has been implicated in the persistence of 
chronic wounds.4,5 NO and NO prodrugs are currently utilized as therapeutic agents for the 
treatment of cardiovascular and pulmonary ailments, although the controlled administration of 
therapeutic NO for wound-healing applications is complicated by the fact that NO is a highly 
reactive radical species with a relatively short half-life under atmospheric or physiological 
conditions (0.09 to >2 s in extravascular tissue) and exhibits acute toxicity at higher 
concentrations.6,7 As a result, there has been considerable interest in the development of NO-
releasing materials for the localized delivery of NO at biological interfaces. One way this has 
                                                          
This chapter was adapted from: 
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of chitin and chitosan for biomedical applications. J. Mater. Chem. B 2014, 2, 7449-7458. Adapted by permission 





been achieved involves the coupling of NO donor groups such as N-diazeniumdiolates and S-
nitrosothiols (RSNOs) to polymer systems to prepare materials that release NO as a result of the 
decomposition of the donor group under physiological conditions.8,9  
More recently, derivatives of the naturally-occurring β-(1,4)-linked polysaccharide chitin 
have been investigated as NO-releasing materials. Chitin is an abundant biopolymer primarily 
consisting of N-acetyl-D-glucosamine units and is commercially derived from marine 
crustaceans, where it occurs as a major structural component of the exoskeleton.10 The most 
significant derivative of chitin is chitosan, a polysaccharide produced through the deacetylation 
(≥50%) of the parent polymer to form primary amine groups.11 This process confers solubility in 
aqueous acid, as well as enhanced mucoadhesive and hemostatic properties.12 Both polymers 
have been employed in a variety of biological applications, including use in surgical sutures and 
wound dressings that exploit their well-established biocompatibility and biodegradability.13,14 
The concept of utilizing chitin and chitosan derivatives as platforms for the controlled delivery of 
pharmaceutical agents has received significant attention in literature, due to the versatility of the 
materials and their inherently low toxicity and unique interactions with biological systems.15,16 In 
the case of NO delivery for wound repair, chitin and chitosan offer the advantage of exhibiting 
hemostatic properties that may balance the reported ability of NO to inhibit platelet adhesion and 
aggregation, potentially expanding the application of NO-releasing derivatives to acute 
hemorrhagic wound care.17,18,19 Furthermore, chitin and chitosan have previously been observed 
to independently accelerate wound healing in animal models.20,21 
Chitin and chitosan derivatives are often synthesized through modification or substitution 
of the C6 and C3 hydroxyl groups, while chitosan derivatives may also be prepared through 




reactions.22 In previously reported NO-releasing materials developed from chitosan or chitosan 
oligosaccharides, the primary amine of the glucosamine units was either directly reacted with 
gaseous NO to form the N-diazeniumdiolate donor group or converted to a secondary amine 
prior to N-diazeniumdiolate synthesis.23,24 An alternative strategy involving the conjugation of N-
acetyl-DL-penicillamine to chitosan in an amide-forming reaction followed by S-nitrosation with 
NaNO2/HCl has also been described.25 In these prior examples, the inherent reactivity of the C2 
amine was used to introduce the desired NO donor group. Herein, we report the first synthesis of 
NO-releasing S-nitrosated chitin and chitosan derivatives prepared through the substitution of the 
C6 hydroxyl group. This was accomplished through the reaction of tosylated intermediates with 
the symmetrical dithiols 1,2-ethanedithiol (EDT), 1,3-propanedithiol (PDT), and 1,6-
hexanedithiol (HDT), which were subsequently S-nitrosated with tert-butyl nitrite (t-BuONO) to 
form the corresponding S-nitrosothiol NO donor group. In addition, this work represents the first 
reported synthesis of S-nitrosated chitin derivatives for biomedical applications. The S-
nitrosothiol donor group was selected largely due to its role as an endogeneous NO transfer 
agent, as in the case of S-nitrosoglutathione, and its decomposition into neutral products (2 
RSNO → 2 NO + RSSR) under mild thermal conditions.26,27 In the case of chitosan derivatives, 
substitution of the C6 hydroxyl group leads to a retention of the primary amine that is frequently 
used for derivatization, permitting further modification of the polysaccharides. Moreover, the use 
of harsh concentrated acid (as in the case of NaNO2/HCl) was avoided by employing an alkyl 
nitrite as the S-nitrosating agent under comparatively mild conditions. 
The total NO content of each S-nitrosated material was determined through analysis of NO 
released during thermal decomposition of the S-nitrosothiol groups, and the NO release profiles 




time for at least 24 h, depending on the release time of the material. To assess the suitability of 
the thiolated parent materials for biomedical applications, the in vitro cytotoxicity of each 
derivative was evaluated by extract test. MTS and LIVE/DEAD assays were used to determine 
the viability of the cells, and any changes in morphology were observed by morphological 
assays. 
 
2.2. Materials and methods 
2.2.1. Materials 
Chitin, 1,2-ethanedithiol (EDT), 1,3-propanedithiol (PDT), 1,6-hexanedithiol (HDT), hydrazine 
monohydrate, lithium chloride, p-toluenesulfonyl chloride (TsCl), and triethylamine (TEA) were 
purchased from Alfa Aesar (Ward Hill, MA, USA). Chitosan (PROTASAN UP B 90/20, 80 kDa 
MW) was purchased from NovaMatrix (Sandvika, Norway). 5,5′-Dithiobis(2-nitrobenzoic acid) 
(DTNB), phthalic anhydride, tert-butyl nitrite (t-BuONO), and tris(2-carboxyethyl)phosphine 
hydrochloride (TCEP·HCl) were purchased from Sigma-Aldrich (St. Louis, MO, USA). 
Phosphate buffered saline (PBS) tablets were purchased from EMD Chemicals (Gibbstown, NJ, 
USA). DL-Dithiothreitol (DTT) was purchased from AMRESCO (Solon, OH, USA). 
Spectra/Por 7 dialysis membrane (8 kD molecular weight cut-off) was purchased from Spectrum 
Laboratories, Inc. (Rancho Dominguez, CA, USA). Human dermal fibroblasts (HDF) were 
purchased from ZenBio, Inc. (Durham, NC, USA). Amphotericin B, gentamicin, and Media 106 
fetal bovine serum supplement were purchased from Gibco® (Grand Island, NY, USA). Alexa 
Fluor® 568 Phalloidin, DAPI, PBS, propidium iodide, SYTO9, and trypsin-EDTA (0.25%) were 
purchased from Life Technologies (Grand Island, NY, USA). (3-(4,5-dimethylthiazol-2-yl)-5-(3-




(Madison, WI, USA). 75T tissue culture (TC) plates were obtained from VWR (Denver, CO, 
USA). TEA was distilled from calcium hydride before use. 
 
2.2.2. Characterization techniques 
1H NMR spectra were acquired using a Varian Inova 400 MHz FT-NMR spectrometer (Varian 
NMR Systems, Palo Alto, CA, USA). ATR-FTIR spectra were collected between 4000 and 650 
cm-1 using a Nicolet 6700 spectrometer (Thermo Electron Corporation, Madison, WI, USA) 
equipped with a Smart iTR ATR sampling accessory. UV-Vis analysis was carried out using a 
Nicolet Evolution 300 spectrophotometer (Thermo Electron Corporation) equipped with a 
Praying Mantis accessory (Harrick Scientific Products, Inc., Pleasantville, NY, USA) for diffuse 
reflectance studies. 
Ellman’s assay for thiol quantification. For all materials, the incorporation of unoxidized thiol 
was quantified using Ellman’s assay under heterogeneous conditions.28,29 Samples of each 
polymer (n ≥3) were suspended in 100 mM phosphate buffer (pH 8) and treated with 100 µL of 
10 mM DTNB in buffer. The samples were agitated for 1 h at room temperature, then 
centrifuged prior to the removal of 200 µL aliquots of sample solution for analysis. The aliquots 
were transferred to a 96-well microtiter plate and absorbance values were acquired at 450 nm 
using a BioTek Synergy 2 plate reader (BioTek, Winooski, VT, USA). Thiol content was 
calculated using cysteine standards. 
Chemiluminescence-based NO analysis. NO release from S-nitrosated polymer samples was 
recorded in real-time using Sievers nitric oxide analyzers (NOA 280i, GE Analytical, Boulder, 
CO, USA). Calibration was performed with nitrogen (zero gas) and 45 ppm NO/nitrogen. NO 




NO-releasing thermal decomposition of the S-nitrosothiol groups.28 The corresponding NO 
emission from this process was measured and used to calculate the amount of thermally 
releasable NO present in each material. For studies performed under physiological conditions, 
polymer samples (n ≥3) were suspended in 10 mM PBS (pH 7.4) at 37 °C and the NO release 
was measured for at least 24 h. 
 
2.2.3. Cell studies 
For cell culture, human dermal fibroblasts were cultured in media 106 supplemented with 2% v/v 
fetal bovine serum, 1 µg/mL hydrocortisone, 10 ng/mL human epidermal growth factor, 3 ng/ 
mδ basic fibroblast growth factor, 10 µg/mδ heparin, 125 µg⁄mδ amphotericin B, and 5 mg/mδ 
gentamicin on a 75T TC plate. HDF were incubated at 37 °C in a humid atmosphere with 5% 
CO2. When confluent, the cells were collected from a 75T flask by adding 2 mL of a trypsin-
EDTA (0.25%) solution, and re-suspended at different concentrations (cells/mL) depending on 
the specific experiment. 
Preparation of extracts. All cytotoxicity experiments were performed according to ISO 
standards.30 Extracts from the six thiolated polysaccharides were obtained at physiological 
temperature (37 °C). To prepare extracts, each material was incubated in regular cell culture 
media (concentration of 1 mg material/mL cell media) for 24 h. After 24 h, the resulting extracts 
were used for cell experiments.  
Extract study. To perform experiments with extracts, 8,000 cells per well were seeded in a 96-
well plate for MTS assay, 25,000 cells per well were seeded in a 24-well plate for LIVE/DEAD 
assay and 50,000 cells per well were seeded in a 24-well plate for assessing the morphology of 




MTS assay. For MTS assay, cells were incubated for 48 h. Six wells containing only cell culture 
media were used as a blank, six wells were used as a positive control, six wells were used as a 
negative control, and six wells were used for each material. For negative control, cells were 
exposed to methanol to reduce viability. After 45 min of exposure, the methanol was replaced by 
PBS to rinse the wells. PBS was replaced by fresh warm cell culture media. A 20 µL aliquot of 
MTS solution was added to each well. After 2 h incubation at 37 °C, absorbance readings were 
measured with a plate reader (BioTek Synergy 2) at 490 nm. 
LIVE/DEAD assay. To prepare the LIVE/DEAD solution, PI (to stain dead cells) and SYTO9 
(to stain live cells) were added to PBS at concentrations of 3 ε and 0.5 ε, respectively. Each 
time, three wells were used for positive control, three were used for negative control, and three 
wells were used for each material. For negative control, cells were exposed to methanol. After 45 
min of exposure, the methanol and the media in the other wells was replaced with PBS. The PBS 
was then removed and 500 µL of LIVE/DEAD solution was added to each well and incubated 
for 1 h at room temperature. Subsequently, the LIVE/DEAD solution was removed and PBS was 
added to each well. Fluorescence microscopy images were obtained using an Olympus IX73 
fluorescence microscope.  An excitation wavelength of 543 nm was used for PI (617 nm 
emission observed), and a wavelength of 488 nm was used for SYTO9 (500 nm emission 
observed). Images of cells used for LIVE/DEAD assay are composed of two overlayed images 
(PI and SYTO9), combined using the Olympus CellSens software. 
Morphological observations. Staining solution consisted of DAPI and Alexa Fluor® 568 
Phalloidin at concentrations of 7.60 ε and 6.60 ε, respectively, in PBS. Each time, three 
wells were used for positive control, three were used for negative control, and three wells were 




exposure, methanol was removed and all wells were rinsed twice with 150 mM PBS, and fixed 
with 3.7% methanol-free formaldehyde in PBS for 10 min at room temperature. All wells were 
rinsed twice with PBS and exposed to acetone cooled to 0 °C for 4 min, rinsed twice again with 
PBS, and stained using 0.5 mL of staining solution for 20 min at room temperature. All wells 
were finally rinsed three times with PBS and imaged. Fluorescence microscopy images were also 
taken using an Olympus IX73 fluorescence microscope. An excitation wavelength of 358 nm 
was used for DAPI (461 nm emission observed), and a wavelength of 578 nm was used for 
Alexa Fluor® 568 Phalloidin (600 nm emission observed). Images of cells are composed of two 
overlayed images (DAPI and Alexa), combined using the Olympus CellSens software. 
 
2.2.4. Synthesis of materials 
Chitin derivatives 
6-O-Tosyl chitin (1). Tosylated chitin was prepared by modifying a previously reported 
method.31 1.00 g chitin and 2.00 g lithium chloride were stirred in 50 mL DMA overnight to 
swell the polymer. The mixture was cooled to 0 °C and 7.56 mL TEA was added, followed by 
9.38 g of TsCl dissolved in 10 mL of DMA. The reaction was stirred for 24 h at 5 °C. The 
resulting solution was decanted into 200 mL acetone to precipitate the polymer and the mixture 
was stirred for 30 min. The material was filtered and washed with 200 mL methanol, 100 mL DI 
water, and 200 mL acetone, then placed under vacuum with constant stirring to evaporate 
residual solvent and homogenize the powder. IR max/cm-1 3600-3200 (O-H), 3281 (amide N-H), 
1657 (amide I), 1598 (aromatic C-C), 1538 (amide II), 1174 (S=O), 811 (tosyl aromatic C-H). 
Chitin-EDT (CH-EDT) (2a). 0.400 g of 6-O-tosyl chitin (1) and 0.750 g of lithium chloride 




were added, and the mixture was stirred for 20 h at 60 °C under nitrogen. The solution that 
formed over the course of the reaction was decanted into 200 mL acetone to precipitate the 
polymer and stirred for 30 min. The polymer was filtered, washed with 200 mL methanol and 
200 mL acetone, then vigorously stirred to homogenize the powder. The material was then 
suspended in 10 mL of 10 mM DTT and TEA in DMA and stirred for 1 h at room temperature. 
The product was recovered by filtration and washed with 200 mL methanol and 100 mL acetone, 
then placed under vacuum to remove residual solvent. IR νmax/cm-1 3600-3200 (O-H), 3277 
(amide N-H), 1652 (amide I), 1548 (amide II), 1027 (C-O). 
Chitin-PDT (CH-PDT) (3a). An analog was prepared following the general method provided 
for 2a, using 0.511 mL of PDT. IR νmax/cm-1 3600-3200 (O-H), 3293 (amide N-H), 1653 (amide 
I), 1537 (amide II), 1028 (C-O). 
Chitin-HDT (CH-HDT) (4a) . An analog was prepared following the general method provided 
for 2a, using 0.778 mL of HDT. IR νmax/cm-1 3600-3200 (O-H), 3280 (amide N-H), 1652 (amide 
I), 1541 (amide II), 1029 (C-O). 
S-Nitrosated chitin-EDT (2b). Chitin-EDT (2a) (40 mg/mL) was suspended in 80% 
DMA/methanol. 0.500 mL t-BuONO was added, and the mixture was stirred at RT for 14 h. 
After the reaction, the nitrosated polymer was briefly stirred in 100 mL methanol, then filtered 
and washed with 100 mL acetone and 25 mL diethyl ether. The material was placed under 
vacuum to evaporate any remaining solvent/t-BuONO, then immediately stored at -20 °C for 
future use. IR νmax/cm-1 3600-3200 (O-H),  3285 (amide N-H), 1652 (amide I), 1537 (amide II), 




S-Nitrosated chitin-PDT (3b). An analog was prepared from CH-PDT (3a) following the 
general method provided for 2b. IR νmax/cm-1 3600-3200 (O-H), 3282 (amide N-H), 1655 (amide 
I), 1544 (amide II), 1026 (C-O). UV-Vis max/nm 552 (S-nitrosothiol, nN → π*). 
S-Nitrosated chitin-HDT (4b). An analog was prepared from CH-HDT (4a) following the 
general method provided for 2b. IR νmax/cm-1 3600-3200 (O-H), 3272 (amide N-H), 1652 (amide 
I), 1546 (amide II), 1024 (C-O). UV-Vis max/nm 551 (S-nitrosothiol, nN → π*). 
Chitosan derivatives 
N-Phthaloyl chitosan (5). N-Phthaloyl chitosan was prepared by adapting a method for the 
selective N-phthaloylation of chitosan.32  3.00 g chitosan was added to a solution of 8.28 g 
phthalic anhydride dissolved in 57 mL of anhydrous DMF. The mixture was stirred for 4 h at 120 
°C, then briefly cooled below 100 °C and 3 mL DI water was added. After stirring for an 
additional 4 h at 120 °C, the solution was decanted into 1 L of cold DI water to precipitate the 
polymer, then filtered and washed with 200 mL methanol. The material was stirred overnight in 
300 mL methanol, then filtered and washed with methanol and acetone. IR νmax/cm-1 3600-3200 
(O-H), 1775 (C=O), 1704 (C=O), 1064 (C-O), 719 (aromatic C-H). 1  NεR H/ppm (400 MHz, 
DMSO-d6, Me4Si) 7.80 (s, N-phthaloyl), 7.45 (s, O-phthaloyl), 5.4 - 2.6 (m, carbohydrate). 
6-O-Tosyl-N-phthaloyl chitosan (5b). The tosylation of 5 was carried out by stirring 1.00 g of 
the polymer and 1.4 g LiCl in 35 mL DMA to form a solution. This solution was cooled to 0 °C 
and 5.29 mL TEA was added, followed by 6.57 g TsCl in 5 mL DMA.  The reaction was stirred 
for 24 h at 5 °C, then the solution was decanted into 200 mL acetone and stirred for 30 min. The 
precipitated polymer was washed with 200 mL methanol, 50 mL water, and 200 mL acetone, 




3600-3200 (O-H), 1776 (C=O), 1711 (C=O), 1175 (S=O), 1066 (C-O), 813 (tosyl aromatic C-H), 
720 (phthaloyl C-H). 
Chitosan-EDT (CS-EDT) (6a). 0.800 g of 5b was dissolved in 30 mL of DMA containing 1.5 g 
LiCl. 1.64 mL TEA was added, followed by 0.598 mL EDT. The mixture was stirred for 20 h at 
60 °C under nitrogen, then decanted into 200 mL methanol and stirred for 30 min. The polymer 
was filtered, washed with 100 mL methanol, then briefly stirred in 100 mL water adjusted to pH 
9 using TEA. This mixture was precipitated into methanol and the material was washed with 200 
mL methanol and 50 mL diethyl ether. The polymer was then stirred overnight at RT in 95% 
DMA/water. The following day, the polymer was recovered by filtration and stirred in 5 mL of 
hydrazine monohydrate at 80 °C for 5 h under nitrogen, then decanted into 50 mL methanol and 
recovered by filtration. The material was suspended in 10 mL 1% acetic acid containing 30 mg 
TCEP·HCl, and the mixture was stirred at RT for 1 h. The material was purified by 1 day of 
dialysis against 1% NaCl, followed by 2 days of dialysis against DI water. In all cases, the 
dialysis medium was adjusted to pH 5 using 1% HCl. The final product was isolated by 
lyophilization. IR νmax/cm-1 3600-3200 (O-H), 3334 (N-H), 3258 (N-H), 1061 (C-O). 
Chitosan-PDT (CS-PDT) (7a). An analog was prepared following the general method provided 
for 6a, using 0.716 mL of PDT. IR νmax/cm-1 3600-3200 (O-H), 3334 (N-H), 3260 (N-H), 1063 
(C-O). 
Chitosan-HDT (CS-HDT) (8a). An analog was prepared following the general method provided 
for 6a, using 1.09 mL of HDT. IR νmax/cm-1 3600-3200 (O-H), 3320 (amine N-H), 3242 (amine 
N-H), 1062 (C-O). 
S-Nitrosated chitosan-EDT (6b). 6a (5 mg/mL) was suspended in 70% methanol/water. 0.100 




stirred for 30 min at RT, then decanted into 25 mL of methanol. The polymer was briefly stirred 
in methanol, then filtered and washed with 100 mL methanol and 50 mL diethyl ether. The 
material was placed under vacuum to evaporate any remaining solvent/t-BuONO, then 
immediately stored at -20 °C for future use. IR νmax/cm-1 3600-3200 (O-H), 3335 (amine N-H), 
3253 (amine N-H), 1055 (C-O). UV-Vis max/nm 547 (S-nitrosothiol, nN → π*). 
S-Nitrosated chitosan-PDT (7b). An analog was prepared from 7a following the general 
method provided for 6b. IR νmax/cm-1: 3600-3200 (O-H), 3341 (amine N-H), 3224 (amine N-H), 
1058 (C-O). UV-Vis max/nm 546 (S-nitrosothiol, nN → π*).  
S-Nitrosated chitosan-HDT (8b). An analog was prepared from 8a following the general 
method provided for 6b. IR νmax/cm-1: 3600-3200 (O-H), 3344 (amine N-H), 3234 (amine N-H), 
1053 (C-O). UV-Vis max/nm 544 (S-nitrosothiol, nN → π*). 
 
2.3. Results and discussion 
2.3.1 Synthesis and characterization of thiolated polymers 
Thiolated chitin derivatives were prepared by synthesizing a 6-O-tosyl intermediate, 
followed by nucleophilic displacement with the symmetrical dithiols EDT, PDT, and HDT 
(Figure 2.1a). The tosylation reaction had been previously established by literature to occur 
preferentially at the C6 primary hydroxyl group over the less accessible C3 hydroxyl group.33,34 
Performing the reaction at low temperature further improves the selectivity and decreases the 
rate of undesirable side reactions.35 Effective tosylation of the polymer was supported by the 
development of IR features at 1598 cm-1 (aromatic C-C stretch), 1174 cm-1 (sulfonyl), and 811 
cm-1 (aromatic C-H out-of-plane bend), as well as a corresponding decrease in the feature at 




(amide II) confirmed the retention of the acetyl groups. The resulting 6-O-tosylated polymer 
exhibited high solubility in DMA/LiCl. Chitosan derivatives were prepared following a similar 
procedure, although it was necessary to protect the glucosamine units as the N-phthaloyl 
derivative to prevent the formation of sulfonamide during the tosylation step (Figure 2.1b). This 
was carried out by modifying a previously reported procedure for the selective N-phthaloylation 
of chitosan with phthalic anhydride in DMF.32 The synthesis of N-phthaloyl chitosan was 
confirmed by the loss of IR bands at 3359 and 3295 cm-1 orresponding to the N-H stretches of 
the primary amine, and the appearance of bands at 1775 cm-1 (C=O), 1704 cm-1 (C=O), and 719 
cm-1 (aromatic C-H out-of-plane bend) arising from the presence of the phthalimido 
moiety,while the band at 3600-3200 cm-1 (O-H) remained largely unchanged (Figure 2.3). 1H 
NMR further supports the selective protection of the primary amine through the distinct signal 
from the aromatic protons at 7.80 ppm (N-phthaloyl), with the significantly smaller peak at 7.45 
ppm corresponding to unhydrolyzed O-phthaloyl groups. Tosylation of the N-phthaloylated 
intermediate gave 6-O-tosyl-N-phthaloyl chitosan with distinguishing IR peaks at 1776 
 
Figure 2.1 (a) Synthesis of thiolated chitin derivatives. (i) TsCl, TEA in DMA/LiCl, 
24 h, 5 °C, (ii) HS(CH2)mSH (where methylene units, m, are 2, 3, or 6), TEA in 
DMA/LiCl, 20 h, 60 °C, DTT, TEA in DMA, 1 h, RT. (b) Synthesis of thiolated 
chitosan derivatives. (i) Phthalic anhydride in DMF, 8 h, 120 °C, (ii) TsCl, TEA in 
DMA/LiCl, 24 h, 5 °C, (iii) HS(CH2)mSH, TEA in DMA/LiCl, H2NNH2·H2O, 5 h, 80 
°C, TCEP·HCl in 1% AcOH, 1 h, RT. Reproduced by permission of The Royal 






(phthaloyl C=O), 1711 (phthaloyl C=O), 1175 (tosyl S=O), 813 (tosyl aromatic C-H), and 720 
(phthaloyl aromatic C-H). Symmetrical dithiols were selected as a convenient method of 
thiolating the tosylated intermediates, since their symmetrical structure avoids chemoselectivity 
issues that would be present in a bifunctional nucleophile or additional protection/deprotection 
steps requiring harsh conditions. To avoid the formation of polydisulfides or extensive 
crosslinking, the thiolations were performed under a nitrogen atmosphere. For all polymers, 
inclusion of the dithiols was confirmed by thiol quantificaton with Ellman’s assay (Table 2.1), 
and the diminished IR peak at 3600-3200 cm-1 that corroborated the expected loss of the C6 
hydroxyl group. While the IR bands associated with sulfhydryl, thioether, and disulfide groups 
are too weak to be clearly identified in the ATR-FTIR spectra of the thiolated derivatives, 
displacement of the tosyl group was monitored by the reduction in the features at approximately 
1600 cm-1, 1175 cm-1, and 815 cm-1.36 The weak feature retained at approximately 815 cm-1 in 
 
Figure 2.2 ATR-FTIR spectra of thiolated chitin derivatives. Reproduced by 





the IR spectra of all three thiolated chitin derivatives is attributable to formation of sulfonamide 
groups, which resulted from the reaction of glucosamine units with TsCl during the initial 
tosylation of chitin. This feature is not distinct in the spectra of the thiolated chitosan materials, 
where protection as the N-phthaloyl derivative may have prevented this reaction. Prior to thiol 
quantification, the primary amine groups of the chitosan derivatives were deprotected with 
aqueous hydrazine, which resulted in the reappearance of the characteristic N-H stretches at 
3400-3200 cm-1 corresponding to the primary amine groups and the loss of the IR features 
associated with incorporation of the phthaloyl group. Since the materials were uniformly 
insoluble in pH 8 phosphate buffer, it was necessary to perform Ellman’s assay under 
heterogeneous conditions, a method that had previously been employed to study other thiolated 
chitosan derivatives.29 In all cases, the samples were allowed to react with DTNB for 1 h prior to 
removal of aliquots for spectroscopic analysis. Extension of the reaction period did not result in 
 
Figure 2.3 ATR-FTIR spectra of thiolated chitosan derivatives. Reproduced by 





increased chromophore concentration and higher apparent thiol content, indicating that 1 h was 
sufficient to complete the reaction with active sulfhydryl groups.  
The thiolated chitin derivatives exhibited improved solubility in DMA/LiCl but did not 
dissolve to any appreciable extent in water, behavior that was consistent with the solubility 
characteristics of the parent polysaccharide.37 In contrast, the chitosan derivatives CS-EDT and 
CS-PDT were soluble in dilute aqueous acid, but only following disulfide reduction with 
TCEP·HCl suggesting that partial oxidation of the thiol groups and crosslinking occurred during 
the synthesis. The water solubility of CS-EDT and PDT was maintained for the entire dialysis 
period (3 days), but the lyophilized materials exhibited poor water solubility (presumably a result 
of disulfide formation) and were largely insoluble after several days of storage, although 
treatment with additional TCEP·HCl restored the original solubility characteristics. CS-HDT 
could not be dissolved in water at any stage before or after reduction, potentially indicating 
increased hydrophobicity due to incorporation of the 6-carbon mercaptohexyl chain.  
Table 2.1 Summarized thiol and NO content data for chitin and chitosan derivatives. 
Data reported as mean (≥3) ± SD. aValues determined by Ellman’s assay. bValues 
determined by NOA via thermal decomposition of the S-nitrosothiol. 
 









0.547 ± 0.021 
 
0.46 ± 0.081 
 
84 ± 15 
Chitin-PDT 0.288 ± 0.038 0.27 ± 0.052 94 ± 22 
Chitin-HDT 0.216 ± 0.009 0.14 ± 0.028 62 ± 13 
Chitosan-EDT 0.460 ± 0.056 0.40 ± 0.032 86 ± 13 
Chitosan-PDT 0.107 ± 0.008 0.040 ± 0.004 37 ± 4 





The thiolated chitosan derivatives exhibit uniformly lower thiol content than their chitin 
analogs, an outcome that is most directly attributable to the extended dialysis and lyophilization 
procedure used to purify the chitosan derivatives. This purification period may result in increased 
disulfide formation and consequently lower thiol content. While the thiolated chitin derivatives 
follow a predictable general trend where the increasing size of the dithiol results in a lower thiol 
content per unit of mass, in the case of the chitosan derivatives, lower thiol content was 
consistently observed for CS-PDT when compared to CS-HDT. This difference may be 
explained by the solubility of CS-PDT during the dialysis period (permitting the solution phase 
formation of disulfide linkages) and the tendency of the material to crosslink through disulfide 
formation, observed when the solubility of the polymer diminished rapidly following isolation. 
Since the chitin derivatives were stored at low temperature (-20 °C) immediately following 
reduction, no similar behavior was observed. 
 
2.3.2 Synthesis and characterization of S-nitrosated polymers 
 Thiol groups were converted to the corresponding S-nitrosothiol via reaction with t-
BuONO in 80% DMA/methanol for 14 h (chitin derivatives) or 70% methanol/water in the 
presence of acid for 30 min (chitosan derivatives) (Figure 2.4). The addition of methanol was not 
necessary to effect the S-nitrosation, but it was found to accelerate the reaction, potentially 
through a combination of solvent effects and the formation of an equilibrium concentration of 
dissolved methyl nitrite.38 The formation of S-nitrosothiols leads to two characteristic UV-Vis 
absorptions, the first between 330-350 nm (nO → π*) and the second in the approximate range of 
550-600 nm (nN → π* ).39 The latter feature was used to evaluate the success of the nitrosation 




prominent absorption in this region.40,41 The successful S-nitrosation of CH-EDT, PDT, and 
HDT was confirmed by the appearance of broad features at 549, 552, and 551 nm, respectively, 
in the DR UV-Vis spectra of the nitrosated materials (Figure 2.5). For CS-EDT, PDT, and HDT, 
these features appeared at 547, 546, and 544 nm. The development of the absorption near 550 
nm resulted in the materials acquiring the distinctive red/pink color characteristic of S-
nitrosothiols. For all polymers, preservation of the carbohydrate structure after the nitrosation 
was confirmed by the retention of characteristic IR peaks. The NO loading and release properties 
of each material were evaluated using NO-selective chemiluminescence-based NO analyzers, 
which rely on the gas-phase reaction of NO with ozone to produce excited state nitrogen dioxide 
(NO + O3 → NO2* + O2).42,43 The light emission from the relaxation of NO2* to the ground state 
is measured and used to quantify NO release. In all cases, measurements were performed in 
custom cells under deoxygenated conditions with a constant flow of nitrogen. The thermally-
releasable NO content of each material was determined by heating samples of the polymers to at 
least 120 °C, producing NO emission as a result of S-nitrosothiol decomposition (Table 2.1).  NO 
 
Figure 2.4 S-nitrosation of (a) thiolated chitin derivatives and (b) thiolated chitosan 





emission was monitored in real time and recorded until reaching baseline (Figure 2.6). In all 
cases, the prolonged heating resulted in visible degradation of the polymer itself, which became a 
blackened mass. This method was previously reported for similar NO-releasing polysaccharides, 
and permitted the calculation of NO content based on initial sample mass.28 To ensure that the 
detected NO could be exclusively attributed to S-nitrosothiol decomposition and not collateral 
thermal degradation of the polymer backbone, control studies were performed using unmodified 
chitin/chitosan both before and after exposure to t-BuONO under identical conditions. For both 
polysaccharides, there was no detectable NO release from the controls within the temperature 
range used to promote thermal decomposition of the S-nitrosated derivatives.  
The variation in total NO content is primarily attributable to differences in the amount of 
available thiol groups in each material. Differences in thiol conversion (defined as mol NO/mol 
thiol) between the three derivatives of each parent polysaccharide are most likely to be a 
consequence of both the rate of parallel S-nitrosothiol decomposition during the nitrosation 
process, as well as varying particle size and consistency between materials, leading to 
differences in the rate of solvent diffusion into the polymer. The former explanation may be a 
 
Figure 2.5 Diffuse reflectance UV-Vis spectra of S-nitrosated (a) chitin and (b) 
chitosan derivatives depicting the characteristic nN → π* transition of S-nitrosothiols. 
UV-Vis max/nm 549 (chitin-EDT), 552 (chitin-PDT), 551 (chitin-HDT), 547 
(chitosan-EDT), 546 (chitosan-PDT), and 544 (chitosan-HDT). Reproduced by 





more important factor in the nitrosation of chitin derivatives due to the extended nitrosation 
period (14 h), while the latter explanation may better account for differences in the chitosan 
derivatives. This process is demonstrated by the low level of conversion (% NO/thiol content) in 
the case of CS-PDT, which was denser than the EDT and HDT analogs (potentially due to 
crosslinking) and had larger particle sizes during the heterogeneous nitrosation.  
To assess the NO loading characteristics of the materials relative to other S-nitrosated NO-
releasing polysaccharides, the chitin and chitosan derivatives were compared with our previously 
reported S-nitrosated dextran derivatives. The NO content of the chitin and chitosan derivatives 
(as high as 0.46 ± 0.081 mmol NO/g polymer for CH-EDT) compares favorably with values for 
the dextran-based materials, where a maximum NO content of 0.205 mmol NO/g polymer was 
determined for an S-nitrosated dextran-cysteamine conjugate.28 The NO content of the S-
nitrosated chitin and chitosan derivatives may also be compared with existing NO releasing 
chitosan derivatives prepared through the formation of N-diazeniumdiolates, which have 
reported total NO content in the range of 0.200 mmol/g for chitosan-NO adducts synthesized 
 
Figure 2.6 Representative thermal decomposition of chitosan-EDT. The material was heated 
to 120 °C under a nitrogen atmosphere and the resulting nitric oxide (NO) emission was 
measured by chemiluminescence-based detection until returning to baseline. This process 
caused accelerated decomposition of the S-nitrosothiol, liberating quantifiable NO, and 
resulted in the concomitant decomposition of the polysaccharide backbone. Reproduced by 





from the direct reaction of NO with chitosan to 0.87 mmol/g for water-soluble N-
diazeniumdiolated chitosan oligosaccharides.23,24 NO release under physiological conditions was 
evaluated by suspending samples of the polymers in deoxygenated 10 mM PBS (pH 7.4) at 37 
°C under a nitrogen atmosphere and recording the resulting NO release profile for at least 24 h 
(Figure 2.7, Table 2.2).44 CH-HDT was observed to release a lower proportion of the total NO 
content over a 24 h period than EDT and PDT derivatives, which may be attributable to impaired 
solvent diffusion due to the greater hydrophobicity of that material. For all chitin derivatives, 
detectable NO release continued for over 72 h, although the majority of the release occurred 
within a 6 h period (Figure 2.8a). In the case of the chitosan derivatives, NO recovery was nearly 
quantitative after 24 h, reflecting the greater hydrophilicity of the deacetylated variants when 
compared to their chitin analogs. As noted for the chitin derivatives, the S-nitrosated chitosan 






Figure 2.7 Cumulative NO release after 24 h from (a) S-nitrosated chitin derivatives and (b) 
S-nitrosated chitosan derivatives under physiological conditions (pH 7.4 PBS, 37 °C). 







2.3.3 Cytotoxicity studies 
The relative biocompatibility of the six thiolated derivatives was evaluated using an extract 
approach based on the commonly accepted ISO regulation 10993 part 5.30 Two cytotoxicity tests 
(MTS and LIVE/DEAD) and morphological observations were used to ensure their suitability for 
Table 2.2 Cumulative NO released over 24 h under physiological conditions. Data 
reported as mean (n  ≥3) ± SD. aValue determined by NOA in 10 mM pH 7.4 PBS, 37 
°C. 
 
Material NO release 
(mmol g-1)a 
NO recovery 




0.19 ± 0.025 
 
42 ± 9 
Chitin-PDT 0.12 ± 0.017 45 ± 11 
Chitin-HDT 0.042 ± 0.005 31 ± 7 
Chitosan-EDT 0.39 ± 0.028 99 ± 11 
Chitosan-PDT 0.042 ± 0.004 110 ± 14 
Chitosan-HDT 0.087 ± 0.007 81 ± 25 
 
Figure 2.8 Initial real-time NO release profile (6 h). (a) S-nitrosated chitin and (b) 





biomedical applications. MTS assay tests mitochondrial activity in live cells and is therefore an 
excellent indicator of the biocompatibility of new materials.44 Figure 2.9 shows the results of 
MTS experiments for extracts from all of the thiolated chitin and chitosan derivatives. For the 
majority of the thiolated derivatives, there was no decrease in cellular viability (normalized with 
the control sample) when cells were exposed to the extracts. On the contrary, residual material 
present in the extract promoted cell proliferation as shown in Figure 2.9 (% viability > 100%). 
These results are not surprising as both chitin and chitosan have been used by other authors to 
enhance cell proliferation.45-47 In addition, the results suggest that there were no toxic leachables 
(i.e. residual solvents/reagents or toxic hydrolysis products) at a cytotoxic concentration present 
in these five extracts. Only CS-EDT resulted in viability lower than 70%, and this polysaccharide 
is consequently the only thiolated derivative considered cytotoxic for human dermal fibroblasts, 
likely indicating the presence of toxic degradation products in the material that are released 
during the extract process.30 Since CS-EDT is purified by dialysis, it is unlikely that solvent or 
 
Figure 2.9 MTS assay results for cultured human dermal fibroblasts in the presence 
of cell culture media. Red line indicates viability of 70% below which the material is 
considered cytotoxic for human dermal fibroblasts. From left to right: (1) positive 
control, (2) negative control, (3) chitin-EDT, (4) chitin-PDT, (5) chitin-HDT, (6) 
chitosan-EDT, (7) chitosan-PDT, and (8) chitosan-HDT. Reproduced by permission 





residual reagents such as TCEP remain present in the polymer, and any such contaminants were 
not detected by ATR-FTIR. It is more plausible that hydrolytic degradation of the polymer 
resulted in the release of trace thiolated (EDT) monomeric or oligomeric species that were 
cytotoxic. Since no cytotoxicity was observed for CH-EDT, this outcome may be explained by 
increased solvent permeation in the case of the chitosan derivative, increasing the extent of 
hydrolysis, or unique degradation products resulting from structural differences between the 
polymers (primarily in the form of N-acetylation in the case of CH-EDT).  
Similar results to MTS assay were observed when the LIVE/DEAD assay was performed. 
Figure 2.10a shows HDF that have not been exposed to methanol or any extract. The green color 
indicates that the cell membrane is intact, therefore the cells are viable. Figure 2.10b shows cells 
exposed to methanol. In the case of this negative control, cells were fixed when exposed to 
 
Figure 2.10 LIVE/DEAD studies. Overlaid fluorescence microscopy images of 
human dermal fibroblasts attached to a TC plate for 72 hours using: cell culture 
media or positive control (a), cell culture media and exposure to methanol prior 
staining or negative control (b) extract from chitin derivatives (c, d, e) and 
extract from chitosan derivatives (f, g, h). Green cells are considered alive and 






methanol and the membrane was disrupted. As a consequence the color of the HDF is a mixture 
of the red and green staining. A comparable ratio of LIVE/DEAD cells was observed in the 
positive control sample and in all thiolated derivatives with the exclusion of CS-EDT. A lower 
number of viable cells were observed for cells cultured with CS-EDT extract and only isolated 
areas were covered with cells (Figure 2.10f), corroborating the lower viability. Therefore, it can 
be said that five out of the six thiolated derivatives are considered biocompatible with HDF. 
In terms of cell morphological observations, Figure 2.11 revealed cells with normal 
morphology, spreading and growing to confluency for all thiolated derivatives except CS-EDT. 
When cells were cultured using the CS-EDT extract, a significant reduction in the area covered 
by HDF was observed. However, cells showed normal morphology and spreading as seen in 
Figure 2.11f, indicating that in the presence of the CS-EDT extract cell morphology is not 
 
Figure 2.11 Morphological studies. Overlaid fluorescence microscopy images of 
human dermal fibroblasts attached to a TC plate for 72 hours using: cell culture media 
(a), cell culture media and exposure to methanol prior staining (b) extract from chitin 
derivatives (c, d, e) and extract from chitosan derivatives (f, g, h). Blue areas are cell 
nuclei and red areas are cell membranes. Reproduced by permission of The Royal 





affected.  This observation confirms that five out the six thiolated derivatives do not induce any 
changes in the HDF morphology, therefore, they are not considered cytotoxic to HDF. 
 
2.4. Conclusions 
NO-releasing derivatives of chitin and chitosan were prepared through conjugation of the 
symmetrical dithiols EDT, PDT, and HDT to the polysaccharides, followed by S-nitrosation of 
the resulting thiolated polymers with -BuONO. In the case of chitin, this work is the first report 
of S-nitrosated derivatives for biomedical applications. For chitosan, a synthetic route to 
thiolated and S-nitrosated derivatives has been presented that results in the retention of the C2 
primary amine, leaving it available for polyelectrolyte formation or further covalent 
derivatization. The free sulfhydryl content of the thiolated intermediates was assessed by 
Ellman’s assay, and the NO loading and physiological release characteristics were evaluated 
using real-time NO chemiluminescence-based NO measurements. In all cases, the primary factor 
in the total NO content of each material was the quantity of unoxidized thiol present prior to the 
nitrosation procedure. All six materials released NO under physiological conditions, with 
continuous release occurring for at least 24 h. In the case of the chitosan derivatives, NO 
recovery from chitosan derivatives was nearly quantitative after the 24 h period, an outcome that 
was attributable to increased solvent permeation. Five of the thiolated derivatives presented cell 
viability higher than 70% and only CS-EDT was considered cytotoxic, as corroborated by MTS 
and LIVE/DEAD assays. In addition, no changes in morphology were observed in the presence 
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Biodegradable polymeric materials have been widely utilized in the development of 
medical devices such as sutures, bioabsorbable or drug-eluting stents, implants for tissue 
engineering, and numerous other products for a variety of biomedical applications.1 The majority 
of existing synthetic biodegradable polymers are polyesters, a broad category that includes 
widely-utilized materials such as polyglycolic acid (PGA), polylactic acid (PLA), poly(lactic-co-
glycolic acid) (PLGA), poly(-caprolactone) (PCL), and numerous others.2 In addition to 
polyesters, other biodegradable polymers have been investigated for use in biomedical 
applications, ranging from natural polysaccharides such as chitosan to synthetic polymers like 
polyanhydrides, polyorthoesters, polyphosphoesters, and polyphosphazenes.3-5 
Polyphosphazenes are a promising class of synthetic polymers that have been extensively 
investigated for various applications, and consist of a polymeric inorganic backbone containing 
alternating phosphorus and nitrogen atoms.6 Geminal substitution of the phosphorus atom to 
incorporate organic pendant groups yields poly(organophosphazenes) (POPs), a particularly 
diverse polymer class that includes hundreds of structurally distinct members with varying 
physicochemical properties determined by the nature of the organic substituents.7 The use of side 
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groups derived from amino acids such as glycine, L-alanine, L-cysteine, and others results in 
hydrolytically-sensitive polymers that slowly hydrolyze to release the amino acid, with the 
polymer backbone degrading to form low-toxicity ammonia and phosphate products.8-11 Such 
materials have been investigated for biomedical applications that range from tissue engineering 
to drug delivery.12  
A critical concern in the development of any polymeric biomaterial has been the potential 
for adverse physiological responses that arise from the interaction of the material and the 
surrounding biological environment.13 Implantation of a biomaterial or medical device initiates a 
complex sequence of biological responses at the biointerface that can lead to persistent 
inflammation, thrombosis, and fouling that may ultimately lead to unfavorable medical 
outcomes.14,15 Efforts to improve the blood and tissue compatibility of biomaterials have 
frequently focused on the development of drug-elution systems that reduce thrombogenicity or 
otherwise mitigate adverse host responses.16,17 Such materials have incorporated various anti-
inflammatory drugs as well as anticoagulative therapeutics such as heparin and nitric oxide 
(NO).18-20 NO is a promising therapeutic agent that occurs endogenously as a regulatory 
molecule in many physiological processes, including vasodilation, neurotransmission, and the 
immune response.21-23 In addition, NO has a crucial role in maintaining the natural function of 
the endothelium.24 Under normal conditions, vascular NO is produced by endothelial cells 
through enzymatic oxidation of L-arginine to citrulline.25 This physiologically-produced NO 
exerts antithrombotic effects by contributing to the inhibition of platelet adhesion to the 
endothelium.26 The disruption of endothelial function that occurs after the introduction of a 
vascular implant may subsequently lead to thrombosis.27 For this reason, numerous authors have 




of the natural endothelium and improving the performance of blood-contacting implants.28 
Furthermore, it has been shown that NO exhibits antimicrobial properties that inhibit bacterial 
proliferation and may prevent the formation of biofilms that often lead to infection following the 
implantation of devices such as catheters.29,30 It has also been shown that NO modulates wound 
repair, and exogenous supplementation with NO has been observed to result in improved wound 
healing time in the case of both soft tissue and bone fractures.31-35  
Although inhaled NO has been utilized as a therapeutic for the treatment of pulmonary 
disorders, its short in vivo half-life (milliseconds to seconds) results in rapidly diminishing 
concentration as the distance from the point of origin increases.36,37 As a consequence, NO 
supplementation as a method of improving biomaterial performance is best achieved through its 
localized delivery at biological interfaces. To effect the controllable administration of therapeutic 
NO at biological interfaces, NO prodrugs are employed in the form of molecules containing 
functional groups that decompose to release NO under physiological conditions. The most 
common NO donor groups of this type are N-diazeniumdiolates and S-nitrosothiols (RSNOs), 
which are respectively synthesized from secondary amines and thiols and have been conjugated 
to various polymer systems to confer NO release properties.38 Additional direct, indirect, or 
conditional NO donor species include inorganic complexes such as sodium nitroprusside and 
Angeli’s salt, as well as the heterocyclic sydnonimines and furoxans, among others.39 One 
potential advantage to the use of S-nitrosothiols is their well-characterized decomposition 
through thermal, photolytic, or transition metal-catalyzed pathways to yield NO and relatively 
benign disulfide according to the equation 2 RSNO → 2 NO + RSSR.40 In comparison, N-
diazeniumdiolates decompose to form the parent secondary amine, which may subsequently 




Nitrosothiols with diverse structures and release properties are easily synthesized from the parent 
thiols in a single step, while many alternative NO donor species may require comparatively 
complex syntheses. Furthermore, unlike wholly synthetic NO donors, S-nitrosothiols have been 
identified as endogenous species in the form of S-nitrosoalbumin and S-nitrosoglutathione 
(GSNO) and have been determined to occur naturally at concentrations in the pM-ε range.42-45 
For these reasons, the use of an S-nitrosothiol to impart NO release function to a 
polyphosphazene may represent a meaningful contribution to the field of NO-releasing 
biomaterials. Such a material may potentially serve in the traditional tissue engineering roles 
proposed for biodegradable polyphosphazenes and presents an alternative to more common 
polyester-based NO-releasing polymers. 
In this work, we report the first synthesis of an NO-releasing poly(organophosphazene) 
containing S-nitrosothiol groups as NO donor moieties. The polymer was prepared by 
substitution of poly(dichlorophosphazene) with ethyl S-methylthiocysteinate, followed by partial 
cleavage of the disulfide linkages to provide free sulfhydryl groups for subsequent conversion to 
the S-nitrosothiol derivative using tert-butyl nitrite (t-BuONO).  The resulting polymer was 
characterized by 1H, 13C, and 31P NMR, ATR-FTIR, and UV-Vis spectroscopy. The free 
sulfhydryl content of the intermediate thiolated polymer was evaluated colorimetrically using a 
modified Ellman’s assay protocol with bis(2,4-dinitrophenyl) disulfide and by 1H NMR 
spectroscopy. The total NO content of the NO-releasing polymer (mmol NO g-1) was determined 
by solution-phase UV decomposition of the S-nitrosothiol functional group and subsequent 
chemiluminescence-based quantification of the corresponding NO release. To demonstrate the 
ability of the material to deliver NO under physiological conditions, polymer samples were 




continuously monitored. In addition, an extract-based approach was employed to evaluate the 
cytotoxicity of both the thiolated and S-nitrosated polymers with respect to human dermal 
fibroblasts (HDF). Our results indicate that poly(organophosphazenes) bearing S-n trosothiol 
functional groups may be suitable as NO-releasing biomaterials. 
 
3.2. Materials and methods 
3.2.1 Materials 
L-Cysteine ethyl ester hydrochloride (98+%), lithium bis(trimethylsilyl)amide (LiHMDS, 99%), 
sulfuryl chloride (97%), and triethylamine (TEA, 99+%) were purchased from Alfa Aesar (Ward 
Hill, MA, USA). 2-Mercaptoethanol (99%) was purchased from AMRESCO (Solon, OH, USA). 
Phosphate buffered saline (PBS) tablets were purchased from EMD Chemicals (Gibbstown, NJ, 
USA). tert-Butyl nitrite (t-BuONO, 90%) was purchased from Sigma-Aldrich (St. Louis, MO, 
USA). Phosphorus pentachloride (98%) and phosphorus trichloride (98+%) were purchased from 
Strem Chemicals, Inc. (Newburyport, MA, USA). S-Methyl methanethiosulfonate (MMTS, 
97+%) was purchased from TCI America (Portland, OR, USA). Human dermal fibroblasts 
(HDF) were grown in the Ketul Popat lab at Colorado State University. High-glucose Dulbecco’s 
modified Eagle’s medium (DεEε) was purchased from Hyclone (εanassas, VA, USA) and 
supplemented with penicillin-streptomycin and fetal bovine serum. CellTiter-Blue was purchased 
from Promega (Madison, WI, USA). Trypsin-EDTA, propidium iodide (PI), SYTO 9, Alexa 
Fluor 568 Phalloidin, and DAPI were purchased from Life Technologies (Grand Island, NY, 
USA). TEA was distilled from calcium hydride. Sulfuryl chloride and phosphorus trichloride 





3.2.2 General characterization techniques 
NMR spectra were acquired using an Agilent (Varian) Inova 400 MHz FT-NMR (Agilent 
Technologies,  Inc., Santa Clara, CA, USA). For 1H NMR spectra in D2O, chemical shifts 
were referenced to maleic acid (H = 6.2 ppm) and shifts for 31P NMR spectra were 
referenced to triphenylphosphine (P = -6 ppm). ATR-FTIR spectra were recorded in the 
range of 650-4000 cm-1 using a Nicolet 6700 spectrometer (Thermo Electron Corporation, 
Madison, WI, USA). UV-Vis absorption studies were performed using a Nicolet 
Evolution 300 spectrophotometer (Thermo Electron Corporation). Polymer molecular 
weight was characterized by gel permeation chromatography (GPC) using a Waters 
University 1500 GPC instrument (Waters, Milford, MA, USA). Thermal properties of the 
polymer were evaluated by differential scanning calorimetry with a TA Instruments DSC 
2920 and the decomposition temperature was determined using a TA Instruments TGA 
2950 (TA Instruments, New Castle, DE, USA). For cell viability studies, absorbance 
measurements were obtained using a BioTek Synergy 2 microplate reader (BioTek, 
Winooski, VT, USA). LIVE/DEAD assay and morphological cell images were taken with 
an Olympus IX73 inverted fluorescence microscope at 10X magnification and processed 
using Olympus CellSens software (Olympus, PA, USA). 
Nitric oxide content determination by UV decomposition. The total NO content of the S-
nitrosated polymer (mmol g-1) was determined using a Sievers chemiluminescence-based NO 
analyzer (NOA 280i) (GE Analytical Instruments, Boulder, CO, USA). Prior to use, the 
NO analyzer was calibrated with UHP nitrogen zero gas and 45 ppm NO/nitrogen. 
Polymer samples (n ≥3, data reported as mean ± SD) were dissolved in DMF (1 mg mL-1) 




spectrum (200-600 nm) was acquired for each dilution and 100 µL aliquots of the polymer 
solutions were injected into customized glass gas-flow cells containing deoxygenated DMF 
with a nitrogen flow/purge gas. The photolytic decomposition of the S-nitrosothiol 
functional group was induced by irradiation with 365 nm light using a 100 W Blak-Ray 
B-100AP UV lamp (UVP, Upland, CA, USA). Released NO was continuously purged 
from the DMF solution and transported into the NO analyzer with nitrogen flow gas (200 
mL min-1). The output concentration as a function of time was related to total NO release 
using a calibration constant (mol NO ppb-1 s-1) previously determined by reduction of 
sodium nitrite and verified by decomposition of the S-nitrosothiol GSNO. This process 
was used to calculate the total quantity of releasable NO present in a given mass of 
polymer. In addition, the NO release resulting from the injection of each aliquot of 
polymer solution was used to establish a linear relationship between releasable NO and 
the UV absorbance feature at 337 nm, and the molar extinction coefficient for the 
polymer-bound S-nitrosothiol was calculated. 
Nitric oxide release. To assess the NO release properties under physiological conditions, 
S-nitrosated polymer samples (n = 3, data reported as mean ± SD) were suspended as 
insoluble coarse powders (0.2 mg mL-1) in 5 mL deoxygenated 10 mM pH 7.4 PBS at 37 
°C and protected from ambient light for the duration of the experiment. Released NO was purged 
from the buffer solution and monitored over 24 h by NO analyzer as described previously. At the 
end of each experiment, the polymer was exposed to 365 nm UV light at 40 °C to decompose 
remaining S-nitrosothiol. Similar procedures were used to evaluate NO release from the polymer 
at 25 °C in pH 7.4 PBS, 37 °C in pH 5.0 acetate buffer (10 mM sodium acetate/acetic acid), and 




dissolved with 2 mL deoxygenated DMF prior to UV decomposition. Statistical differences were 
evaluated by single-factor ANOVA analysis and Tukey’s range test (p < 0.05). 
Polymer degradation study. 20.00 mg samples (n = 5) of both the thiolated and S-
nitrosated polymers were incubated in 5 mL of 10 mM pH 7.4 PBS at 37 °C for 6 weeks. 
During this period, the samples were continuously agitated and protected from exposure to 
ambient light. At the end of each week, the buffer was removed and the samples were washed 
with Millipore water and lyophilized. The dry weight of each sample was subsequently recorded. 
 
3.2.3 Precursor and polymer synthesis 
Ethyl S-methylthiocysteinate hydrochloride (1). 4.00 g (21.5 mmol) L-cysteine ethyl ester 
hydrochloride was dissolved in 80 mL ethanol and 2.24 mL (23.7 mmol, 1.1 eq.) MMTS was 
added. The mixture was stirred overnight at RT, followed by reduction of the solvent volume to 
approximately 20 mL by rotary evaporation. The product was precipitated by the addition of 100 
mL diethyl ether, then filtered and washed with 3 × 50 mL diethyl ether. Residual solvent was 
removed by vacuum to yield 3.01 g (60%) of fine white crystals. 1H NMR H/ppm (400 MHz, 
D2O): 4.34 (dd, -CH-), 4.18-4.07 (m, -OCH2-), 3.20-3.09 (m, -SSCH2-), 2.25 (s, -SSCH3), 1.12 
(t, -CH3). 
Trichloro(trimethylsilyl)phosphoranimine (2).  16.6 g (99 mmol) of LiHMDS was suspended 
in 200 mL of anhydrous diethyl ether under an inert nitrogen atmosphere and cooled to 0 °C. 
8.70 mL (99 mmol, 1 eq.) of phosphorus trichloride was slowly added to the mixture over 30 
min.  The reaction was allowed to warm to RT and was stirred for 1 h, then cooled to 0 °C and 
7.98 mL (99 mmol, 1 eq.) sulfuryl chloride was added over 30 min. The mixture was stirred for 1 




filtered and the solvent was removed under vacuum to isolate the crude product. The purified 
compound was collected by vacuum distillation (21 °C, 1 Torr) as a colorless liquid and was 
stored at -20 °C prior to use. The final recovery was 15.0 g (67%). 1H NMR H/ppm (400 MHz, 
CDCl3): 0.18 ppm (d, -Si(CH3)3).  31P NMR P/ppm (162 MHz, CDCl3): -55 ppm (s).  
Poly(dichlorophosphazene) (PDCP) (3). 1.5 g of phosphoranimine 2 was dissolved in 5 mL of 
dichloromethane containing 3.5 x 10-2 M phosphorus pentachloride as initiator. The mixture was 
stirred under nitrogen for 2.5 h and the resulting polymer was isolated under vacuum. 31P NMR 
P/ppm (162 MHz, CDCl3): -18 ppm (s). 
Poly(bis(ethyl S-methylthiocysteinyl)phosphazene) (POP-EtCys) (4). A typical synthesis 
proceeded from 3 (0.795 g) as follows: 3.50 g (15.1 mmol, 2.2 eq. relative to 
dichlorophosphazene units) of 1 was suspended in 50 mL dry THF. 5.26 mL (37.8 mmol, 2.5 eq. 
relative to ethyl S-methylthiocysteinate) of TEA was added, and the mixture was stirred under 
nitrogen at 40 °C for 24 h. The mixture was cooled to room temperature and filtered into a 
solution of 3 dissolved in 10 mL dry THF. The resulting cloudy solution was stirred at 40 °C 
under nitrogen for 28 h, then filtered to remove solids and slowly decanted into 400 mL hexanes 
to precipitate the polymer. The polymer was washed with 5 × 100 mL hexanes and placed under 
vacuum to remove residual solvent to recover 1.81 g (61%) of poly(bis(ethyl S-
methylthiocysteinyl)phosphazene) as a coarse powder. 1H NMR H/ppm (400 MHz, CDCl3): 4.6-
4.0 (-CH-, -OCH2-), 3.29 (-SSCH2-), 2.43 (-SSCH3), 1.31 (-CH3). 
Poly(ethyl S-methylthiocysteinyl-co-ethyl cysteinyl phosphazene) (POP-EtCys-SH) (5).  The 
disulfide groups of 4 were partially cleaved by treatment with 2-mercaptoethanol. In a typical 
protocol, the polymer from the previous step was dissolved in a mixture of 60 mL ethanol/30 mL 




under nitrogen at 40 °C for 48 h, then reduced to approximately half the original volume under 
vacuum. This solution was filtered and decanted into 400 mL hexanes to precipitate the polymer, 
which was subsequently washed with 5 × 100 mL hexanes. The polymer was then dissolved in 
10 mL DCM, washed with 3 × 5 mL water to remove remaining 2-mercaptoethanol, then dried 
with anhydrous MgSO4, filtered, and isolated under vacuum. To ensure the removal of water, the 
polymer was frozen with liquid nitrogen and lyophilized for 24 h. The final recovered yield was 
1.14 g. 1H NMR H/ppm (400 MHz, CDCl3): 4.6-4.0 (-CH-, -OCH2-), 3.29 (-SSCH2-), 2.43 (-
SSCH3), 1.83 (-SH), 1.31 (-CH3). 13C NMR C/ppm (100 MHz, CDCl3): 173 (-CO2-), 61 (-
OCH2-), 54 (-CH-), 43 (-SSCH2-), 23 (-SSCH3), 14 (-CH3). 31P NMR P/ppm (162 MHz, 
CDCl3): -2.6 (s). IR νmax/cm-1: 3320, 2980, 2914, 1732, 1417, 1367, 1295, 1180, 1117, 
1026, 948, 853, 792, 760, 698. UV-Vis max/nm (DMF): 267 (disulfide). 
S-Nitrosation of poly(ethyl S-methylthiocysteinyl-co-ethyl cysteinyl phosphazene) (POP-
EtCys-NO) (6) 10% v/v t-BuONO in ethanol was prepared at 0 °C and used to suspend 5 at a
concentration of 125 mg/mL. The resulting solution was agitated at room temperature for 15 
min, then evaporated under vacuum to yield the S-nitrosated polymer. IR νmax/cm-1: 3300, 
2977, 2915, 1732, 1520, 1367, 1296, 1180, 1117, 1024, 950, 920, 853, 794, 763, 750, 
699. UV-Vis max/nm (DMF): 267 (disulfide), 337 (S-nitrosothiol, π→π*, ε = 810 ± 20 M-1 
cm-1 ), 547 (S-nitrosothiol, n→π*). 
 
3.2.4 Cell studies 
HDF were cultured in Hyclone high-glucose DMEM until reaching approximately 90% 




flasks using trypsin-EDTA (0.25%) in order to perform viability, LIVE/DEAD, and 
morphological assays. 
Extract preparation. HDF studies were performed following the general guidelines of 
ISO 10993.46 Polymer samples (POP-EtCys-SH and POP-EtCys-NO) were suspended in 
cell media under physiological conditions (37 °C with 5% CO2 in a humid environment) 
at a concentration of 10 mg/mL for 24 h prior to the cell experiments. Cell media was 
removed after the 24 h extraction period and used to perform subsequent cell 
experiments.   
CellTiter-Blue viability assay. 25,000 cells per well (n = 9) were seeded in a 24-well 
plate (TC polystyrene) for 48 h under physiological conditions (37 °C with 5% CO2 in a 
humid environment), and the cell medium was exchanged after 24 h. When the 48 h 
incubation period had elapsed, the medium was replaced with the respective material 
 
Figure 3.1 Synthesis of S-nitrosated poly(ethyl S-methylthiocysteinyl-co-ethyl 
cysteinyl phosphazene) and precursors. (a) Synthesis of ethyl S-
methylthiocysteinate, (b) synthesis of poly(ethyl S-methylthiocysteinyl-co-ethyl 
cysteinyl phosphazene) (POP-EtCys-SH), (c) S-nitrosation of POP-EtCys-SH (POP-






extract (POP-EtCys-SH/POP-EtCys-NO) or pure cell growth medium as a positive 
control and cells were allowed to grow for an additional 24 h. The medium was 
subsequently removed and wells were washed once with PBS, then exposed to 400 δ 
CellTiter-Blue solution prepared from 20 δ of CellTiter-Blue reagent combined with 
100 δ warmed HDF media. The plate was incubated at 37 °C  for 4 h before 100 δ 
aliquots were transferred to a 96-well plate and the absorbance at 570 and 600 nm was 
obtained using a plate reader. Absorbance values were used to calculate cell viability by 
comparison to positive controls. 
LIVE/DEAD assay. 25,000 cells per well (n = 6) were seeded in a 24-well plate for 48 h, 
with a medium change at 24 h. After 48 h, the medium was replaced with the material 
extract (POP-EtCys-NO) or pure medium as a positive control and cells were allowed to 
grow for an additional 24 h. For negative control, the medium was removed, the wells 
were washed once with sodium chloride solution, then methanol was added. The plate 
was incubated at RT for 45 min to allow the methanol to disrupt the cell membranes 
before proceeding with the assay. The cell medium (or methanol) was removed and wells 
were washed twice with sodium chloride before the two stains (PI and SYTO 9) were 
added to each well. Staining solution was prepared f om 2 δ PI with 0.7 δ SYTO λ/1 
mL NaCl solution. The plates were incubated for 1 h  at RT before imaging by 
fluorescence microscope. The excitiation and emission wavelengths for PI and SYTO 9 
were 533/617 nm and 485/498 nm, respectively. 
Morphological assay. 50,000 cells per well (n = 6) were seeded in a 24-well plate for 48 
h with a medium change at 24 h. After 48 h, the medium was replaced with the respectiv  




an additional 24 h. The medium was subsequently removed and wells were washed twice 
with PBS. Formaldehyde solution (3.7% in PBS) was added to each well and allowed to 
sit at RT for 10 min. The solution was removed, wells were washed twice with PBS, and 
cold acetone was added to the wells for an additional 3 min. The acetone was removed, 
wells were washed twice with PBS, and the two stains (Alexa and DAPI) were added to 
each well. The staining solution was prepared from 25.5 δ Alexa and 1.4 δ DAPI/1 mδ 
PBS. Wells were imaged by fluoresence microscope after sitting for an additional 20 min. 
The excitiation and emission wavelengths for Alexa and DAPI were 578/600 nm and 
360/460 nm, respectively. 
 
3.3. Results and discussion 
3.3.1. Synthesis of poly(bis(ethyl S-methylthiocysteinyl)phosphazene) and deprotection 
Polyphosphazene derivatives with organic pendant groups are commonly 
synthesized from the precursor PDCP, which is prepared from the thermal ring-ope ing 
polymerization of hexachlorocyclotriphosphazene (HCCP) or by PCl5-initiated 
polymerization of trichloro(trimethylsilyl)phosphoranimine.47,48 It was anticipated from 
previous reports and the established behavior of thiol-bearing polymers that disulfide-
forming oxidative crosslinking might impair the solubility of high molecular weight thiol-
substituted POPs, therefore trichloro(trimethylsilyl)phosphoranimine was utilized to prepare 
lower molecular weight PDCP for subsequent modification.10,49 The phosphoranimine was 
synthesized following a protocol previously reported by Wang et al. and gave a 67% total 
recovery after distillation.50 While the synthesis and purification of the highly-reactive 




the purified compound tolerated brief exposure to atmosphere at 20 °C (RH = 25%) without 
detectable changes in the 1H or 31P NMR spectra (Figure 3.2 and 3.3a). The phosphoranimine 
was subsequently polymerized in DCM using PCl5 as initiator to give viscous PDCP as the 
product, which was characterized by 31P NMR and found to be consistent with literature reports 
(Figure 3.3b).51 The synthesis of the cysteine-substituted polyphosphazene was carried out 
using a procedure modified from one previously reported by Weikel t al., where the thiol 
group of ethyl cysteinate was first protected as an asymmetric disulfide derivative prior to 
reaction with PDCP.10 This strategy was employed to avoid chemoselectivity issues 
arising from nucleophilic competition of the thiol and amine groups of ethyl cysteinate 
during reaction with PDCP. While Weikel employed S-ethyl ethanethiosulfinate as the 
thiol protecting agent, we converted ethyl cysteinate hydrochloride to the methyl disulfide 
derivative by treatment with commercially available MMTS, a reagent commonly utilized 
to effect the reversible blockage of cysteine residues in proteins.52,53 This gave ethyl S-
Figure 3.2 1H NMR of trichloro(trimethylsilyl)phosphoranimine. 1H NMR H/ppm 
(400 MHz, CDCl3): (a) 0.45 (Me3SiCl impurity, approx. 5%), (b) 0.18 (distorted 






Figure 3.4 1H NMR of ethyl S-methylthiocysteinate. 1H NMR H/ppm (400 MHz, 
D2O): (a) 4.34 (dd, -CH-), (b) 4.18 - 4.07 (m, -OCH2-), (c) 3.20 - 3.09 (m, -SSCH2-), 
(d) 2.25 (s, -SSCH3), (e) 1.12 (t, -CH3). Spectrum referenced to maleic acid (6.2 ppm, 
not shown). Reproduced by permission of The Royal Society of Chemistry. 
 
Figure 3.3 31P NMR of (a) trichloro(trimethylsilyl)phosphoranimine and (b) 
poly(dichlorophosphazene).31P NMR P/ppm (162 MHz, CDCl3): (a) -55 
(Cl3P=NSiMe3), (b) -18 (-PCl2=N-). Spectra referenced to triphenylphosphine (-6 






methylthiocysteinate hydrochloride in 60% yield (Figure 3.4), which was subsequently reacted 
with PDCP in THF at 40 °C for 28 h to form the substituted POP-EtCys. The polymer was 
recovered by precipitation with hexanes and characterized by 1H NMR before proceeding to the 
following step (Figure 3.5). 1H NMR gave broad features, with peaks at 4.22 (-OCH2-) and 1.31 
ppm (-CH3)  corresponding to the ethyl ester of the ethyl S-methylthiocysteinyl substituents, and 
the resonance from the methyl  group of the disulfide linkage is observed at 2.43 ppm. A peak 
associated with the methylene group of cysteine is present at 3.29 (-CH2-) ppm, and a feature 
between 4.6 and 4.0 ppm is partially attributable to the methine proton (-CH-) and overlaps the 
 
Figure 3.5 1H NMR of poly(bis(ethyl S-methylthiocysteinyl)phosphazene) (POP-
EtCys) and poly(ethyl S-methylthiocysteinyl-co-ethyl cysteinyl phosphazene) (POP-
EtCys-SH). 1H NMR H/ppm (400 MHz, CDCl3): (a,b) 4.6 - 4.0 (-CH-, -OCH2-), (c) 
3.29 (-SSCH2-), (c2) 2.95 (-SCH2-), (d) 2.43 (-SSCH3), (e) 1.31 (-CH3), (f) 1.83 (-






methylene resonance from the ethyl group. The N-H resonance is not well-defined and may 
occur in a region of considerable overlap with more prominent features, while a broad, subtle 
feature corresponding to trace free thiol is present at 1.83 ppm. The polymer was suspended in a 
mixture of DCM/ethanol and thiol groups were partially deprotected using 2-mercaptoethanol at 
40 °C for 48 h to form POP-EtCys-SH. After disulfide cleavage, 1H NMR features were 
generally conserved from the spectrum of poly(bis(ethyl S-methylthiocysteinyl)phosphazene), 
with an expected reduction in the peak associated with the methyl disulfide and the appearance 
of a new resonance at 2.95 ppm arising from the partial upfield shift of the cysteine methylene 
protons adjacent to thiol. The 13C NMR spectrum was consistent with the expected structure, 
with peaks at 173, 54, and 43 ppm corresponding to the carbonyl, methine, and methylene 
carbons of cysteine (Figure 3.6). The methylene and methyl carbons of the ethyl ester appear at 
61 and 14 ppm, respectively, while the methyl group from the remaining disulfide produces a 
Figure 3.6 13C NMR of poly(ethyl S-methylthiocysteinyl-co-ethyl cysteinyl 
phosphazene) (POP-EtCys-SH). 13C NMR c/ppm (100 MHz, CDCl3): (a) 173 (-CO2-
), (b) 61 (-OCH2-), (c) 54 (-CH-), (d) 43 (-SSCH2-), (e) 23 (-SSCH3), (f) 14 (-CH3). 





resonance at 23 ppm. Partial cleavage of the disulfide bond results in the appearance of a weak, 
poorly-resolved feature at 16 ppm that corresponds to the methylene protons of cysteine. 31P 
NMR gave a broad resonance centered at approximately -2.6 ppm, as depicted in Figure 3.7. 
Major IR bands provide additional structural confirmation and include the features characteristic 
of the cysteine-derived substituents at 3320 (N-H stretch), 2980, 2914 (C-H stretch), 1732 (C=O 
stretch), 1417, 1367 (C-H bend) 1180, and 1117, and 1026 (C-O stretch) (Figure 3.8). The bands 
appearing at 1295 and 853 cm-1 are associated with vibration of the polyphosphazene backbone, 
while the band at 950 cm-1 is most directly attributable to P-N vibrations resulting from 
substitution at the phosphorus atom.54,55 The weak thiol S-H stretch was not clearly resolved in 
the IR spectrum, and S-S vibrations arising from disulfide linkages are typically expected to 
occur below 650 cm-1.56,57 However, the minor feature at 698 cm-1 was assigned to C-S 
stretching. As previously established by Weikel for the corresponding ethyl disulfide, the methyl 
disulfide scission is incomplete using 5 equivalents of 2-mercaptoethanol and increasing the 
 
Figure 3.7 31P NMR of poly(ethyl S-methylthiocysteinyl-co-ethyl cysteinyl 
phosphazene) (POP-EtCys-SH). 31P NMR P/ppm (162 MHz, CDCl3): -2.6. 
Spectrum referenced to triphenylphosphine (-6 ppm, not shown) to determine 
central value, then reacquired in the absence of a reference to avoid peak 
overlap. Concentration: 200 mg mL-1. Reproduced by permission of The Royal 





concentration of the reagent does not significantly improve the outcome of the reaction.  The 
thiol content of the polymer subsequent to disulfide cleavage with 2-mercaptoethanol was 
estimated by both 1H NMR spectroscopy and colorimetrically using a modification of Ellman’s 
assay for thiol determination. For 1H NMR, the ratio of the protons of the methyl disulfide group 
(2.43 ppm) to the methyl protons of the ester group (1.31 ppm) was used to estimate the relative 
extent of disulfide scission and therefore the thiol content. This method suggested that 50% of 
the methyl disulfide linkages were cleaved during the reaction, an outcome that is consistent with 
the values reported by Weikel for the ethyl disulfide. However, this method may not account for 
symmetrical disulfide resulting from either oxidation of free thiol or by disulfide exchange, 
which leads to features that may significantly overlap in the observed 1H NMR spectrum of the 
polymer. As a further estimate of thiol content, polymer samples were evaluated using a 
modified Ellman’s assay with bis(2,4-dinitrophenyl) disulfide in DMF, following a previously 
reported protocol.58 The calculated thiol content was 1.45 ± 0.13 mmol g-1 (mean ± SD, n = 5), 
 
Figure 3.8. ATR-FTIR spectra of polymers. Poly(ethyl S-methylthiocysteinyl-co-ethyl 
cysteinyl phosphazene) (POP-EtCys-SH) (top), and its S-nitrosated derivative (POP-
EtCys-NO) (bottom). POP-EtCys-SH: IR νmax/cm-1: 3320, 2980, 2914, 1732, 1417, 
1367, 1295, 1180, 1117, 1026, 948, 853, 792, 760, 698. POP-EtCys-NO: IR 
νmax/cm-1: 3300, 2977, 2915, 1732, 1520, 1367, 1296, 1180, 1117, 1024, 950, 







corresponding to an estimated 20% deprotection (Table 3.1). This more conservative value was 
used in subsequent calculations, in the event that crosslinking from disulfide formation is a 
significant factor in the deprotection process. An alternative deprotection strategy utilizing tris(2-
carboxyethyl)phosphine as the disulfide reducing agent resulted in the apparent total cleavage of 
the methyl disulfide, however the expense of this reagent and inefficient removal prohibits its 
use on larger scales. Harsher reducing conditions (Zn/HCl) were previously reported by Weikel 
to lead to concomitant decomposition of a similar polymer. The deprotected polymer was soluble 
in chloroform, DCM, DMF and THF, poorly soluble in acetone, ethanol, and methanol, and did 
not exhibit appreciable solubility in water or diethyl ether. GPC analysis (DMF) gave an average 
molecular weight of Mn = 4.73 × 103 g mol-1 with a PDI of 1.25, while TGA indicated an onset 
decomposition temperature of 166 °C. DSC gave an initial Tg of 24 °C, however subsequent 
thermal cycles continuously increased the temperature of the transition, an observation which 
may arise from disulfide exchange between free sulfhydryl groups and the methyl disulfide 
linkage. This process potentially results in crosslinking that could account for the observed 
increase in Tg as a function of heating cycle.59,60 
 
Table 3.1 Total thiol (POP-EtCys-SH) and nitric oxide (POP-EtCys-NO) content. Data 
reported as mean ± SD (n ≥ 3). aValue determined by modified Ellman’s assay protocol. 
bValue determined by UV decomposition of S-nitrosothiol (100 W, 365 nm, 40 °C). 
cCalculated as mol NO/mol SH × 100%. 
 
 
Thiol content  
(mmol g-1)a 
NO content by UV-Vis 
decomposition (mmol g-1)b 
Conversion to S-nitrosothiol  
(%)c 
 
1.45 ± 0.13 
 
 
0.55 ± 0.04 
 





3.3.2. Synthesis of S-nitrosated poly(ethyl S-methylthiocysteinyl-co-ethyl cysteinyl 
phosphazene) 
S-Nitrosothiols are most commonly synthesized through the reaction of thiols with reagents 
such as nitrous acid or nitrosyl chloride (both typically formed in situ by the reaction of nitrite 
with aqueous hydrochloric acid) and by oxygen-to-sulfur transnitrosation reactions with alkyl 
nitrites.61 In the case of S-nitrosothiols bound to hydrolytically-sensitive polymers, it can be 
anticipated that the presence of aqueous acid may result in concomitant hydrolysis of the 
polymer. Since polyphosphazenes may be expected to experience an increased rate of  hydrolytic 
degradation under highly acidic conditions, the S-nitrosation was carried out under milder 
conditions using t-BuONO in organic solvent. Although the S-nitrosation slowly proceeded in 
both DCM and DMF, the use of DCM resulted in accelerated decomposition of the S-nitrosothiol 
and DMF prevented isolation of the polymer due to low volatility. Despite poor solubility in 
ethanol, a system consisting of 10% v/v t-BuONO/ethanol was found to effectively S-nitrosate 
the material while avoiding the complications found in other solvents, since this mixture did not 
greatly accelerate decomposition and was easily removed in vacuo. As noted in prior reports, the 
reaction of t-BuONO and ethanol may lead to the formation of an equilibrium concentration of 
ethyl nitrite that is also capable of acting as a nitrosating agent.62 The successful S-nitrosation 
of the polymer was accompanied by the development of a distinct red/pink color and was 
confirmed by the appearance of bands in the UV-Vis spectrum at 337 and 547 nm, 
corresponding to what have been variably described as π→π*  or nO→π* (approximately 
340 nm) and nN→π* (approximately 550 nm) transitions of the S-nitrosothiol functional 
group (Figure 3.9).63,64  The removal of t-BuONO was confirmed by the absence of 




features developed that indicated the formation of N-nitroso species.65,66 As further 
confirmation, IR features at 1520 and 750 cm-1 appeared that were assigned to 
fundamental N=O and C-S stretching vibrations (Figure 3.8).57,67,68 In 10% v/v t-
BuONO/ethanol, the extent of S-nitrosation (monitored by UV-Vis) did not increase after 
15 min at RT and began to decline thereafter, corresponding to the gradual decomposition 
of S-nitrosothiol. The S-nitrosated polymer generally retained the same solubility 
characteristics as the parent thiolated material and readily dissolved in chloroform, DCM, 
DMF, and THF at concentrations in excess of 150 mg mL-1. Unlike the parent polymer, 
the S-nitrosated polyphosphazene exhibited diminishing solubility over time and was no 
longer appreciably soluble in DCM or DMF after storage for 24 h at 25 °C under ambient 
light. This behavior can be attributed to crosslinking arising from the formation of disulfide 
linkages during decomposition of the S-nitrosothiol. Storage of the S-nitrosated polymer at -20 
 
Figure 3.9 UV-Vis spectra of polymers. Poly(ethyl S-methylthiocysteinyl-co-
ethyl cysteinyl phosphazene) (POP-EtCys-SH) and its S-nitrosated derivative 
(POP-EtCys-NO) in DMF.  The characteristic absorbances associated with the 
successful formation of primary S-nitrosothiols are shown in (a), while (b) 
illustrates the relationship between polymer concentration and the prominent 
absorbance at 337 nm that is often attributed to a π→π* transition. 





°C greatly inhibited decomposition, with 103 ± 5% (mean ± SD, n = 3) of S-nitrosothiol (UV-
Vis) remaining at the end of 7 weeks and no loss of solubility in DMF. Interestingly, when 
ethyl cysteinate hydrochloride was treated with t-BuONO under similar nitrosating 
conditions, the compound rapidly decomposed with vigorous evolution of gas and the 
formation of a transient red color that quickly faded. This observation may indicate that 
covalent attachment of ethyl cysteinate to the polyphosphazene backbone prevents 
reaction of the primary amine with nitrosating agents, and consequently inhibits 
diazotization-related decomposition pathways.69 It is difficult to attribute the increased 
stability of the polymer-bound S-nitrosothiol to a single factor. However, the development 
of a hydrogen bond involving the N-H group of pendant ethyl cysteinyl moieties is 
indicated by the shift in vibrational frequency from 3320 to 3300 cm-1 subsequent to S-
nitrosation. Hydrogen bonding interactions in computational models of S-nitrosocysteine 
and S-nitroso-N-acetylcysteine have been previously suggested to induce polarization of 
the N=O bond that may increase thermal stability.70 Although this phenomenon may be 
operative in the case of POP-EtCys-NO, it is difficult to make direct comparisons with S-
nitrosated ethyl cysteinate due to its rapid decomposition.  
 
3.3.3. Nitric oxide release 
Additional characterization was performed by evaluating the ability of POP-EtCys-
NO to release gaseous NO under various conditions. NO measurements were carried out 
using commercial chemiluminesence-based NO-selective analyzers that rely on the gas-
phase reaction of NO with ozone to produce nitrogen dioxide in the excited state (NO + 




detected by the instrument and used to quantify NO concentration as a function of time. In all 
cases, solvents were deoxygenated by nitrogen purge prior to use, and released NO was swept 
into the instrument with a constant nitrogen flow/purge following previously reported protocols. 
Since S-nitrosothiols are known to rapidly and quantitatively decompose to release NO through 
distinct photolytic and copper-catalyzed pathways, both methods were utilized to assess the NO 
content of the S-nitrosated polymer.40,72 Photolytic decomposition with UV light (365 nm) at 40 
°C in DMF resulted in a total NO content of 0.55 ± 0.04 mmol g-1 (mean ± SD, n ≥ 3), 
corresponding to the conversion of 38 ± 4% of thiol groups (Ellman’s assay) to S-nitrosothiol 
(Table 3.1). This value suggests that the efficacy of the S-nitrosation reaction is limited when 
considering the total quantity of available thiol, which may be a consequence of poor polymer 
solubility in ethanol or loss of nitrosating agent as ethyl nitrite, which exists as a gas below room 
temperature. Control samples consisting of non-nitrosated polymer exposed to UV light did not 
produce detectable NO. Decomposition with 5.0 × 10-4 M copper(II) chloride at ambient 
temperature in ethanol gave a total NO content of 0.46 ± 0.05 mmol g-1. However, the poor 
solubility of the polymer in ethanol may have resulted in impaired catalyst access and incomplete 
decomposition of the S-nitrosothiol, since the majority of the NO release occurred comparatively 
slowly (2 h) and continuing low-level NO emission persisted. The reaction could not be carried 
out in DMF, since the activity of the copper catalyst was significantly reduced in that solvent, 
and other organic solvents exhibited impractically high volatility or did not effectively dissolve 
the polymer or catalyst. The values obtained from UV decomposition were therefore utilized in 
subsequent calculations. In addition, a molar extinction coefficient of 810 ± 20 M-1 cm-1 (mean ± 
SD, 337 nm, DMF) for the polymer-bound S-nitrosothiol was determined by relating the UV 




with prior studies reporting molar extinction coefficients of various S-nitrosothiols near 1000 M-1 
cm-1 for the absorbance centered near 340 nm.63 
S-nitrosothiols have been frequently invoked as useful sources of releasable NO due 
to their ability to decompose under physiological conditions through thermal or transition 
metal ion-mediated pathways to produce NO and disulfide. Moreover, S-nitrosothiols 
such as S-nitrosocysteine (commonly in the form of S-nitrosated protein residues as in S-
nitrosoalbumin) have been established to exist endogenously as participants in various 
physiological processes. To evaluate the ability of the S-nitrosated polymer to release NO 
under physiological conditions, NO release profiles were collected at 37 °C in pH 7.4 PBS 
over 24 h (Figure 3.10). At the end of the 24 h period, cumulative NO release was 0.35 ± 0.02 
mmol g-1 (mean ± SD, n = 3), corresponding to 64% of theoretical NO. The remaining theoretical 
NO was recovered by UV-induced photolytic decomposition at 40 °C, and suggested the 
potential for continuing NO release over an extended period. 
 
Figure 3.10 NO release profiles of S-nitrosated poly(ethyl S-methylthiocysteinyl-co
ethyl cysteinyl phosphazene). Left: Representative NO release profile of POP-EtCys-
NO over 24 h (37 °C, pH 7.4 PBS, n = 3). Right: Cumulative NO release of POP-
EtCys-NO under varying conditions (n = 3). Reproduced by permission of The Royal 





The physiological release profile was generally consistent with second-order exponential decay 
following initial equilibration, with the greater portion of this NO release occurring within 
approximately 4 h. This data indicates that POP-EtCys-NO exhibits a relatively high level of 
total NO content and serves as an effective source of releasable NO under physiological 
conditions. In comparison, our previously reported NO-releasing polyester consisting of S-
nitrosated L-cysteine covalently attached to poly(lactic-o-glycolic-co-2,2-
bis(hydroxymethyl)propionic acid) demonstrated a total NO content of 0.17 mmol g-1 and 
released 93% of available NO over 48 h at 37 °C in pH 7.4 PBS, while the citrate-based 
elastomer poly(citric-co-maleic acid-co-1,8-octanediol) modified to incorporate S-nitrosated 
ethyl cysteinyl pendant groups contained 0.16 mmol g-1 NO and released 41% over 4 days.73,74 
Frost reported another cysteine-based NO-releasing material consisting of fumed silica particles 
with covalently incorporated S-nitrosocysteine that exhibited total NO loading of 0.021 mmol g-1 
and released a maximum of 40% of available NO in toluene in the presence of a copper 
initiator.75 POP-EtCys-NO exhibits a greater extent of total NO loading than these prior cysteine-
based systems and retains solubility in organic solvents, permitting subsequent processing. 
Although the chemical behavior of S-nitrosothiols has been comprehensively elucidated in prior 
reports, change in the NO release properties of the S-nitrosated polyphosphazene in response to 
varying temperature and pH was briefly investigated. To this end, additional release profiles 
were acquired over the same 24 h interval at 25 °C in pH 7.4 PBS, 37 °C in pH 5.0 acetate 
buffer, and 37 °C under anhydrous, solvent-free conditions (Table 3.2, Figure 3.10, Figure 3.11). 
In PBS, the temperature dependence of NO-producing S-nitrosothiol decomposition was 
apparent in the slower NO release kinetics observed at 25 °C. This behavior resulted in a 58% 




may be attributable in part to increased stability of the S-N bond at lower temperature. In pH 5.0 
acetate buffer, a similar 63% decline in cumulative NO release to 0.13 ± 0.03 mmol g-1 over 24 h 
was observed, an outcome that could be explained by previous studies that proposed increased 
stabilization of S-nitrosothiols under acidic conditions.76,77 However, UV decomposition of the 
remaining S-nitrosothiol at 40 °C resulted in a total recovery of only 50 ± 10% of theoretical NO. 
This suggests that the apparent reduction in NO release may be a consequence of S- itrosothiol 
decomposition in acetate buffer through a process that does not generate detectable NO. The 
 
Figure 3.11 24 h cumulative NO release for S-nitrosated poly(ethyl S-
methylthiocysteinyl-co-ethyl cysteinyl phosphazene). (mean ± SD, n = 3). Statistical 
differences evaluated by single-factor ANOVA analysis and Tukey’s range test (p < 
0.05). Reproduced by permission of The Royal Society of Chemistry. 
 
Table 3.2 Cumulative nitric oxide release from S-nitrosated poly(ethyl S-
methylthiocysteinyl-co-ethyl cysteinyl phosphazene). Data reported as mean ± SD (n 
= 3) over 24 h of release. a0.2 mg mL-1, 5 mL pH 7.4 PBS, 37 °C. a0.2 mg mL-1, 5 mL 
pH 7.4 PBS, 25 °C. c0.2 mg mL-1, 5 mL pH 5.0 acetate buffer, 37 °C. d1 mg, 37 °C. 
 
 37 °C, pH 7.4 
PBSa 
25 °C, pH 7.4 
PBSb 







release (mmol g-1) 
 






results for this system are therefore consistent with reports that indicate a significant 
destabilization and loss of S-nitrosothiol at acidic pH.78 24 h NO release from the polymer at 37 
°C in the absence of solvent was reduced by 38% relative to pH 7.4 PBS at the same 
temperature, but remained marginally higher than the release observed in pH 7.4 PBS at 25 °C. 
These results suggest that decomposition of the polymer-bound S-nitrosothiol is not solely a 
function of temperature, but that the presence of PBS facilitates this process in a temperature-
dependent manner. 
 
3.3.4. Degradation study 
To assess the degradation characteristics of both POP-EtCys-SH and the S-nitrosated 
derivative POP-EtCys-NO under physiological conditions, samples (n = 5) were 
immersed in pH 7.4 PBS at 37 °C for a total of 6 weeks (Figure 3.12). At intervals of 1 week, 
the buffer was removed and samples were washed thoroughly with Millipore water. The samples 
were subsequently lyophilized for 24 h to remove water and the mass of dry polymer was 
recorded. The thiolated polymer was found to undergo a 36% average mass loss over 6 weeks, 
with more rapid degradation occurring in the first three weeks of the study. The S-nitrosated 
derivative experienced 41% mass loss over the same period, with a gradual decrease in the rate 
of degradation that paralleled the properties of the thiolated material. The pH of the buffer 
solutions was generally not observed to vary significantly relative to PBS controls, except in the 
case of the S-nitrosated derivative, where the release of NO during the first week decreased the 
pH to 6-7. This may have resulted from the formation of low concentrations of HNO2 or HNO3 
produced from the reaction of NO with water and atmospheric oxygen, and was an anticipated 




the rate of hydrolysis is most directly responsible for the greater degree of degradation observed 
at the end of the study. The declining rate of degradation for both polymers was attributed to 
crosslinking arising from disulfide formation, which may be attributed to thiol oxidation under 
mildly basic, oxygenated conditions or to S-nitrosothiol decomposition.80 After the end of the 6 
week degradation period, the IR spectra of both the thiolated and S-nitrosated materials were 
consistent with those initially obtained for the thiolated polymer, indicating that no significant 
compositional changes occurred. Furthermore, the polymers no longer exhibited any appreciable 
solubility in DCM, DMF, or other common organic solvents, which may provide further 
indication of crosslinking. 
 
3.3.5. Cell  studies 
Preliminary assessment of the cytotoxicity of both the thiolated (POP-EtCys-SH) and S-
nitrosated materials (POP-EtCys-NO) was carried out through exposure of HDF to polymer 
extracts obtained following the general method described in ISO 10993.46 This method provides 
insight into the toxicity of leachables that may be removed or formed from the polymer samples 
 
Figure 3.12 Degradation of polymers over 6 weeks (37 °C, PBS, mean ± SD, n = 5). 





over the 24 h extraction period and has been previously utilized to evaluate the potential toxicity 
of biomaterials.74,81 The CellTiter-Blue assay was used to evaluate HDF viability after exposure 
to polymer extracts (n = 9), a method that exploits the reductive conversion of resazurin to 
resorufin as a consequence of cellular metabolic activity.  For both POP-EtCys-SH and POP-
EtCys-NO, the percentage of viable cells (normalized to the positive control) remained above the 
70% cell viability threshold, indicating low relative cytotoxicity for extracts obtained over 24 h 
(Figure 3.13).  In the case of POP-EtCys-SH, leachables were anticipated to primarily take the 
form of trace ethanol liberated from hydrolysis of the ethyl ester, cysteine and cysteine 
derivatives, and the phosphate and ammonia products typically produced from the degradation of 
polyphosphazenes.11 Since the majority of such leachables have been previously established to 
possess relatively low toxicity, it is perhaps more significant to note that the methyl disulfide 
group introduced by reaction of ethyl cysteinate with MMTS did not induce significant leaching-
related toxicity at the tested extraction concentration. POP-EtCys-NO introduces the additional 
possibility of NO release that may lead to the formation of various byproducts under aerobic 
 
Figure 3.13. CellTiter-Blue viability assay results for HDF (mean ± SD , n = 9) 
exposed to polymer extracts. Dashed line indicates the 70% cell viability threshold. 





conditions, but this was not observed to produce any significant decrease in cell viability relative 
to the thiolated material. For this reason, only POP-EtCys-NO was subjected to further 
assessment.  
In addition to the CellTiter-Blue cell viability assay, fluorescence microscopy was utilized 
to evaluate both the qualitative viability (LIVE/DEAD assay) of HDF exposed to extracts from 
POP-EtCys-NO and to ensure that cell morphology was preserved. Figure  3.14a-c depicts the 
results of the LIVE/DEAD assay, where all cells exhibit the characteristic green color of the
SYTO 9 fluorescent stain, while only non-viable cells with disrupted membranes exhibit the red 
color associated with PI. Figure 3.14a depicts the positive control, with the majority of cells 
exhibiting intact membranes, while the negative control in Figure 3.14b shows the development 
of the red color associated with disruption of cell membranes after exposure to methanol. Figure 
 
Figure 3.14 LIVE/DEAD and cell morphology images after 24 h polymer extract 
exposure. Fluorescence microscope images for LIVE/DEAD assay are (a) positive 
control consisting of HDF cultured in cell medium, (b) negative control (methanol 
exposure), and (c) HDF after exposure to extracts from POP-EtCys-NO. 
Morphological images are (d) positive control, and (e) HDF after exposure to extracts 
from POP-EtCys-NO. For LIVE/DEAD and cell morphology experiments,  = 6. 





3.14c shows the outcome of HDF exposure to extracts from POP-EtCys-NO (n = 6), which 
results in cells that exhibit similar staining to those seen in the positive control. In order to 
examine cellular morphology after exposure to the material extracts, the stains Alexa and DAPI 
were added to the HDF. Alexa has the ability to stain the cell actin cytoskeletons and appears 
red, while DAPI stains only the cell nuclei and appears blue. Figure 3.14d shows the results of 
the morphological assay for the positive TC control and Figure 3.14e shows cells exposed to 
extracts from POP-EtCys-NO (n = 6). Both the control and sample show the predicted cellular 
morphology of HDF, indicating that there is no distortion or alteration in morphology after 24 h 
exposure to the S-nitrosated polymer extract.  
 
3.4. Conclusions 
We have synthesized and characterized the biodegradable cysteine-based polyphosphazene 
poly(ethyl S-methylthiocysteinyl-co-ethyl cysteinyl phosphazene) (POP-EtCys-SH) and 
demonstrated NO release capability from an S-nitrosated derivative of this material (POP-EtCys-
NO) under physiological conditions. The total average NO content of POP-EtCys-NO was found 
to be 0.55 ± 0.04 mmol g-1, corresponding to a conversion of 38 ± 4% of thiol groups to S-
nitrosothiol. Over the course of 24 h, 0.35 ± 0.02 mmol g-1 NO (64% of theoretical) was released 
under physiological conditions (37 °C, pH 7.4 PBS), with NO emission continuing at a low level 
thereafter. Slower NO release was observed over the same interval at physiological temperature 
under solvent-free conditions (0.22 ± 0.02 mmol g-1), and both reduced temperature (25 °C, pH 
7.4) and pH (37 °C, pH 5) produced decreased 24 h release of 0.15 ± 0.02 and 0.13 ± 0.03 mmol 
g-1 NO, respectively. Both POP-EtCys-SH and POP-EtCys-NO were found to degrade in PBS at




cytotoxicity of extracts obtained from POP-EtCys-NO was evaluated by CellTiter-Blue assay, 
where HDF viability was found to remain above the 70% cytotoxicity threshold at the tested 
extract concentration. In addition, LIVE/DEAD assay and fluorescence microscopy imaging 
after staining with Alexa Fluor 568/SYTO 9 indicated that extracts did not produce significant 
disruption of cell membranes or alteration of cell morphology. Since polyphosphazenes have 
been extensively investigated for various biomedical purposes, these results suggest that POP-
EtCys-NO may serve as an effective candidate material for such applications where the 
therapeutic properties of NO release are desirable. 
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Nitric oxide (NO) is a naturally-occurring bioactive molecule with well-established 
physiological functions in the cardiovascular and immune systems.1,2 Endogenous NO is 
primarily formed by the action of NO synthase (NOS) enzymes on L-arginine or through the 
NOS-independent nitrate-nitrite-nitric oxide pathway.3,4 NO produced by endothelial cells serves 
as a regulator of vascular tone and inhibitor of platelet adhesion and aggregation, while 
phagocytes utilize NO as an antimicrobial agent as part of the immune response.5,6 Supplemental 
NO gas has been employed in medicine as a vasodilator and as an FDA-approved treatment for 
pulmonary hypertension.7,8 Furthermore, the ability of NO to exert antithrombotic, wound-
healing, and broad-spectrum antimicrobial effects has led to continued interest in the 
development of NO-based therapies for a variety of biointerfacial applications.9 However, the 
fact that NO is rapidly consumed by reaction with biomolecules (e.g. oxyhemoglobin) or 
molecular oxygen complicates its physiological delivery and necessitates the synthesis of 
materials capable of localized NO release.10 Because NO exhibits pronounced antiplatelet 
effects, NO-releasing polymers form an important class of therapeutic materials that have been 
frequently proposed for use in the fabrication of thromboresistant, blood-contacting medical 
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devices such as stents and catheters.11 Other NO-releasing polymers have been found to exhibit 
promising antimicrobial activity as both solution-phase sources of NO and in the form of 
bactericidal wound dressings for treatment of injuries.12,13 NO-releasing materials are most 
commonly prepared by incorporation of species such as N-diazeniumdiolates and S-nitrosothiols 
(RSNOs), which form NO under physiological conditions or when triggered by environmental 
stimuli.14,15 RSNOs including S-nitrosoglutathione (GSNO) and macromolecular S-
nitrosoalbumin are present in blood and decompose as part of their natural biochemical function 
to form benign disulfides (2 RSNO → 2 NO + RSSR), and it has been argued that this category 
of NO donor possesses certain advantages over wholly synthetic NO-forming species.16  For 
example, N-diazeniumdiolates have occasionally been shown to form potentially carcinogenic N-
nitrosamines as a byproduct of their decomposition, and alternative NO donors like 
sydnonimines, furoxans, and metal nitrosyls are frequently complex to synthesize, 
toxicologically unsuitable, or lacking the versatility required for biomaterials applications.17 As 
the therapeutically-relevant component of many NO-releasing polymer systems, RSNOs have 
been widely utilized in biomaterials. Brisbois et al. reported that polyurethane-based catheters 
doped with S-nitroso-N-acetylpenicillamine (SNAP) were capable of extended NO release, 
resulting in reduced thrombus formation and bacterial adhesion in sheep.18  Li and Lee 
demonstrated that conjugates of GSNO or S-nitrosated phytochelatins and poly(vinyl methyl 
ether-co-maleic anhydride) could be complexed with poly(vinyl pyrrolidone) to produce NO-
releasing materials capable of accelerating wound healing in diabetic mice.19  Moreover, Vogt et 
al. reported the development of a gelatin-based, light-triggered material derivatized with SNAP 




demonstrated that S-nitrosated polysiloxane-derived xerogels exhibited promising antibacterial 
effects against Pseudomonas aeruginosa (P. aeruginosa).20,21  
More recently, we reported on the use of S-nitrosated biodegradable 
poly(organophosphazenes) (POPs) as potential platforms for therapeutic NO release.22 POPs 
possess a polymeric inorganic backbone consisting of alternating nitrogen and phosphorus 
atoms, and are frequently synthesized by substitution of poly(dichlorophosphazene) (PDCP) with 
amines or alkoxides.23 Inclusion of organic substituents results in variable physical and chemical 
characteristics that have permitted the development of POPs that range from specialty elastomers 
for industrial use to materials intended for biomedical applications.24 In an example of their 
potential for medical device fabrication, a study conducted by Huang et al. found that coronary 
stents coated with poly(bis(trifluoroethoxy)phosphazene) (PTFEP) exhibited long-term 
biocompatibility after implantation in pigs.25 Similarly, Henn et al. showed that PTFEP-coated 
stents inhibited thrombus formation and reduced in-stent stenosis and inflammation in a porcine 
model.26 The use of amino acid-based substituents has led to the development of a wide variety 
of bioerodible POPs incorporating esters of glycine, alanine, phenylalanine, and others.27 Such 
polymers are understood to degrade hydrolytically through liberation of the amino acid and 
decomposition of the polyphosphazene backbone into low-toxicity and self-neutralizing 
phosphate and ammonia.28 Biodegradable POPs of this type have been proposed as materials 
suitable for bone tissue engineering, drug delivery, and the development of coatings for medical 
devices.29-31 In these roles, polyphosphazenes substituted with amino acid derivatives or similar 
naturally-occurring, non-toxic compounds represent a potential alternative to widely-used 




We previously demonstrated that cysteine-based poly(ethyl S-methylthiocysteinyl-co-ethyl 
cysteinyl phosphazene) could be effectively S-nitrosated to form a biodegradable, NO-releasing 
material. However, the stability of the polymer-bound primary S-nitrosothiol was found to be 
limited under physiological conditions, resulting in the release of 64% (0.35 mmol g-1) of 
available NO over 24 h in pH 7.4 phosphate buffered saline (PBS) at 37 °C. The greater reported 
stability of tertiary RSNOs (such as SNAP) has led to their frequent use as longer-term NO 
donors.32  For this reason, it was anticipated that prolonged NO release could be achieved via 
development of a polyphosphazene bearing tertiary RSNO substituents. Herein, we present the 
development of S-nitrosated poly(bis(3-mercapto-3-methylbut-1-yl glycinyl)phosphazene) (POP-
Gly-MMB), the first NO-releasing POP based on a tertiary RSNO architecture. The organic 
pendant group was derived from glycine and 3-mercapto-3-methylbutan-1-ol (MMB), a food-
grade tertiary thiol identified in wine produced from Vitis rotundifolia and both commercial 
lagers and coffee.33-35 To evaluate the ability of the polymer to function as an NO-releasing 
surface, the thiolated material (POP-Gly-MMB-SH) was adhered to glass test substrates and 
subsequently converted to the S-nitrosated derivative POP-Gly-MMB-NO. The NO release 
properties of this coating were evaluated at physiological pH and temperature (pH 7.4 PBS, 37 
°C), where it was determined to maintain a physiologically-relevant NO flux (6.5-0.09 nmol min-
1 cm-2) over a 2 week period by chemiluminescence-based NO detection. The hydrolytic 
degradation properties of both POP-Gly-MMB-SH and POP-Gly-MMB-NO were assessed over 
6 weeks (pH 7.4 PBS, 37 °C), and their primary hydrolytic degradation products were identified 
by time-of-flight mass spectrometry (TOF-MS). Results indicate that POP-Gly-MMB-NO 
coatings function as comparatively long-term macromolecular reservoirs of NO, exhibiting 




the greater stability and correspondingly slower NO release from POP-bound tertiary RSNOs 
represents significant progress toward the development of biodegradable polymers capable of 
sustained NO release. 
 
4.2. Materials and methods 
4.2.1. Materials 
4-(Dimethylamino)pyridine (DMAP, 99%), chloroacetic acid (99%), N,N'-
dicyclohexylcarbodiimide (DCC, 99%), lithium bis(trimethylsilyl)amide (LiHMDS, 99%), 
sulfuryl chloride (97%), and triphenylphosphine (99%) were purchased from Alfa Aesar (Ward 
Hill, MA, USA). Disodium ethylenediaminetetraacetate dihydrate (EDTA-Na2, 99%), food-
grade 3-mercapto-3-methylbutan-1-ol (MMB, 98%), sodium azide (99.5%), and tert-butyl nitrite 
(t-BuONO, 90%) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Phosphorus 
pentachloride (98%) and phosphorus trichloride (98%) were obtained from Strem Chemicals, 
Inc. (Newburyport, MA, USA). Phosphate buffered saline (PBS) tablets and triethylamine (TEA, 
99%) were purchased from EMD Chemicals (Gibbstown, NJ, USA). A Millipore Direct-Q water 
purification system was used to produce deionized water for general use and the preparation of 
PBS (EMD Millipore, Billerica, MA, USA).  Phosphorus trichloride and sulfuryl chloride were 
distilled prior to use. Triethylamine was distilled from calcium hydride. tert-Butyl nitrite was 
treated with 10% w/v EDTA-Na2 to remove trace metal impurities. All other chemicals were 







4.2.2. Characterization methods 
General characterization techniques. NMR spectra were obtained using an Agilent (Varian) 
Inova 400 MHz FT-NMR spectrometer (Agilent Technologies, Inc., Santa Clara, CA, USA). 1H 
NMR and 13C NMR spectra were referenced relative to the solvent (CDCl3), and 
31P NMR 
spectra were referenced relative to triphenylphosphine (-6 ppm) or triphenylphosphine oxide (29 
ppm) standards. ATR-FTIR spectra were collected between 650-4000 cm-1 using a Nicolet 6700 
FTIR spectrometer (Thermo Electron Corporation, Madison, WI, USA) fitted with a Smart iTR 
ATR sampling accessory and ZnSe crystal plate. UV-Vis measurements were carried out using a 
Nicolet Evolution 300 spectrophotometer (Thermo Electron Corporation). Gel permeation 
chromatography (GPC) utilized a Waters 515 HPLC pump, a Waters 717 autosampler, and a 
Waters 2414 refractive index (RI) detector. Separation was performed with a PLgel guard 
column (Polymer Labs) and three PLgel mixed-C columns (7.5 × 300 mm, 5 µm; Polymer Labs) 
using HPLC grade DMF at 30 °C with a flow rate of 1.0 mL/min. The instrument was calibrated 
with poly(methyl methacrylate) standards, and the chromatograms were processed with Waters 
Empower software (version 2002). 
Contact angle measurements. To evaluate wettability of polymer coatings, water contact angle 
(WCA) measurements (n = 8) were performed by sessile drop technique under ambient lab 
conditions using a Krüss DSA10 contact angle goniometer (Hamburg, Germany). All samples 
were dosed with 2 μL of deionized water and still images were immediately acquired. The 
contact angle was then determined by manually selecting the baseline and using Tangent Method 





Nitric oxide release measurements. NO release measurements were obtained using Sievers 
chemiluminescence-based NO analyzers (NOA 280i) (GE Analytical Instruments, 
Boulder, CO, USA). The instruments were calibrated with UHP nitrogen and 45 ppm 
NO/nitrogen. To collect 24 h NO release profiles, polymer-coated substrates (n = 3) were 
placed in custom gas-flow cells connected to the NO analyzers and immersed in 5 mL of 
deoxygenated 10 mM pH 7.4 PBS maintained at 37 °C and protected from exposure to 
ambient light. The buffer solution and headspace were purged with a constant flow of nitrogen to 
sweep NO into the analyzer, and the NO concentration (ppb/ppm) was recorded as a function of 
time. NO concentration was converted to NO release (mol) using a calibration constant (mol NO 
ppb-1 s-1) obtained from the reduction of sodium nitrite and verified by copper-catalyzed 
decomposition of GSNO. To obtain NO flux measurements over 14 d, the NO release from 
polymer-coated substrates (n = 3) was measured at regular intervals following immersion in 5 
mL of deoxygenated 10 mM pH 7.4 PBS at 37 °C. The initial NO release measurement (t = 0) 
corresponds to the maximum mean NO release observed after immersion in PBS, while 
subsequent measurements (t = 1-14 d) correspond to mean NO release. Between measurements, 
samples were incubated in 5 mL of 10 mM pH 7.4 PBS at 37 °C under ambient atmosphere and 
protected from exposure to light. NO release (ppb) was converted to NO flux (nmol min-1 cm-2) 
using the NO analyzer calibration constant and the surface area of the sample. To determine total 
NO content, polymer-coated substrates (n = 3) were irradiated with UV light in PBS at 40 °C 
using a 100 W Blak-Ray B-100AP UV lamp (UVP, Upland, CA, USA) to photolytically 
decompose RSNO. The resulting NO release was used to calculate the quantity of releasable NO 
present in the material. The sum of NO released over 24 h (10 mM pH 7.4 PBS, 37 °C) and the 




material (mmol g-1). An identical process was used to quantify remaining NO after incubation of 
polymer-coated substrates in 5 mL of 10 mM pH 7.4 PBS at 37 °C for 3, 7, and 14 d. In all 
cases, glassware used for NO release measurements was washed with saturated EDTA-Na2 
followed by deionized water (18.2 MΩ·cm) prior to use. 
Molar extinction coefficient determination. The RSNO molar extinction coefficient for POP-
Gly-MMB-NO was determined by correlation of UV-Vis absorbance with NO release. The 
absorbance (341 nm) of dissolved POP-Gly-MMB-NO in DMF was obtained by UV-Vis 
spectroscopy at 5 different concentrations (n = 3) within the linear range, and an aliquot of each 
solution was injected into an NO analyzer gas-flow cell. Decomposition of the RSNO was 
induced by exposure to UV light as described previously, and the resulting NO release was used 
to establish a linear relationship between absorbance and NO content. 
Degradation study. POP-Gly-MMB-SH samples (20 mg, n = 5) were weighed out and 
immersed in 5 mL of 10 mM PBS 7.4 PBS. Additional POP-Gly-MMB-SH samples (20 mg, n = 
5) were weighed out, converted to the S-nitrosated derivative POP-Gly-MMB-NO by reaction 
with t-BuONO, and similarly immersed in 5 mL of 10 mM PBS 7.4 PBS. The samples were 
incubated at 37 °C under ambient atmosphere while protected from light for a total of six weeks. 
PBS was replaced on a weekly basis through the removal and addition of buffer by pipette under 
ambient laboratory conditions, with care taken to avoid the unwanted transfer of  non-degraded 
polymer.   At the end of each week, the material was removed from the buffer solution, washed 
twice with 1 mL Millipore water, and lyophilized for 24 h to remove residual water. For each 
sample, the dry mass of the material and the pH of the buffer solution was recorded after removal 




Mass spectrometry. To identify potential hydrolytic degradation products, samples of POP-Gly-
MMB-SH and POP-Gly-MMB-NO were hydrolyzed in deionized water at 37 °C under ambient 
atmosphere for two weeks. The media were subsequently analyzed using time-of-flight mass 
spectrometry (TOF-MS) to characterize the polymer degradation products. All mass 
spectrometry analyses were performed using an Agilent 6224 LC-MS. The instrument was 
equipped with an Agilent multimode ionization (MMI) source capable of electrospray ionization 
(ESI) and atmospheric pressure chemical ionization (APCI). For all experiments, mixed mode 
ionization in both positive and negative polarity was employed with the range of mass analysis 
set at 70 - 3200 m/z. The sample solutions were introduced into the ion source using flow 
injection at a flow-rate of 2.2 µL/min via the ESI nebulizer using methanol as the mobile phase 
(n ≥3). The ion source conditions were as follows: capillary voltage, 2500 V; fragmentor voltage, 
120 V; skimmer voltage, 60 V; charge voltage, 2000 V; drying gas temperature, 310 °C; drying 
gas flow-rate (nitrogen gas), 10 L/min; and nebulizer pressure, 45 psi. All data was processed 
using Agilent MassHunter Qualitative Analysis B.07.00. 
Statistical analysis. Data reported as mean ± standard deviation of ≥ 3 replicate measurements, 
unless otherwise noted. 
 
4.2.3. Synthetic methods 
3-Mercapto-3-methylbut-1-yl chloroacetate (1). MMB (30 mmol) was dissolved in 30 mL dry 
THF and cooled to 0 °C. Chloroacetic acid (30 mmol), DMAP (1.5 mmol), and DCC (30 mmol) 
were added and the solution was stirred for 1 h at 0 °C, followed by 2 h at RT. The solvent was 
evaporated and the mixture was taken up in 45 mL DCM and washed twice with both 0.5 M 




(30 mL). The solution was dried over anhydrous MgSO4, filtered, and the solvent was 
evaporated to give a cloudy oil. The oil was stored at -20 °C overnight to precipitate residual 
dicyclohexylurea, and then filtered to isolate the crude product as a clear, colorless oil (5.01 ± 
0.19 g, 85 ± 3%): 1H NMR (400 MHz, CDCl3) δ 4.42 (t, J = 7.2 Hz, 2H), 4.06 (s, 2H), 1.98 (t, J 
= 7.2, 2H), 1.76 (s, 1H), 1.44 ppm (s, 6H). 13C NMR (100 MHz, CDCl3) δ 167.23, 63.84, 44.13, 
42.78, 40.85, 33.10 ppm. 
3-Mercapto-3-methylbut-1-yl azidoacetate (2).  1 (5 mmol) was dissolved in 30 mL DMF 
without further purification and cooled to 0 °C. Sodium azide (1 eq. by crude mass) was added 
and the mixture was stirred for 30 min at 0 °C, then 1.5 h at RT. The solution was decanted into 
ice-cold water (60 mL) and the product was extracted twice with diethyl ether (60 mL), then 
washed 4 times with water (15 mL) and dried with anhydrous MgSO4. After filtration, the ether 
was evaporated to yield the crude product as a clear, pale yellow oil (4.42 ± 0.06 g, 89 ± 3%): 1H 
NMR (400 MHz, CDCl3) δ 4.43 (t, J = 7.2 Hz, 2H), 3.88 (s, 2H), 1.99 (t, J = 7.2, 2H), 1.76 (s, 
1H), 1.44 ppm (s, 6H). 13C NMR (100 MHz, CDCl3) δ 168.23, 63.44, 50.41, 44.15, 42.74, 33.08 
ppm. 
3-Mercapto-3-methylbut-1-yl glycinate hydrochloride (3). 2 (5 mmol) was dissolved in dry 
THF (10 mL) and cooled to 0 °C. Triphenylphosphine (1 eq.) was added and the mixture was 
stirred for 15 min at 0 °C, then 1.5 h at RT. Deionized water (0.5 mL) was added and the mixture 
was stirred for 1 h, followed by removal of solvent under vacuum. The amine was extracted 3 
times from DCM (5 mL) with ice-cold 0.5 M hydrochloric acid (5 mL), and the combined 
aqueous layers were washed 3 times with DCM (5 mL). The aqueous hydrochloride salt was 
subsequently filtered and lyophilized to isolate the crude product as a white solid (est. by 1H 




2H), 4.03 (q, J = 6.0, 2H), 1.97 (t, J = 7.2, 2H), 1.86 (s, 1H), 1.41 ppm (s, 6H). 13C NMR (100 
MHz, CDCl3) δ 167.77, 64.12, 43.98, 42.80, 40.76, 33.09 ppm. 
Trichloro(trimethylsilyl)phosphoranimine (4). LiHMDS (100 mmol) was suspended in dry 
diethyl ether (200 mL) and cooled under nitrogen to 0 °C. PCl3 (100 mmol) was slowly added 
over 30 min, then the resulting suspension was allowed to warm to RT and stirred for 1 h. The 
mixture was again cooled to 0 °C and SO2Cl2 (100 mmol) was added over 30 min.  After this 
addition, the mixture was warmed and stirred for 1 h, filtered, and the solvent was removed 
under vacuum. The product was distilled twice under vacuum (1 Torr, 21 °C) and was recovered 
as a clear, colorless liquid (8.78 g, 39%): 1H NMR (400 MHz, CDCl3) δ 0.18 ppm (d, 4JHP = 1.2 
Hz, 9H). 31P NMR (162 MHz, CDCl3) δ -55 ppm (s). 
Poly(dichlorophosphazene) (PDCP) (5). In a typical procedure, 0.50 g of 4 was stirred in a 
solution of 5 × 10-3 M PCl5 in DCM (5 mL) for 18 h under nitrogen at RT. The solvent was 
removed under vacuum to yield a viscous polymer (quantitative): 31P NMR (162 MHz, CDCl3) δ 
-18 ppm. 
Poly(bis(3-mercapto-3-methylbut-1-yl glycinyl)phosphazene) (POP-Gly-MMB-SH). In a 
typical procedure, 3 (1.15 g, 5.39 mmol) was dissolved in THF (25 mL) and TEA (1.80 mL) was 
added. The mixture was stirred at RT for 1 h, then filtered into a solution of 5 (0.25 g) in 5 mL 
THF. The reaction was stirred under nitrogen for 48 h at 25 °C. The solvent was subsequently 
removed under vacuum and the residue was redissolved in THF (10 mL) and precipitated with 
100 mL hexanes. The precipitated solid was allowed to settle, then the supernatant was decanted 
and the polymer washed three times with hexanes (25 mL). The polymer was redissolved in 10 
mL toluene and washed twice with deionized water (5 mL) and once with 10% sodium chloride 




removed under vacuum. The polymer was taken up in THF (10 mL) and precipitated with 100 
mL hexanes, then the supernatant was decanted and the polymer was again washed three times 
with hexanes (25 mL). Evaporation of residual solvent under vacuum yielded a yellow-white 
powder (0.745 ± 0.014 g, 87 ± 2%): 1H NMR (400 MHz, CDCl3) δ 4.28, 3.90, 3.73, 1.95, 1.83, 
1.42 ppm. 13C NMR (100 MHz, CDCl3) δ 172.76, 62.22, 44.29, 43.14, 42.87, 33.17 ppm. 31P 
NMR (162 MHz, CDCl3) δ -0.41 ppm. IR ν 3349, 2961, 2923, 2865, 2563, 1737, 1455, 1416, 
1388, 1367, 1190, 1122, 1008, 975, 865, 707 cm-1 
Preparation of S-nitrosated poly(bis(3-mercapto-3-methylbut-1-yl glycinyl)phosphazene) 
films. POP-Gly-MMB-SH was dissolved in THF at a concentration of 75 mg mL-1 and cast onto 
12 mm diameter glass circles to form a single-sided 5 mg coating. After evaporation of THF, the 
coated substrates were individually immersed in 1 mL 10% t-BuONO/pentane and agitated at 
ambient temperature (20 °C) for 60 min. Following this reaction, the liquid was removed and the 
coated substrates were washed with 2 × 1 mL pentane and placed under vacuum to remove 
residual t-BuONO/pentane, yielding a faintly green film (POP-Gly-MMB-NO): IR ν 3323, 2965, 
2928, 2867, 1737, 1492, 1455, 1418, 1389, 1367, 1194, 1128, 1006, 971, 879, 780, 709, 665 cm-
1. UV-Vis λ 341 (915 ± 9 M-1 cm-1), 600 nm. 
 
4.3. Results and discussion 
4.3.1. Synthesis of poly(bis(3-mercapto-3-methylbut-1-yl glycinyl)phosphazene) 
NO-donating RSNOs are generally prepared from the reaction of thiols with nitrous acid or 
similar nitrosating reagents. It has been established that tertiary RSNOs (obtained directly from 
tertiary thiols) frequently exhibit significantly greater thermal stability than primary equivalents. 




while its primary analog S-nitroso-N-acetylcysteine rapidly decomposes when concentrated.36 
For this reason, the use of tertiary RSNOs (or unusually stable primary species such as GSNO) 
represents an obvious method of delaying decomposition and thereby extending the effective NO 
release period. To exploit this difference in stability, POP-Gly-MMB-SH was prepared from the 
substitution of PDCP with the tertiary thiol 3-mercapto-3-methylbut-1-yl glycinate, an ester 
derived from MMB and glycine (Figure 4.1).  MMB is a naturally-occurring bifunctional 
tertiary thiol found in a variety of food sources and utilized commercially as a flavoring/odor 
agent.33-35 MMB is also present in the biochemistry of certain felines as a metabolite of the 
amino acid felinine.37   Because PDCP is easily substituted by amino acids, it was reasoned that a 
glycine-MMB ester would permit straightforward conjugation of the tertiary thiol to the 
polyphosphazene. Toward this end, 3-mercapto-3-methylbut-1-yl glycinate hydrochloride was 
synthesized from the Steglich esterification of monochloroacetic acid with MMB, followed by 
substitution with sodium azide and reduction of this intermediate with triphenylphosphine. After 
 
Figure 4.1 Synthesis of S-nitrosated poly(bis(3-mercapto-3-methylbut-1-yl 
glycinyl)phosphazene) from poly(dichlorophosphazene). Copyright 2017 





acidic work-up and isolation by lyophilization, the hydrochloride salt was obtained in crude form 
(approximately 92% by 1H NMR). Although the corresponding thioester was also a potential 
product of the carbodiimide-mediated esterification of MMB, it was not recovered in any 
detectable quantity (1H NMR) from the reaction. Instead, the major product was the ester 3-
mercapto-3-methylbut-1-yl chloroacetate. The amino acid ester was reacted with PDCP in the 
presence of triethylamine to form the thiolated polymer POP-Gly-MMB-SH, which was isolated 
in 87% yield. The 1H NMR spectrum of POP-Gly-MMB-SH was largely consistent with that of 
3-mercapto-3-methylbut-1-yl glycinate, with broadened features appearing at 4.28 and 1.95 ppm 
corresponding to the methylene protons of MMB, and a prominent peak at 1.42 ppm originating 
from the gem dimethyl group (Figure 4.2).  The thiol proton appeared at 1.83 ppm, while 
features at 3.90 and 3.73 ppm were assigned to the PN-H proton and the methylene group of the 
glycinyl residue, respectively. 13C NMR peaks (assigned by HSQC) at 173.8 and 43.1 ppm 
originated from the carbonyl and methylene carbons of the glycinyl moiety, while the remaining 
peaks at 62.2 (-OCH2-), 44.3 (-CH2-), 42.9 (CSH), and 33.2 (-CH3) were attributable to the 3-
Figure 4.2 1H NMR spectrum of poly(bis(3-mercapto-3-methylbut-1-yl 
glycinyl)phosphazene). 1H NMR (400 MHz, CDCl3)  4.28, 3.90, 3.73, 1.95, 1.83, 




methyl-3-mercaptobut-1-yl ester (Figure 4.3). In the case of 31P NMR, a relatively broad feature 
centered at -0.41 ppm was consistent with previous reports of amine-substituted 
polyphosphazenes, with a feature at 18 ppm potentially attributable to minor hydrolysis of the 
backbone during aqueous work-up (Figure 4.4).22 ATR-FTIR was used to further characterize the 
polymer and the spectrum was found to be consistent with the anticipated structure, with key 
vibrational bands originating from the pendant group at 3349 (PN-H stretch), 2961, 2923, 2865 
(C-H stretch), 2563 (S-H stretch), 1737 (ester C=O), 1190, and 1122 cm-1 (ester) (Figure 4.5). 
Amine-substitution at phosphorus (P-N) is likely to produce the band observed at 975 cm-1, 
while additional vibrations from the polyphosphazene backbone itself appear at 1367 and 865 
cm-1.38,39 The presence of the thiol S-H stretch and the absence of the distinct 
asymmetric/symmetric N-H stretching pattern of primary amines supports P-N bond formation 
as the primary mode of substitution. POP-Gly-MMB-SH exhibited solubility in many common 
organic solvents, including toluene, DCM, and DMF. Solubility was minimal in diethyl ether, 
and the polymer was insoluble in aliphatic hydrocarbons such as hexane and pentane. GPC 
Figure 4.3 13C NMR spectrum of poly(bis(3-mercapto-3-methylbut-1-yl 
glycinyl)phosphazene). 13C NMR (100 MHz, CDCl3)  172.76, 62.22, 44.2λ, 43.14, 




analysis indicated a molecular weight (Mn) of 616 kDa with a polydispersity of 1.29, resulting in 
a calculated degree of polymerization (Mn/M0) of 1550 using a presumed monomeric unit mass 
of 397.5 Da. 
Thiolated polymers have attracted significant interest due to their ability to participate in 
both reversible (disulfide formation) and irreversible (thiol-ene) crosslinking, permitting 
inducible changes to their physical and mechanical properties. Furthermore, conversion of 
polymer-bound thiol to the corresponding RSNO derivative has been widely utilized to prepare 
NO-releasing materials for biomedical applications. Despite the wide interest in the development 
of thiolated polymers, few thiolated poly(organophosphazenes) have been reported to date. Potta 
et al. described the development of a crosslinkable poly(organophosphazene) prepared from the 
substitution of PDCP with α-amino-ω-methoxy-poly(ethylene glycol), isoleucine ethyl ester, and 
cystamine, followed by reduction of the disulfide linkages with dithiothreitol.40 Weikel et al. 
synthesized a thiolated polymer from deprotection of poly(bis(cysteine ethyl disulfide ethyl 
ester)phosphazene) with dithiothreitol or 2-mercaptoethanol.41 In both reports, the precursor 
 
Figure 4.4 31P NMR spectrum of poly(bis(3-mercapto-3-methylbut-1-yl 
glycinyl)phosphazene). 31P NMR (162 MHz, CDCl3)  -0.41 ppm. Minor additional 
peaks at 29 (triphenylphosphine oxide reference) and 18 ppm not depicted. 





PDCP was substituted with amine-bearing disulfides which were subsequently cleaved to 
liberate free thiol using common disulfide reducing agents. Weikel et al. observed that the direct 
introduction of thiol in the form of cysteine ethyl ester resulted in competitive substitution at 
phosphorus by both the amine and thiol groups, necessitating the use of a disulfide-based 
protection/deprotection strategy to avoid chemoselectivity issues. In contrast, we observe that 3-
mercapto-3-methylbut-1-yl glycinate preferentially substitutes PDCP through the amine group 
without protection of the thiol, potentially indicating that a significant level of chemoselectivity 
is attained through simple hindrance of the tertiary thiol. This may represent a useful method of 
preparing future thiolated polyphosphazenes, since it does not require the formation of 
asymmetric disulfide linkages that are often incompletely cleaved and retained in the final 
polymer, or the use of potentially toxic disulfide scission reagents (e.g. 2-mercaptoethanol). 
  
Figure 4.5 ATR-FTIR spectra of polymers. Top: ATR-FTIR spectrum of poly(bis(3-
mercapto-3-methylbut-1-yl glycinyl)phosphazene) (POP-Gly-MMB-SH). IR: 3349, 
2961, 2923, 2865, 2563, 1737, 1455, 1416, 1388, 1367, 1190, 1122, 1008, 975, 865, 
707 cm-1. Bottom: ATR-FTIR spectrum of S-nitrosated poly(bis(3-mercapto-3-
methylbut-1-yl glycinyl)phosphazene) (POP-Gly-MMB-NO). IR: 3323, 2965, 2928, 
2867, 1737, 1492, 1455, 1418, 1389, 1367, 1194, 1128, 1006, 971, 879, 780, 709, 665 





4.3.2. S-Nitrosation of poly(bis(3-mercapto-3-methylbut-1-yl glycinyl)phosphazene) 
coatings 
S-Nitrosation of POP-Gly-MMB-SH was achieved using t-BuONO, an alkyl nitrite that 
functions as a mild nitrosating agent in the presence of free sulfhydryl groups. While S-
nitrosation of the polymer proceeds under both heterogeneous and homogeneous conditions, it 
was found that dissolution in organic solvents leads to comparatively rapid decomposition of the 
RSNO. Furthermore, the solubility of POP-Gly-MMB-NO is significantly impaired relative to 
the thiolated precursor and results in limited access to solution-phase coating techniques or other 
processing methods based on dissolution. For this reason, POP-Gly-MMB-SH was first applied 
as a single-sided coating to glass substrates, followed by immersion in 10% t-BuONO/pentane. 
POP-Gly-MMB-SH was also found to adhere to (and blend with) medically-relevant, 
biodegradable polymers such as polycaprolactone and poly(lactic acid) (PLA). However, the 
need for a comparatively inert substrate for S-nitrosation and subsequent NO release experiments 
dictated the use of glass over polymer surfaces. Using this approach, the insoluble polymer 
remained attached to the substrate during the S-nitrosation process, while the volatility of t-
BuONO/pentane permitted their straightforward removal under vacuum following the reaction. 
Since the non-nitrosated precursor POP-Gly-MMB-SH exhibits excellent solubility in a diverse 
range of organic solvents, this method demonstrates that it can be applied as a coating or 
otherwise processed into a usable form prior to conversion to the S-nitrosated derivative. As 
previously noted, the S-nitrosated polymer exhibits poor solubility that is most directly 
explainable by crosslinking arising from disulfide formation. Such an outcome is predicted by 




S-N bond is accompanied by the subsequent formation of disulfide according to the equation 2 
RSNO → 2 NO + RSSR.41 This limited solubility and  the continuous thermal decomposition of 
the RSNO hindered the use of NMR and GPC as reliable characterization techniques. However, 
RSNOs are routinely characterized by UV-Vis spectroscopy and exhibit distinctive absorption 
features at approximately 340 (variably described as π→π* or n
O
→π* transitions) and 550 
(n
N
→π*) nm.32,42 Further discrimination between primary/secondary and tertiary 
 
Figure 4.6 UV-Vis spectra of polymers. (a) UV-Vis spectra of POP-Gly-MMB-SH 
(dotted line) and POP-Gly-MMB-NO (solid line) in DMF at arbitrary concentration. 
Characteristic absorptions arising from the RSNO functional group are identified on 
the plot and occur at 341 (π→π*) and 600 nm (nN→π*). (b) ATR-FTIR spectra of 
(i) POP-Gly-MMB-SH, (ii) POP-Gly-MMB-NO immediately following S-
nitrosation, and (iii) POP-Gly-MMB-NO after six weeks of immersion in pH 
7.4 PBS at 37 °C. The diagnostic N=O vibrational band is identified at 1492 cm-1. 





substitution patterns is possible due to a bathochromic shift in the n
N
→π* transition 
toward 600 nm in the case of tertiary RSNOs. In the case of POP-Gly-MMB-NO, 
solubility was sufficient to acquire UV-Vis spectra of the polymer in DMF, and the 
successful formation of RSNO was confirmed by the appearance of diagnostic absorptions at 341 
and 600 nm in the UV-Vis spectrum (Figure 4.6a).  UV-Vis absorptions attributable to alkyl 
nitrites (e.g. t-BuONO) or N-nitroso species were not observed.43,44 The molar extinction 
coefficient of 915 ± 9 M-1 cm-1 (DMF) determined for the absorbance feature at 341 nm was 
consistent with the approximate value of 1000 M-1 cm-1 typically found for RSNOs.15 While the 
non-nitrosated polymer has a colorless or faintly yellow appearance, POP-Gly-MMB-NO the 
non-nitrosated precursor, although S-nitrosation resulted in the disappearance of the thiol S-H 
stretch and the appearance of new bands at 1492 and 665 cm-1 that were attributable to N=O and 
N-S vibrational modes, respectively (Figure 4.5 and 4.6b).45 As shown in Figure 4.6b, the 
diagnostic N=O stretch develops following S-nitrosation and is no longer detectable after 
extended immersion in PBS at physiological temperature and pH. Furthermore, the PN-H stretch 
(centered at 3323 cm-1 in the ATR-FTIR spectrum of POP-Gly-MMB-NO) is retained, indicating 
that reaction with t-BuONO does not produce N-nitrosation under the given reaction conditions. 
 
 
Figure 4.7 Water contact angle images. Representative images of water 
droplets on (a) POP-Gly-MMB-SH and (b) POP-Gly-MMB-NO surfaces, 
displaying the decrease in WCA following S-nitrosation. Copyright 2017 





Contact angle goniometry demonstrated an increase in wettability subsequent to S-nitrosation, 
with the measured WCA decreasing by 16° with the conversion of POP-Gly-MMB-SH (70 ± 7°) 
to POP-Gly-MMB-NO (54 ± 4°) (Figure 4.7). This outcome may be rationalized by introduction 
of the polar, hydrogen bond accepting NO moiety or an alteration of surface roughness following 
exposure to t-BuONO during the S-nitrosation. 
 
4.3.3. Nitric oxide release measurements 
NO release measurements were obtained using commercial Sievers chemiluminescence-
based NO analyzers. The function of these instruments relies on  the chemiluminescent 
reaction of NO with ozone (NO + O3 → NO2 + O2), which results in the formation of excited-
state NO2.
46 The relaxation of excited-state NO2 is accompanied by the release of light, which is 
quantified by the instrument to determine gas-phase NO concentration (ppb/ppm). NO 
concentration is subsequently converted to NO release (mol) using a calibration constant 
obtained from the reduction of sodium nitrite and verified by decomposition of GSNO. This 
method is highly selective for NO and is widely utilized in the quantification of NO release from 
NO donors such as RSNOs. The NO-forming thermal or photolytic decomposition of RSNOs is 
generally theorized to proceed through homolytic cleavage of the S-N bond, followed by either 
non-productive recombination or the irreversible generation of NO and disulfide according to the 
equation 2 RSNO → 2 NO + RSSR.15,47 It has also been demonstrated that transition metals such 
as copper are capable of  catalytically initiating the NO-forming decomposition of RSNOs 
through more complex mechanisms that are not fully elucidated.48  To assess the ability of POP-
Gly-MMB-NO to release NO at physiological pH and temperature, samples were immersed in 




and the resulting NO release was recorded. To permit calculation of NO content (mmol g-1) and 
NO flux (nmol min-1 cm-2), all release measurements were obtained from 12 mm diameter glass 
circles coated with a single-sided layer of POP-Gly-MMB-NO of known mass derived from 
triplicate syntheses. Since NO release profiles arising from the decomposition of RSNOs 
frequently display exponential decay, NO release was monitored continuously over the initial 24 
h release period to illustrate the relatively rapid change in NO release over this period (Figure 
4.8a and 4.8b). To avoid the influence of dissolved copper on the observed decomposition 
profiles, glassware used in NO analysis experiments was treated with a saturated solution of 
EDTA-Na2, then washed with Millipore water before use. Furthermore, PBS was analyzed by 
ICP-AES and not found to contain detectable levels of dissolved copper. Over 24 h of 
immersion, 0.15 ± 0.01 mmol NO g-1 was released, corresponding to 17 ± 2% of total available 
NO. This indicates a significantly slower rate of RSNO decomposition relative to the previously 
 
Figure 4.8 24 h NO release profiles of S-nitrosated poly(bis(3-mercapto-3-methylbut-
1-yl glycinyl)phosphazene) coatings. (a) Mean NO flux profile obtained over 24 h 
from 12 mm diameter POP-Gly-MMB-NO coated substrate suspended in pH 7.4 PBS 
at 37 °C (n = 3). Inset: Interval between 4 - 24 h, after the initial burst of NO release. 
Recurrent spikes in NO release may be attributable to the release of trapped gaseous 
NO within the polymer coating.  (b) Mean cumulative NO release from POP-Gly-
MMB-NO films over 24 h at pH 7.4 PBS at 37 °C (n = 3). Reported data obtained 






reported S-nitrosated polyphosphazene derived from poly(S-methylthiocysteinyl-co-ethyl 
cysteinyl phosphazene), where  64% of available NO was released over 24 h under identical 
conditions. The formation of NO from the tertiary RSNO groups of POP-Gly-MMB-NO was 
anticipated to follow the general thermal decomposition pathway established for small-molecule 
RSNOs, wherein the S-N bond undergoes homolytic scission to form NO and the corresponding 
thiyl radical. As mentioned previously, these species may recombine non-productively, or thiyl 
radicals may combine to form disulfide with the concomitant release of NO. When compared to 
the previous cysteine-based NO-releasing POP, the reduction in the rate of NO release observed 
for POP-Gly-MMB-NO may largely result from the greater stability of the tertiary RSNO groups 
present in this polymer. Computationally, this difference in stability has been attributed to 
considerable steric congestion during dimerization of tertiary thiyl radicals, which favors 
recombination with NO.36 Following each 24 h experiment, remaining NO was recovered by 
exposure of the coated substrates to UV light at 40 °C to obtain a total releasable NO content of 
0.89 ± 0.09 mmol g-1, or 4.3 ± 0.6 μmol cm-2. Exposure to UV light was not found to produce 
any detectable NO release from POP-Gly-MMB-SH controls immersed in an identical medium. 
Comparison of the NO content of POP-Gly-MMB-NO with other materials based on tertiary 
RSNOs indicates a relatively large NO storage capacity. For example, Riccio et al. reported NO 
storage in the range of 0.87-1.78 μmol cm-2 for an NO-releasing xerogel incorporating a tertiary 
RSNO derived from N-acetylpenicillamine.21  The ability of POP-Gly-MMB-NO to produce a 
prolonged NO flux was examined by measuring NO release from the coated substrates at regular 
intervals over a period of 14 d (Figure 4.9a).  To represent the exponential decay observed for the 
NO release profile, the value of the initial flux (t = 0) was obtained from the maximum mean NO 




mean NO release recorded at subsequent measurement points, where rapid changes in the rate of 
NO release no longer occurred. Between measurements, samples were incubated in pH 7.4 PBS 
at 37 °C under ambient atmosphere. The maximum initial NO flux of 6.5 ± 0.2 nmol min-1 cm-2  
was followed by rapid decay to 0.43 ± 0.04 nmol min-1 cm-2 at the end of 24 h, followed by 
further decline to 0.090 ± 0.003 nmol min-1 cm-2  at the end of 14 d. To evaluate the stability of 
POP-Gly-MMB-NO under physiological conditions, substrates coated with the polymer were 
incubated in 5 mL of pH 7.4 PBS at 37 °C for 3, 7, and 14 days and their residual NO content 
was quantified by UV decomposition as previously described (Figure 4.9b). After 3 days, 46 ± 
7% of the original NO content remained, with this value declining over 7 and 14 days of 
incubation to 35 ± 4% and 10 ± 1%, respectively.  
 
Figure 4.9 14 d NO flux from S-nitrosated poly(bis(3-mercapto-3-methylbut-1-yl 
glycinyl)phosphazene) coatings and residual NO content. (a) Mean NO flux  over 14 
d from glass substrates coated with POP-Gly-MMB-NO and suspended in pH 7.4 
PBS at 37 °C. (b) Remaining NO at 1, 3, 7, and 14 d as determined by 
thermal/photolytic decomposition of polymer-coated substrates. Data points/bar 
height represent mean values and error bars represent standard deviation (n = 3). 
Reported data obtained from three discrete polymer syntheses. Copyright 2017 





Interpretation of the NO release properties of POP-Gly-MMB-NO requires reference to the 
body of literature concerning the effect of NO release with respect to various biological 
applications. It was reported by Ramamurthi and Lewis that platelet inhibition was largely 
complete at an NO surface flux between 0.3 and 0.6 fmol s-1 cm-2  (2 × 10-5-4 × 10-5 nmol min-1 
cm-2) .49 In the case of NO-releasing sol-gel microarrays, Robbins et al. found that an NO flux of 
0.4 pmol s-1 cm-2 (0.02 nmol min-1 cm-2) was sufficient to reduce platelet adhesion under certain 
conditions.50 Furthermore, cultured bovine endothelial cells were found to exhibit an NO flux as 
low as 0.05 nmol min-1 cm-2, while the endothelium has been mathematically estimated to 
produce an NO flux as high as 6.8 × 10-14 μmol s-1 μm-2 (0.41 nmol min-1 cm-2).51,52 This range 
has previously been used for comparative purposes to assess the potential utility of NO-releasing 
materials.53,54 Substrates coated with POP-Gly-MMB-NO demonstrated an NO flux that 
remained within this broad endothelial range for the entirety of the two week measurement 
period. Moreover, the measured NO flux was significantly greater than the minimum level 
observed to exert antiplatelet effects, suggesting potential use as a source of antithrombotic NO 
in the case of bioresorbable stents or similar devices. Nablo and Schoenfisch reported that a 
sustained NO flux greater than 20 pmol s-1 cm-2 (1.2 nmol min-1 cm-2) was required to prevent 
75% of P. aeruginosa adhesion to a PVC-coated sol-gel, with the maximum antibacterial effect 
attributed to NO fluxes greater than 35 pmol s-1 cm-2 (2.1 nmol min-1 cm-2).55 Furthermore, 
Hetrick and Schoenfisch found that NO-releasing xerogels producing an NO flux of ~21 pmol s-1 
cm-2 (1.3 nmol min-1 cm-2) reduced P. aeruginosa adhesion by ~65%, with effective reduction in 
bacteria coverage also observed at significant lower NO fluxes.56 Substrates coated with POP-
Gly-MMB-NO exhibited a maximal NO flux at least 3 times greater than that required for the 




However, this NO flux is maintained for significantly less than 24 h, and thereafter the flux is 
limited to a range without significant antibacterial effects. While increased NO flux may 
theoretically be obtained from the deposition of a greater quantity of S-nitrosated polymer, 
doubling the mass of the coating did not produce any corresponding elevation in NO release. 
This observation was a probable consequence of the inability of the nitrosating agent t-BuONO 
to access the bulk polymer. Assessment of the swelling characteristics of POP-Gly-MMB-SH in 
t-BuONO/pentane using a gravimetric approach indicates no appreciable uptake of solvent over 
the course of the nitrosation. This lack of solvent diffusion suggests that S-nitrosation is largely 
confined to the surface of the polymer coating. NO has also been shown to influence wound 
healing under a variety of circumstances, which has led to the development of NO-releasing 
materials for the treatment of injuries.9 For example, Diwan et al. observed that suppression of 
endogenous NO production impaired bone fracture healing, and that delivery of supplemental 
NO directly to the site of injury using a polymer-bound N-diazeniumdiolate ameliorated this 
impairment.57 Because biodegradable polyphosphazenes have frequently been proposed as useful 
materials in bone tissue engineering, this may suggest a potential role for POP-Gly-MMB-NO 
beyond the development of NO-releasing coatings.28 
 
4.3.4. Degradation study 
 Biodegradation of amine-substituted polyphosphazenes has been previously established 
to occur through gradual hydrolysis that liberates the organic substituents and ultimately converts 
the phosphorus-nitrogen backbone into self-neutralizing phosphate and ammonia.28 For this 
reason, biodegradable POPs substituted with amino acids may be less likely to produce the local 




esters, POP degradation is accompanied by hydrolytic cleavage of the ester linkage to regenerate 
the parent alcohol. The specific degradation characteristics of POP-Gly-MMB-SH and POP-Gly-
MMB-NO were assessed by immersion in pH 7.4 PBS at 37 °C for a total of six weeks (Figure 
4.10).  
To permit direct comparison with POP-Gly-MMB-SH, the initial mass of POP-Gly-MMB-
NO was recorded in the form of the non-nitrosated precursor. This results in a subsequent mass 
increase from the conversion of thiol groups  to RSNO.  The buffer solution was replaced at the 
end of each week and found to maintain a constant pH. In the case of POP-Gly-MMB-SH, 
continuous degradation was observed during immersion in PBS, with 56.9 ± 0.6% of the initial 
mass remaining after the six week incubation period. POP-Gly-MMB-NO experienced a 
significantly slower rate of degradation when compared to the thiolated precursor, and 86.1 ± 
0.5% of the initial mass remained at the end of the study. As noted previously, decomposition of 
the RSNO functional groups of POP-Gly-MMB-NO is accompanied by disulfide formation, a 
process that decreases the rate of degradation through crosslinking. This curing phenomenon 
 
Figure 4.10 Degradation of polymers over six weeks. Conditions: pH 7.4 PBS at 37 
°C. Data points represent mean values and error bars represent standard deviation (n = 






confers greater resistance to hydrolytic decomposition and improves the durability of POP-Gly-
MMB-NO relative to the non-nitrosated material. After the six week degradation study had 
concluded, neither polymer exhibited any appreciable solubility. ATR-IR spectra of both POP-
Gly-MMB-SH and POP-Gly-MMB-NO were generally consistent with that of the original non-
nitrosated material (Figure 4.11). POP-Gly-MMB-NO no longer exhibited IR absorbance bands 
at 1492 (N=O) and 665 cm-1 (N-S) or the green color of tertiary RSNOs, supporting the expected 
decomposition of the NO donor moieties. In separate experiments, additional samples of the 
nitrosated and non-nitrosated polymer were suspended in deionized water for three weeks at 37 
°C to evaluate the result of their degradation without buffering. POP-Gly-MMB-SH produced a 
minor pH elevation to 7.4, an outcome that was generally consistent with the anticipated near-
neutrality of POP decomposition and lack of substantial acidic product formation.28 In contrast, 
Figure 4.11 Top: ATR-FTIR spectrum of poly(bis(3-mercapto-3-methylbut-1-yl 
glycinyl)phosphazene) (POP-Gly-MMB-SH), following a 6-week degradation study. 
IR: 3326, 2963, 2926, 2866, 1737, 1682, 1542, 1456, 1418, 1388, 1365, 1196, 1128, 
1028, 967, 873, 695 cm-1. Bottom: ATR-FTIR spectrum of S-nitrosated poly(bis(3-
mercapto-3-methylbut-1-yl glycinyl)phosphazene) (POP-Gly-MMB-NO), following a 
6-week degradation study. IR: 3326, 2961, 2924, 2865, 1736, 1676, 1541, 1456, 






degradation of POP-Gly-MMB-NO produced a pH decline to the range of 3-4, which likely 
arises from the oxidation of NO to HNO2 or HNO3 in the presence of water and atmospheric 
oxygen and was an anticipated consequence of NO release under unbuffered conditions.59  
To identify organic hydrolysis products of the polymers, samples were incubated in water 
for two weeks and the resulting media were analyzed by TOF-MS. The primary identifiable 
degradation products common to both polymers were glycine (C2H5NO2), MMB (C5H12OS), and 
3-mercapto-3-methylbut-1-yl glycinate (C7H15NO2S), as shown in Table 4.1. This outcome is 
consistent with the anticipated degradation pattern of amine-substituted POPs, and suggests that 
glycine and MMB are the ultimate products of hydrolysis of the polymer and the liberated 
glycine-MMB ester. In the case of the S-nitrosated POP-Gly-MMB-NO, several additional ions  
Table 4.1 Mass spectrometry data. 

















































































consistent with the disulfides 3-((4-hydroxy-2-methylbutan-2-yl)disulfanyl)-3-methylbut-1-yl 
glycinate (C12H25NO3S2) and 3-((4-(glycyloxy)-2-methylbutan-2-yl)disulfanyl)-3-methylbut-1-yl 
2-hydroxyacetate (C14H27NO5S2) were found. Both molecules are likely to represent products of 
the disulfide-forming decomposition of RSNO. In the former case, the mass is consistent with a 
disulfide dimer of the glycine-MMB ester after the hydrolytic removal of a single glycine unit. In 
the latter case, the mass is attributable to a similar dimer with the substitution of a single glycine 
unit with glycolic acid. This apparent substitution is likely to arise from N-nitrosation of the 
glycine unit via nitrosating agents formed in situ by oxidation of released NO, such as nitrous 
acid or N2O3. This N-nitrosated intermediate is expected to lead to the diazotization of the amine 
group, followed by displacement of nitrogen gas and the formation of a glycolate derivative 
through reaction with water.60 
 
4.4. Conclusions 
This work presents the first use of a tertiary RSNO to achieve NO release from a 
biodegradable polyphosphazene. Previously, the synthesis of thiol-bearing polyphosphazenes 
from PDCP has been complicated by thiol protection schemes required to achieve selective 
substitution by amine groups. Unlike prior examples, it was found that no thiol 
protection/deprotection steps were necessary to achieve amine-selective substitution of PDCP 
during the synthesis of POP-Gly-MMB-SH, an outcome that was attributable to the use of a 
tertiary thiol. Substrates coated with POP-Gly-MMB-NO maintain a physiologically-relevant 
NO flux in the range of 6.5-0.090 nmol min-1 cm-2 for at least two weeks when compared to a 
reported natural endothelial flux of 0.05-0.4 nmol min-1 cm-2. In addition, the overall NO content 




releasable NO. 86.1 ± 0.5% of the original mass of POP-Gly-MMB-NO was found to remain 
after six weeks of immersion in pH 7.4 PBS at 37 °C, with the formation of degradation products 
that are consistent with the hydrolysis of amino ester-substituted polyphosphazenes in the 
presence of NO. This hydrolytic degradation largely resulted in the production of glycine and 
various esters derived from the naturally-occurring thiol MMB. Collectively, the data suggest 
that polyphosphazenes incorporating tertiary RSNOs are capable of physiologically-relevant NO 
release for an extended duration, and may be adaptable for use in biomaterials applications. 
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Nuclear magnetic resonance spectra 
Figure 4.12 1H NMR spectrum of trichloro(trimethylsilyl)phosphoranimine. 1H NMR 
(400 MHz, CDCl3)  0.18 ppm (d, λH). Chlorotrimethylsilane impurity at 0.45 ppm. 







Figure 4.13 31P NMR spectra of trichloro(trimethylsilyl)phosphoranimine and 
poly(dichlorophosphazene). (a) Trichloro(trimethylsilyl)phosphoranimine 31P NMR 
(162 MHz, CDCl3)  -55 ppm. (b) Poly(dichlorophosphazene). 31P NMR (162 MHz, 





Figure 4.14 1H NMR spectrum of 3-mercapto-3-methylbutan-1-ol. 1H NMR (400 
MHz, CDCl3)  3.86 (t, J = 6.8 Hz, 2H), 1.97 (s, 1H), 1.89 (t, J = 6.8, 2H), 1.81 (s, 





Figure 4.15 13C NMR spectrum of 3-mercapto-3-methylbutan-1-ol. 13C NMR (100 






Figure 4.16 1H NMR spectrum of 3-mercapto-3-methylbut-1-yl chloroacetate. 1H 
NMR (400 MHz, CDCl3)  4.42 (t, J = 7.2 Hz, 2H), 4.06 (s, 2H), 1.98 (t, J = 7.2, 2H), 





Figure 4.17 13C NMR spectrum of 3-mercapto-3-methylbut-1-yl chloroacetate. 13C 
NMR (100 MHz, CDCl3)  167.23, 63.84, 44.13, 42.78, 40.85, 33.10 ppm. Copyright 






Figure 4.18. 1H NMR spectrum of 3-mercapto-3-methylbut-1-yl azidoacetate. 1H 
NMR (400 MHz, CDCl3)  4.43 (t, J = 7.2 Hz, 2H), 3.88 (s, 2H), 1.99 (t, J = 7.2, 2H), 






Figure 4.19 13C NMR spectrum of 3-mercapto-3-methylbut-1-yl azidoacetate. 13C 
NMR (100 MHz, CDCl3)  168.23, 63.44, 50.41, 44.15, 42.74, 33.08 ppm. Copyright 







Figure 4.20 1H NMR spectrum of 3-mercapto-3-methylbut-1-yl glycinate 
hydrochloride. 1H NMR (400 MHz, CDCl3)  8.53 (s, 3H), 4.42 (t, J = 7.2 Hz, 2H), 
4.03 (q, J = 6.0, 2H), 1.97 (t, J = 7.2, 2H), 1.86 (s, 1H), 1.41 ppm (s, 6H). Copyright 




Figure 4.21 13C NMR spectrum of 3-mercapto-3-methylbut-1-yl glycinate 
hydrochloride. 13C NMR (100 MHz, CDCl3)  167.77, 64.12, 43.98, 42.80, 40.76, 
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FUTURE DIRECTIONS AND PRACTICAL CONSIDERATIONS 
 
 
5.1. S-Nitrosothiols as useful sources of therapeutic nitric oxide 
The frequent use of RSNOs as NO donor molecules over the last two decades demonstrates 
continued interest in their unique NO-forming properties. However, it must be recognized that 
several notable shortcomings currently restrict the practical implementation of RSNOs in a 
medical context. The inability to control the fundamental instability of the RSNO functional 
group is arguably the most crucial limitation, and represents a significant barrier to long-term use 
within a biological setting. Exposure to heat and light accelerate the NO-forming decomposition 
of the RSNO functional group, which imposes the requirement that suitable storage conditions be 
maintained until use.1 Although this is not a unique concern and applies to many 
pharmaceuticals, the comparatively rapid decomposition of RSNOs presents a challenge with 
respect to routine clinical use. As a partial consequence of the known susceptibility of RSNOs to 
temperature and light, the kinetics of the NO-forming decomposition of RSNOs depends upon 
prevailing conditions, which may complicate the controlled in vivo delivery of specific NO 
dosages. While N-diazeniumdiolates show clean first-order decomposition kinetics leading to the 
release of NO, RSNOs frequently exhibit much more complex behavior, including fractional 
kinetic orders.2,3 This variation in kinetics may be attributable to the sensitivity of RSNOs to pH 
conditions, the presence of certain transition metal ions, thiols, and even dissolved gases, among 
other species known to influence the rate of RSNO decomposition.1,4,5 Nevertheless, certain 




within polymers. For example, Brisbois et al. observed that the incorporation of SNAP within a 
polyurethane matrix permitted the retention of 82% of the initial quantity of RSNO after storage 
for 2 months at 37 °C.6 This outcome is not representative of the more rapid decomposition 
typically observed for polymer-RSNO conjugates (where useful release periods are frequently 
limited to hours or days), and is most directly attributable to isolation of SNAP within a 
polymeric matrix. In general, it can be stated that finer control over the kinetics of decomposition 
and extension of the useful NO release period are desirable goals in the development of future 
RSNO-based biomaterials. This may be achieved on a fundamental l vel through the use of 
RSNOs that exhibit greater inherent stability, or through the engineering of materials that 
modulate exposure to environmental decomposition triggers.  
For the purposes of this discussion, it should be understood that the most common method 
of preparing RSNO-based biodegradable materials is through the polymeric incorporation of a 
small molecule thiol, which is subsequently converted to the RSNO derivative. This thiol may be 
directly included as a monomer during polymerization,or may be conjugated to the backbone of 
a structurally-unrelated polymer after its synthesis.7,8 The latter (and most common) approach 
produces numerous pendant groups that may exhibit chemical behavior that is quite distinct from 
that of the original polymer chain. As such, it is often useful to consider the RSNO moiety as a 
discrete (and potentially modular) component rather than an integral element of the polymer. In 
the past, many NO-releasing biomaterials have incorporated primary RSNO groups, often 
derived from naturally-occurring thiols such as L-cysteine.9 With the exception of GSNO, the 
majority of primary RSNOs are remarkably unstable and generally do not permit extended (i.e. 
multi-day or multi-week) NO release when bound to polymers. While GSNO remains an 




molecular weight and the chemical properties of its tripeptide structure may limit the versatility 
of materials that include it as an NO donor moiety. In general, the greater stability of tertiary 
RSNOs (in comparison to primary or secondary examples) suggests that future RSNO-based 
biomaterials should preferentially target these structures.10 Unfortunately, the library of 
synthetically-useful, commercially-available tertiary thiols is limited and many entries have 
uncertain toxicological behavior. Moreover, even commonly used tertiary RSNOs such as 
racemic SNAP may warrant toxicity concerns. In the absence of definitive biological data, the 
formation of racemic SNAP in vivo during biodegradation of a polymer can be anticipated to 
produce health concerns related to the potential regeneration of the toxic pyridoxine inhibitor and 
metal chelator, L-penicillamine.11 Chapter 4 of this dissertation utilized the food-grade tertiary 
thiol 3-mercapto-3-methylbutanol as an alternative to penicillamine-based compounds, but does 
not evaluate the toxicity of this compound with respect to mammalian cell lines.  
Overall, the synthesis of biodegradable RSNO-based polymers would greatly benefit from 
the thorough chemical and toxicological characterization of new tertiary thiols/RSNOs that can 
be effectively incorporated within polymer structures. Because the major utility of the RSNO 
functional group is as an instrument of useful NO release, access to a larger library of well-
characterized, stable RSNOs will encourage the thoughtful development of future NO-releasing 
materials. This groundwork is crucial in a field that has haphazardly paired RSNOs with various 
polymer architectures without clear alignment between their respective properties. This concern 
is not limited to NO release duration, and extends to fundamental incompatibilities between the 
RSNO unit and practical use of the polymer. In cases where hydrophobicity is desirable, it may 
be inappropriate to utilize amino acid-based RSNOs (particularly those with remaining amine or 




acidic or basic functional groups are likely to influence the rate of polymer hydrolysis. Toxic 
thiols and their derivative RSNOs should not be utilized in any capacity if the polymer is 
intended to degrade in a biological environment. The mechanical properties of a polymer are also 
likely to be affected by disulfide-forming RSNO decomposition, since this process may facilitate 
crosslinking. It is therefore sensible to advise that future work should carefully consider whether 
the local structure of the incorporated RSNO supports the intended application of the polymer. In 
summary, while the usefulness of RSNOs as polymer-bound NO donors remains clear, additional 
work is needed at a fundamental level to ensure that chemically-compatible donors are utilized 
with controlled, biologically-relevant NO release. 
 
5.2. The use of chitin and chitosan as nitric oxide release platforms 
Although chitin has been investigated for select biomedical applications, it is not easily 
processed from solution into useful forms.12 The most effective solvents are concentrated 
solutions of lithium chloride/dimethylacetamide or calcium chloride/methanol.13,14 Furthermore, 
the useful antibacterial and hemostatic properties of chitin are largely attributable to the presence 
of glucosamine units, leading to the natural conclusion that the more fully deacetylated 
derivative chitosan represents a more useful material. For this reason, the development of NO-
releasing chitin derivatives is likely to remain limited and of little practical consideration. In 
contrast, recent interest in NO-releasing chitosan derivatives (often in the oligosaccharide form) 
has been persistent and well-represented among multiple publications.15-17 A  a hemostatic agent, 
bulk chitosan is inherently unsuitable for development into an NO-releasing ntithrombotic 
material.12 Consequently, NO-releasing chitosan derivatives are restricted to antibacterial or 




as an NO-release platform originates from the retention of its therapeutic characteristics. 
However, both RSNO formation and NO release from chitosan is not necessarily chemically 
innocuous with respect to the polysaccharide, and may produce undesirable structural changes 
that influence the ultimate behavior of the material. For example, the exposure of chitosan to 
nitrosating agents typically used in the preparation of RSNOs may result in the formation of 
alkyl nitrites (RONO) from the C3/C6 hydroxyl groups or deamination through diazotization and 
the subsequent displacement of nitrogen by opportunistic nucleophiles (or potentially by ring-
contraction, as in the case of heparin).18,19 In Chapter 2, ATR-FTIR was used to characterize the 
NO-releasing chitosan derivatives and the loss of either the hydroxyl groups or the primary 
amine was not evident. This was achieved through acidification of the reaction solution, which is 
likely to suppress N-nitrosation by protonation of primary amine groups.20 Furthermore, the 
addition of methanol may produce an equilibrium that favors the formation of gaseous methyl 
nitrite over nitrosation of the polysaccharide hydroxyl groups.21 It has also been demonstrated 
that HNO2 (either used deliberately as a nitrosating agent or formed as a product of NO release) 
may effect the depolymerization of certain polysaccharides.18 Regardless of the specific mode of 
interactivity, it is clear that chitosan cannot be expected to function as an inert NO release 
platform. Instead, chitosan should be treated as a reactive substrate that may be actively modified 
by NO chemistry. It is therefore the case that future NO-releasing chitosan derivatives must be 
carefully evaluated for evidence of deleterious chemical changes after NO release (particularly 
under biologically relevant conditions) or exposure to nitrosating agents. A greater degree of 
rigor in the general characterization protocols used for NO-releasing chitosan materials may 
permit the elimination of unwanted side reactions and facilitate their development into products 




A second area of refinement concerns the synthetic methods used during incorporation of 
the RSNO donor group. The most direct approach to thiolation of chitosan involves the 
conjugation of a thiol-bearing carboxylic acid to the C2 primary amine via amide formation, an 
outcome that may be achieved through the use of carbodiimide chemistry.22 Carbodiimide-based 
protocols have been utilized with varying degrees of success, and may be inhibited by the 
interception of reactive intermediates by sulfhydryl groups or other competitive nucleophiles.23 
Notably, Kurita et al. were unable to effectively acetylate chitosan using 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide, even in the absence of a thiol group. The possibility of 
interference from thiol groups has previously led to the use of S-protection strategies that 
complicate the otherwise straightforward synthesis.24 Moreover, the use of an amide-forming 
strategy requires the permanent functionalization of the C2 primary amine, which is likely to 
impair both the aqueous solubility and critical antibacterial and hemostatic properties of chitosan 
as the degree of derivatization increases. For these reasons, Chapter 2 discusses the use of an 
alternative approach involving modification of hydroxyl groups. This strategy begins with 
protection of the primary amine groups as the N-phthaloyl derivative, followed by O-tosylation, 
the thioether-forming introduction of the sulfhydryl group as the free end of a symmetrical 
dithiol, and deprotection by hydrazine. The resulting materials qualitatively retain the primary 
amine group, but exhibit impaired solubility that may be attributable to disulfide formation. 
Consequently, this comparatively chemistry-intensive synthesis can be described as altering the 
fundamental properties of chitosan — a non-ideal outcome from both preparative and applicative 
perspectives. Furthermore, the overall complexity of this synthesis increases the likelihood that 
side reactions or contaminants remain present that are not detected by ATR-FTIR. Future 




significant alteration of the relevant physicochemical properties of chitosan itself, using the 
minimum number of synthetic steps. Furthermore, elimination of the dithiol reagents used to 
introduce the sulfhydryl functionality may reduce the likelihood of toxicity. While incorporation 
of RSNO by substitution of the hydroxyl groups is a useful protocol from a purely synthetic 
perspective, practical applications (e.g. processable chitosan derivatives for the preparation of 
bandages) will likely require less dramatic structural alteration. Since the water solubility of 
chitosan is maintained even at relative high degrees of acetylation, it is probable that the most 
chemically-benign strategy remains the functionalization of the C2 amine group via 
carbodiimide chemistry. The use of a carboxylic acid bearing a tertiary thiol may eliminate 
(through steric hindrance) certain concerns related to the reactivity of the sulfhydryl group, 
although this outcome cannot be assured. The implementation of S-protection chemistry has 
experimental utility as a method of screening for thiol-mediated side reactions, but may not be 
desirable as a component of a finalized protocol. As a general direction, the selection of an 
appropriate thiol for the modification of chitosan and the methodical evaluation of various 
coupling conditions is a sensible approach to the development of next-generation NO-releasing 
derivatives. In this context, the methodology described in Chapter 2 is complementary to direct, 
amine-targeted strategies that are less synthetically complex and more likely to produce 
polymers suited to biomedical applications. 
 
5.3. The use of polyphosphazenes as nitric oxide release platforms 
Although S-nitrosated polyesters have been widely employed as biodegradable NO release 
platforms, demonstrations of polyphosphazenes in this role are currently constrained to the two 




the inorganic phosphorus-nitrogen polyphosphazene backbone permits the attachment of various 
organic substituents at the phosphorus atom, including thiols that may be subsequently converted 
to RSNOs. While the use of polyphosphazenes as NO-releasing polymers may be justified by 
their widespread investigation as biomaterials (primarily for tissue engineering or device 
coatings), much of their appeal is derived from synthetic considerations. 
Poly(dichlorophosphazene) (PDCP) can be accessed by multiple techniques, including the 
conceptually straightforward ring-opening reaction of hexachlorocyclotriphosphazene or the 
polymerization of phosphoranimines.25,26 In the latter case, molecular weights generally exhibit 
relatively narrow polydispersities.27 As demonstrated in Chapter 3 and 4, replacement of the 
geminal chlorine atoms by substitution with suitable thiol-containing nucleophiles occurs under 
mild conditions (as low as 25 °C), with good reproducibility. Although the nitrogen atom of the 
phosphazene unit exhibits some degree of basicity, S-nitrosation occurs without any apparent 
reaction of the polyphosphazene backbone when characterized by IR spectroscopy.28 In both 
evaluated cases, the release of NO from S-nitrosated polyphosphazenes does not result in any 
apparent structural changes beyond the loss of RSNO and the hypothesized formation of 
disulfide (resulting in impaired solubility). Furthermore, the P=N backbone repeating unit has a 
total mass of only 45 Da, compared to a mass of 58 Da for the repeating unit of the simplest 
polyester, poly(glycolic acid). Consequently, the contribution of RSNO substituents to the 
overall mass and physicochemical properties of the polymer is vastly greater in the case of 
polyphosphazenes than for NO-releasing polyesters prepared from the conjugation of thiols. As 
such, the polyphosphazene backbone represents a platform for nitric oxide release (or other 
useful functions) in a much more literal sense than any other existent polymer system. As an 




be conceptualized as an immobilized, macromolecular form of the 3-mercapto-3-methylbut-1-yl 
glycinyl substituents, which comprise 89% of its repeating unit mass. Although only a fraction of 
the theoretical thiol is converted to RSNO, this suggests the potential for remarkably high NO 
loading (mol NO/mass polymer). 
Many of the drawbacks of the first reported NO-releasing polyphosphazene, S-nitrosated 
poly(ethyl S-methylthiocysteinyl-co-ethyl cysteinyl phosphazene) (POP-EtCys), are addressed in 
some form by the development of the subsequent material POP-Gly-MMB, following certain 
principles outlined in Section 5.1 of this chapter. As originally observed by Weikel t al., 
incorporation of the ethyl cysteinyl pendant groups of POP-EtCys required the use of an S-
protection strategy to prevent chemoselectivity issues arising from the competitive substitution 
of PDCP by thiol instead of amine.29 Because most common thiol protecting groups require 
deprotection conditions that are poorly tolerated by polyphosphazenes, the primary thiol ethyl 
cysteinate was protected as the methyl disulfide using the malodorous, expensive, and potentially 
toxic reagent S-methyl methanethiosulfonate. Following synthesis of the S-protected polymer, 
the similarly noxious disulfide-cleaving agent 2-mercaptoethanol was employed to produce free 
thiol groups. This process did not proceed to completion, and resulted in the retention of 
potentially labile (through disulfide exchange) methyl disulfide groups. In the case of POP-Gly-
MMB, it was anticipated that the greater steric congestion of the tertiary thiol would favor 
substitution of PDCP by the amine group of 3-mercapto-3-methylbut-1-yl glycinate. This 
hypothesis was supported by the outcome that a single major product was observed, 
corresponding to covalent attachment of the amine and preservation of thiol. When immersed in 
pH 7.4 phosphate buffered saline (PBS) at 37 °C, the relatively rapid decay of the primary 




tertiary RSNO groups of POP-Gly-MMB-NO (83% remaining after 24 h). This slower 
decomposition resulted in maintenance of physiologically-relevant NO release for 2 weeks, with 
16% of the initial NO content remaining. The apparent increase in stability may be attributable to 
a variety of factors, however the use of tertiary RSNO groups remains the most probable 
explanation. Although the toxicity of POP-Gly-MMB has not been evaluated, the use of glycine 
and naturally-occurring, food-grade 3-mercapto-3-methylbutan-1-ol as building blocks and the 
elimination of protection/deprotection steps with hazardous reagents represents meaningful 
progress toward biomedically-useful polymers. 
 While their value from a purely synthetic perspective is clear, it is currently unknown 
whether NO-releasing polyphosphazenes are suitable for use as biomaterials. Future 
development in this area must emphasize the identification of practical applications for such 
materials and a tailored approach to their design. Because polyphosphazenes may be substituted 
with multiple, chemically-distinct pendant groups (frequently achieved through sequential 
reactions), the properties of NO-releasing polyphosphazenes may be tunable through the 
inclusion of new substituents. In the case of amino acid ester-substituted polyphosphazenes (such 
as the polymers discussed in this work), the relative fragility of these materials may be enhanced 
through the use of appropriate organic substituents.30 This may permit both the retention of NO 
release and the ability to confer mechanical properties that are better suited to a target 
application, such as tissue engineering or the fabrication of medical devices. In spite of the fact 
that NO-releasing polyphosphazenes have yet to be assessed in vivo for specific biological 
applications, the established therapeutic effects of NO and the great synthetic versatility of the 
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